Substituted pyrrolidines as g-protein coupled receptor 43 agonists

ABSTRACT

The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

The present invention relates to novel compounds including theirpharmaceutically acceptable salts, solvates and prodrugs, which areagonists or partial agonists of G-protein coupled receptor 43 (GPR43)and are useful as therapeutic compounds, particularly in the treatmentand/or prevention of Type 2 diabetes mellitus and conditions that areoften associated with this disease including, lipid disorders such asdyslipidemia, hypertension, obesity, atherosclerosis and its sequelae.

BACKGROUND OF THE INVENTION

Under normal conditions, Free Fatty Acids (FFAs) are implicated innumerous physiological processes by serving as fuel in various metabolicpathways and/or acting as signaling molecules in different tissues suchas the heart, liver, skeletal muscle, adipocytes and the pancreas(Newsholme et al., Biochem. J., 80 pp 655-662, 1961; Prentki et al.,Endocrine Reviews, PubMed print ahead, 2008). Among FFAs, theshort-chain fatty acids (SCFAs, carbon length C2-C6) are generatedduring anaerobic bacterial fermentation of fiber in the gut (Sellin etal., News. Physiol. Sci., 14, pp 58-64, 1999). Long-chain fatty acids(LCFAs, carbon length C14-C24) are products of dietary intake fromadipose tissues and liver (McArthur et al., J. Lipid. Res., 40, pp1371-1383, 1999).

Obesity is an increasing, worldwide public health problem associatedwith devastating pathologies such as type 2 diabetes (T2D) anddyslipidemia (Wild et al., Diabetes Care 27, pp 1047-1053, 2004).Dyslipidemia is characterized by high levels of triglycerides and/or LDL(bad cholesterol) or low levels of HDL (good cholesterol). Dyslipidemiais a key independent risk factor for cardiovascular diseases. It haslong been suggested that FFAs are implicated in the regulation and/orgenesis of these diseases (Fraze et al., J. Clin. Endocrinol. Metab.,61, pp 807-811, 1985). It is well established that regular intake ofdietary fiber has several beneficial metabolic effects such as loweringof plasma cholesterol and triglyceride levels (Anderson et al., J. Am.Coll. Nutr., 23, pp 5-17, 2004). Specifically, dietary fiber has beenshown to increase endogenous levels of SCFAs, leading to the suppressionof cholesterol synthesis and improvement in glucose tolerance in rat(Berggren et al., Br. J. Nutr., 76, pp 287-294, 1996), as well as thereduction of hyperglycemia in a diabetic mice model (Sakakibara et al.,Biochem. Biophys. Res. Com., 344, pp 597-604, 2006).

Drug therapies are available to address both T2D and dyslipidemia.Specifically, statins, fibrates and nicotinic acid or combinationsthereof are often considered as a first line therapy in dyslipidemiawhereas metformin, sulphonylureas and thiazolidinediones are three,widely-used classes of oral anti-diabetic drugs (Tenenbaum et al.,Cardiovascular Diabetology, 5, pp 20-23, 2006). Although thesestherapies are widespread in their use, the common appearance of adverseeffects or lack of efficacy after long-term use causes concern.Moreover, the growing patient population suffering from T2D,dyslipidemia and associated metabolic diseases creates a demand for newentrants into this therapeutic market.

GPR43 (also named FFA2R) belongs to a subfamily of G-Protein-CoupledReceptors (GPCRs), including GPR40 and GPR41 that have been identifiedas receptor for FFAs (Le Poul et al., J. Biol Chem. 278, 25481-489,2003; Covington et al., Biochemical Society transaction 34, 770-773,2006). The 3 family members share 30 to 40% sequence identity withspecificity toward different fatty acids carbon chain lengths, withSCFAs (short chain fatty acids: six carbons molecules or shorter)activating GPR41 and GPR43; and medium and long chain fatty acids (MCFA,LCFA) activating GPR40 (Rayasam et al., Expert Opinion on therapeutictargets, 11 661-671, 2007). C2 acetate and C3 propionate are the mostpotent activators of GPR43. GPR43 is mainly coupled with Gq-proteins,with some evidence for its possible coupling with Gi/o pathways as well.

GPR43 is strongly expressed in adipocytes. Also there is evidencesuggesting that GPR43 is overexpressed in pancreatic β-cells inprediabetic states as shown in WO2006/036688A2. Recent papers confirmedthe GPR43 expression in pancreatic islets (Ahren, Nature Reviews, 8 pp396-385; 2009; Regard et al., J; Clin. Invst., 117 pp 4034-4043, 2007).In adipocyte cells, GPR43 is induced during the differentiation processand increased during the high fat feeding in rodents, suggesting thatGPR43 may affect adipocyte functions (Hong et al., Endocrinology, 146 pp5092-5099, 2005). Indeed, it has been reported that acetate andpropionate may stimulate adipogenesis via GPR43. In addition siRNAresults hinted that acetate and propionate may inhibit lipolysis inadipocytes via GPR43 activation (Hong et al., Endocrinology, 146 pp5092-5099, 2005). It is interesting to note that the effect of acetateon reducing plasma free fatty acids level has been documented in humans(Suokas et al., Alcoholism, clinical and experimental research, 12 pp52-58, 1988; Laurent et al., European journal of clinical nutrition, 49pp 484-491, 1995). In addition, it has been shown that (i) adipocytestreated with GPR43 endogenous SCFA ligands exhibit a reduction inlipolytic activity and such inhibition of lypolysis is the result ofGPR43 activation and (ii) GPR43 activation by acetate results in thereduction of plasma free fatty acids level in vivo (Ge et al.,Endocrinology, 149 pp 4519-26, 2008). Recently two GPR43 positiveallosteric modulator molecules have been shown able to inhibit thelipolysis in adipocytes similarly to that of GPR43 endogenous SCFAligands (Lee et al., Mol Pharmacol, 74(6) pp 1599-1609, 2008). Suchresults suggest a potential role of GPR43 in regulating plasma lipidprofiles and aspects of metabolic syndrome.

On this basis, new agonists or partial agonists of GPR43 may be oftherapeutic value for T2D mellitus and conditions that are associatedwith this disease including, lipid disorders such as dyslipidemia,hypertension, obesity, atherosclerosis and its sequelae.

SUMMARY OF THE INVENTION

The invention encompasses compounds of general Formula I, theirpharmaceutically acceptable salts, solvates and prodrugs as well asmethods of use of such compounds or compositions comprising suchcompounds as modulators of GPR43 activity.

In a general aspect, the invention provides compounds of general formulaI:

and pharmaceutically acceptable salts,solvates and prodrugs thereof,

-   wherein-   Ar¹ is a 5- to 6-membered aryl or heteroaryl group, 3- to 8-membered    cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, or a    linear or branched C₃-C₆ alkyl group, each of which being optionally    substituted by one or more group(s) selected from halo, cyano,    alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl,    alkenyl, alkynyl, heteroalkyl, heterocyclyl, heterocyclylalkyl,    aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, alkoxy,    haloalkoxy, cycloalkyloxy, heterocyclyloxy, aryloxy, amino,    alkylamino, aminoalkyl, carboxy, alkoxycarbonyl,    cycloalkyloxycarbonyl, heterocyclyloxycarbonyl, aryloxycarbonyl,    heteroaryloxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    heterocyclylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    arylalkyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, heterocyclylcarbonylamino    arylcarbonylamino, heteroarylcarbonylamino, alkylcarbonylaminoalkyl,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or two substituents    form an alkylenedioxy group or a haloalkylenedioxy group, or two    substituents form a cycloalkyl or heterocycloalkyl moiety together    with the cycloalkyl or heterocycloalkyl group they are attached to,    or fused to the aryl, heteroaryl, cycloalkyl or heterocycloalkyl    group may be one or more cycloalkyl, aryl, heterocyclyl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl,    heteroalkyl, hydroxyl, alkoxy, haloalkoxy, cycloalkyloxy,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino or oxo;-   L¹ is a single bond, C₁-C₃ alkylene, C₃-C₆ cycloalkylene, C₂-C₃    alkenylene, C₂-C₃ alkynylene, each of which being optionally    substituted by one or more group(s) selected from halo, alkyl,    haloalkyl, hydroxyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl;-   R¹ is H, linear or branched C₁-C₄ alkyl;-   E is N, C—R⁵ where R⁵ is H, linear or branched C₁-C₄ alkyl;-   D is CO or D is where D is

linked to E eiher on the nitrogen or the carbonyl and R⁶ is H, alkyl,C₂-C₄ alkenyl, C₂-C₄ alkynyl, haloalkyl, cycloalkyl, cycloalkylalkyl,hydroxyalkyl or alkoxyalkyl, and under the condition that E is C—R⁵;

-   L² is a single bond, C₁-C₄ alkylene, C₃-C₆ cycloalkylene, C₂-C₃    alkenylene, C₂-C₃ alkynylene each of which being optionally    substituted by one or more group(s) selected from halo, alkyl,    haloalkyl, hydroxyl, alkoxy, haloalkoxy, hydroxyalkyl or    alkoxyalkyl;-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo, cyano, nitro, alkyl, haloalkyl,    cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heteroalkyl,    heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl,    benzoxazol-2-yl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy,    haloalkoxy, alkoxyalkoxy, cycloalkyloxy, heterocyclyloxy, aryloxy,    heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, cycloalkylalkyloxy,    arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,    amino, alkylamino, aminoalkyl, arylcarbonyl, carboxy,    alkoxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl,    aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, heterocyclylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, heterocyclylcarbonylamino    arylcarbonylamino, heteroarylcarbonylamino, alkylcarbonylaminoalkyl,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, oxo or two    substituents form an alkylenedioxy group or a haloalkylenedioxy    group, or two substituents form a cycloalkyl or heterocycloalkyl    moiety together with the cycloalkyl or heterocyclyl group they are    attached to, or fused to the aryl, heteroaryl, cycloalkyl or    heterocyclyl group may be one or more cycloalkyl, aryl, heterocyclyl    or heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, heteroaryl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy, cycloalkyloxy, cycloalkylalkyloxy, aryloxy,    aralkyloxy optionally substituted by a fluoro group, alkylamino,    carboxy, alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    amino, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy,    carbamoylamino, alkylcarbamoylamino, carbamimidoyl,    hydroxycarbamimidoyl, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino, oxo, aralkyl, heteroarylalkyl, alkoxyalkoxy,    alkoxyalkyl, and haloalkoxyalkyl.-   R² is H;-   L³ is a single bond, C₁-C₃ alkylene, C₃-C₆ cycloalkylene, C₂-C₃    alkenylene or C₂-C₃ alkynylene each of which being optionally    substituted by one or more group(s) selected from halo, alkyl,    haloalkyl, hydroxyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl;-   Z is selected from the group consisting of —COOR,

wherein R is H or linear or branched alkyl, aryl, acyloxyalkyl,dioxolene, R⁷ is H, methyl or ethyl, and R^(7′) is hydroxyl —SO₂CH₃,—SO₂cyclopropyl or —SO₂CF₃;

-   the bond represented by the dotted line is either absent or present;-   R³ is H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,    cycloalkylalkyl, alkenyl, alkynyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,    hydroxyl, alkoxy, alkoxyalkyl, haloalkoxy, cycloalkyloxy,    heterocyclyloxy, aryloxy, amino, alkylamino, aminoalkyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, arylalkyloxy, acetyl,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoylalkyl,    carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, heteroarylsulfonylsulfamoyl, alkylsulfamoyl,    arylsulfamoyl, heteroarylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, heterocyclylsulfonylamino,    arylsulfonylamino, heteroarylsulfonylamino, haloalkylsulfonylamino,    or fused to the aryl, heteroaryl, cycloalkyl or heterocycloalkyl    group may be one or more cycloalkyl, aryl, heterocyclyl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, heterocyclyl,    aryl, heteroaryl, cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy,    haloalkoxy, cycloalkyloxy, alkylamino, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo;-   R^(3′) is H or C₁-C₄ alkyl, or R^(3′) is absent if the dotted line    is present;-   R⁴ is H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, amino, alkylamino,    aminoalkyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, arylalkyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or fused to the    aryl, heteroaryl, cycloalkyl or heterocycloalkyl group may be one or    more cycloalkyl, aryl, heterocyclyl or heteroaryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl,    cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, alkylamino, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, or R⁴ forms together with R³ a    cyclopropane ring optionally substituted by one or more group    selected from halo, alkyl, haloalkyl, hydroxyl, alkoxy, or    haloalkoxy, under the condition that the dotted line is absent;-   R^(4′) is H, C₁-C₄ alkyl, or R^(4′) is absent if the dotted line is    present;    under the condition that the compound of formula (I) is not-   (2S)-methyl 1-benzoyl-5-mesitylpyrrolidine-2-carboxylate,-   (2S)-methyl    1-benzoyl-5-(2,4,6-triethylphenyl)pyrrolidine-2-carboxylate,-   (2S,5S)-1-benzoyl-5-mesitylpyrrolidine-2-carboxylic acid,-   (2S)-methyl 1-benzoyl-5-propylpyrrolidine-2-carboxylate,-   (2S,5S)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate,-   (2S,5R)-methyl 1-benzoyl-5-propylpyrrolidine-2-carboxylate,-   (2S,5R)-5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylic    acid,-   (2S,5R)-methyl    5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylate,-   (2R,5R)-1-(4-bromothiophene-2-carbonyl)-5-phenylpyrrolidine-2-carboxylic    acid,-   (2R,5S)-1-(3-bromo-2,6-dimethoxybenzoyl)-5-phenylpyrrolidine-2-carboxylic    acid,-   tert-butyl    2-[(2R,5S)-2-ethoxycarbonyl-5-phenyl-pyrrolidine-1-carbonyl]indoline-1-carboxylate,-   (2R,5S)-1-(1-tert-butoxycarbonylindoline-2-carbonyl)-5-phenyl-pyrrolidine-2-carboxylic    acid,-   1-[7-(4-tert-butyl-phenoxy)-1-cyclopentylmethyl-isoquinoline-3-carbonyl]-(5R)-phenyl-pyrrolidine-(2S)-carboxylic    acid.-   Advantageously, the compounds of the invention or pharmaceutically    acceptable salts, solvates and prodrugs thereof are those described    above in respect to formula (I) with the following provisos:-   Ar² is not phthalazin-6-yl, pyrido[2,3-d]pyridazin-2-yl,    pyrido[2,3-d]pyridazin-3-yl, or pyrazino[2,3-d]pyridazin-2-yl;    and/or-   each of R³ and R⁴ is not a pyrimid-2-ylamino group substituted at    position 6 by a bicyclic heteroaryl group, if the bond represented    as a dotted line is absent; and/or-   R³ is not a mono substituted hydroxymethyl; and/or-   The D-L²-Ar² moiety is not

wherein L is H or alkyl and L′ is selected from phenyl, naphtyl,indolyl, quinolyl, phenylamino.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising at least one compound according to the inventionor a pharmaceutically acceptable salt or solvate thereof.

The invention also relates to the use of the above compounds or theirpharmaceutically acceptable salts, solvates and prodrugs as modulatorsof GPR43, preferably as agonists or partial agonists of GPR43.

The invention further provides methods of treatment and/or prevention oftype 11 diabetes, obesity, dyslipidemia such as mixed or diabeticdyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDLcholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia,hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemiahypertension, hyperlipoproteinemia, metabolic syndrome, syndrome X,thrombotic disorders, cardiovascular disease, atherosclerosis and itssequelae including angina, claudication, heart attack, stroke andothers, kidney diseases, ketoacidosis, nephropathy, diabetic neuropathy,diabetic retinopathy, nonalcoholic fatty liver diseases such assteatosis or nonalcoholic steatohepatitis (NASH) comprising theadministration of a therapeutically effective amount of a compound orpharmaceutically acceptable salt or solvate of formula (I), to a patientin need thereof. Preferably the patient is a warm-blooded animal, morepreferably a human.

The invention also provides the use of a compound of formula (1) or apharmaceutically acceptable salt or solvate thereof as a medicament.Preferably, the medicament is used for the treatment and/or preventionof type II diabetes, obesity, dyslipidemia such as mixed or diabeticdyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDLcholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia,hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH).

In a preferred embodiment the disease is type II diabetes, a lipiddisorder such as dyslipidemia, hypertension, obesity, or atherosclerosisand its sequelae.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the invention relates to compounds of formula I, as wellas their pharmaceutically acceptable salts, solvates and prodrugs.

Preferred compounds of formula I and pharmaceutically acceptable salts,solvates and prodrugs thereof are those wherein all the followingdescriptions are independently

-   the dotted line is absent and E is N; and/or-   L¹ is a single bond, preferably a single bond drawn as a solid    wedge; and/or-   L³ is a single bond, preferably a single bond drawn as a solid    wedge; and/or-   Z is selected from the group consisting of —COOR wherein R is    defined as above in respect to formula I, preferably Z is COOH;    and/or-   R³ is H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,    cycloalkylalkyl, alkenyl, alkynyl, heteroalkyl, 5-membered    heterocyclyl, heterocyclylalkyl, aryl, aralkyl, 5-membered    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, alkoxyalkyl,    haloalkoxy, cycloalkyloxy, heterocyclyloxy, aryloxy, amino,    alkylamino, aminoalkyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    heterocyclylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    arylalkyloxy, acetyl, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, heterocyclylcarbonylamino    arylcarbonylamino, heteroarylcarbonylamino, alkylcarbonylaminoalkyl,    carbamoylalkyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl,    arylsulfamoyl, heteroarylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, heterocyclylsulfonylamino,    arylsulfonylamino, heteroarylsulfonylamino, haloalkylsulfonylamino,    or fused to the aryl, heteroaryl, cycloalkyl or heterocycloalkyl    group may be one or more cycloalkyl, aryl, heterocyclyl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, heterocyclyl,    aryl, heteroaryl, cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy,    haloalkoxy, cycloalkyloxy, alkylamino, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino or oxo, preferably    R³ is H, cyano, alkyl, haloalkyl, cycloalkylalkyl,    heterocyclylalkyl, aralkyl, heteroarylalkyl, alkoxyalkyl,    haloalkoxy, aminoalkyl, arylalkyloxy, acetyl,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoylalkyl,    sulfamoyl, alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl,    alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or a bicyclic ring    made by an aryl, heteroaryl, cycloalkyl or heterocycloalkyl fused to    one cycloalkyl, aryl, heterocyclyl or heteroaryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl,    cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, alkylamino, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, or R³ forms together with R⁴ a    cyclopropane ring substituted by one or more group selected from    halo, haloalkyl, or haloalkoxy, under the condition that the bond    represented by the dotted line is absent, more preferably R³ is H,    cyano, alkyl, preferably methyl, aralkyl, preferably benzyl, acetyl    linked to the E containing ring by bond drawn as a dotted wedge,    alkoxyalkyl preferably methoxymethyl, even more preferably R³ is H;    and/or-   R⁴ is H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, amino, alkylamino,    aminoalkyl, carboxy, alkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, arylalkyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or fused to the    aryl, heteroaryl, cycloalkyl or heterocycloalkyl group may be one or    more cycloalkyl, aryl, heterocyclyl or heteroaryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl,    cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, alkylamino, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, or R⁴ forms together with R³ a    cyclopropane ring substituted by one or more haloalkyl, haloalkoxy,    under the condition that the dotted line is absent, preferably R⁴ is    H, methyl or cyano, more preferably R⁴ is H; and/or-   R^(3′) and R^(4′) are independently H or methyl, preferably R^(3′)    is H or methyl and R^(4′) is H, more preferably R^(3′) and R^(4′)    are both H; and/or-   D is CO and L² is a single bond; and/or-   Ar¹ is a 5- to 6-membered aryl or heteroaryl group, or a 3- to    6-membered cycloalkyl group, or a linear or branched C₃-C₆ alkyl    group, each of which being optionally substituted by one or more    group(s) selected from halo preferably bromo, chloro or fluoro,    cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄ hydroxyalkyl, C₁-C₄    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl preferably    phenyl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, C₁-C₄ alkoxy    preferably methoxy, C₁-C₄ haloalkoxy preferably OCF₃ or OCHF₂, C₁-C₄    alkylamino, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, heterocyclylcarbonylamino    arylcarbonylamino, heteroarylcarbonylamino, C₁-C₄    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl, C₁-C₄    alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl, carbamoylalkyl,    carbamoylamino, C₁-C₄ alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl,    arylsulfamoyl, heteroarylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, heterocyclylsulfonylamino,    arylsulfonylamino, heteroarylsulfonylamino, haloalkylsulfonylamino,    or two substituents form an alkylenedioxy group or a    haloalkylenedioxy group, or two substituents form a cycloalkyl or    heterocycloalkyl moiety together with the cycloalkyl group they are    attached to, or fused to the aryl, heteroaryl or cycloalkyl group    may be one or more cycloalkyl, aryl, heterocyclyl or heteroaryl    moiety, each of said substituents being optionally substituted by    one or more further substituents selected from halo, cyano, alkyl,    hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl,    hydroxyl, alkoxy, haloalkoxy, cycloalkyloxy, alkylamino,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, more preferably Ar¹ is a phenyl,    pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl, isopropyl,    isobutyl or isopentyl group, each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, aryl preferably    phenyl, heteroaryl, hydroxyl, C₁-C₄ alkoxy preferably methoxy, C₁-C₄    haloalkoxy preferably OCF₃ or OCHF₂, C₁-C₄ alkylamino,    alkylcarbonylamino, carbamoyl, C₁-C₄ alkylcarbamoyl, carbamoylamino,    C₁-C₄ alkylcarbamoylamino, alkylsulfonyl, sulfamoyl, alkylsulfamoyl,    alkylsulfonylamino, or two substituents form an alkylenedioxy group    or a haloalkylenedioxy group, still more preferably Ar¹ is a phenyl,    cyclohexyl, isobutyl or isopentyl group, said phenyl or cyclohexyl,    group being optionally substituted by one or more group(s) selected    from halo preferably bromo, chloro or fluoro, cyano, C₁-C₄ alkyl    preferably methyl, C₁-C₄ haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, aryl preferably phenyl, heteroaryl preferably hydroxyl,    C₁-C₄ alkoxy preferably methoxy, C₁-C₄ haloalkoxy preferably OCF₃ or    OCHF₂, C₁-C₄ alkylamino, alkylcarbonylamino, alkylsulfonyl, or two    substituents form an alkylenedioxy group or a haloalkylenedioxy    group, even more preferably Ar¹ is a phenyl or isobutyl group, said    phenyl group being optionally substituted by one or more group(s)    selected from halo preferably bromo, chloro or fluoro, cyano or    C₁-C₄ alkyl preferably methyl, alkoxy preferably methoxy; and/or-   R¹ is H or methyl, preferably R¹ is H; and/or-   R² is H; and/or-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo preferably chloro and fluoro,    cyano, nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, benzoxazol-2-yl, heteroarylalkyl, hydroxyl,    hydroxyalkyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂,    alkoxyalkoxy, cycloalkyloxy, heterocyclyloxy, aryloxy,    heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, cycloalkylalkyloxy,    arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,    arylcarbonyl, alkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, oxo, or two    substituents form an alkylenedioxy group or a haloalkylenedioxy    group, or two substituents form a cycloalkyl or heterocycloalkyl    moiety together with the cycloalkyl or heterocycloalkyl group they    are attached to, or fused to the aryl, heteroaryl, cycloalkyl or    heterocycloalkyl group may be one or more cycloalkyl, aryl,    heterocyclyl or heteroaryl moiety, each of said substituents being    optionally substituted by one or more further substituents selected    from halo, cyano, nitro, alkyl, hydroxyalkyl, haloalkyl preferably    CF₃, cyanomethyl, cycloalkyl, heterocyclyl, aryl optionally    substituted by a chloro or methyl group, preferably phenyl,    4-chlorophenyl, heteroaryl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy preferably 1,1,1-trifluoroethyloxy, alkoxyalkyl    preferably methoxymethyl, cycloalkyloxy, cycloalkylalkyloxy    preferably cyclopropylmethyloxy, aryloxy, aralkyloxy optionally    substituted with one fluoro, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, amino, alkylamino,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy preferably    carbamoylmethyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl    preferably (piperidin-1-yl)sulfonyl, (morpholin-4-yl)sulfonyl,    arylsulfonyl preferably phenylsulfonyl, sulfamoyl, alkylsulfamoyl,    alkylsulfonylamino, cycloalkylsulfonylamino, haloalkylsulfonylamino,    oxo, aralkyl, heteroarylalkyl, alkoxyalkoxy, alkoxyalkyl, and    haloalkoxyalkyl, more preferably Ar² is an aryl or heteroaryl    preferably pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of said aryl, heteroaryl, cycloalkyl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl,    aralkyl, heteroaryl, benzoxazol-2-yl, heteroarylalkyl, hydroxyl,    alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy,    aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl, or two substituents    form an alkylenedioxy group or a haloalkylenedioxy group, or fused    to the cycloalkyl or heterocycloalkyl group may be one aryl moiety,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, nitro, alkyl preferably methyl, ethyl, propyl,    isopropyl, tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy    preferably methoxy, ethoxy, isopropoxy, cycloalkyl,    cycloalkylalkyloxy, alkoxyalkoxy, aryloxy, aralkyloxy optionally    substituted with one fluoro, amino, alkylcarbonylamino, carbamoyl,    hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino, still more    preferably Ar² is an aryl preferably phenyl, heteroaryl preferably    pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl group    preferably isobutyl, each of said aryl, heteroaryl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, heterocyclyl preferably pyrrolidin-1-yl,    4-methylpiperidin-1-yl, aryl, heteroaryl preferably pyridinyl,    pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazol-2-yl, alkoxy    preferably methoxy, ethoxy and isopropyloxy, alkoxyalkyl,    cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy, phenethyloxy    and 3,3-diphenylpropan-1-oxy heteroarylalkyloxy preferably    pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl preferably    phenoxymethyl, heteroaryloxyalkyl preferably pyridyloxymethyl,    arylcarbonyl, or two substituents form an haloalkylenedioxy group    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, more preferably fluoro, cyano, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    alkoxyalkyl preferably methoxymethyl, alkoxyalkoxy preferably    2-methoxyethoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted with    one fluoro, preferably benzyloxy, 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonyl, alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino.

In one embodiment, preferred compounds of Formula I are those of formulaIb:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹ is as defined above in respect to formula I, preferably Ar¹ is a    5- to 6-membered aryl or heteroaryl group, or a 3- to 6-membered    cycloalkyl group, or a linear or branched C₃-C₆ alkyl group, each of    which being optionally substituted by one or more group(s) selected    from halo preferably bromo, chloro or fluoro, cyano, C₁-C₄ alkyl,    C₁-C₄ hydroxyalkyl, C₁-C₄ haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl preferably phenyl, aralkyl, heteroaryl,    heteroarylalkyl, hydroxyl, C₁-C₄ alkoxy C₁-C₄ haloalkoxy preferably    OCF₃ or OCHF₂, C₁-C₄ alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, C₁-C₄ alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino, C₁-C₄    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or two substituents    form an alkylenedioxy group or a haloalkylenedioxy group, or two    substituents form a cycloalkyl or heterocycloalkyl moiety together    with the cycloalkyl group they are attached to, or fused to the aryl    or heteroaryl group may be one or more cycloalkyl, aryl,    heterocyclyl or heteroaryl moiety, each of said substituents being    optionally substituted by one or more further substituents selected    from halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl,    cycloalkylalkyl, heteroalkyl, hydroxyl, alkoxy, haloalkoxy,    cycloalkyloxy, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, more preferably Ar¹ is a 5- to    6-membered aryl preferably phenyl, 5- to 6-membered heteroaryl group    preferably pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl,    isopropyl, isobutyl or isopentyl each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    alkoxy preferably methoxy, aryl preferably phenyl, still more    preferably Ar¹ is aryl preferably phenyl, cyclohexyl, isobutyl or    isopentyl, said phenyl group being optionally substituted by one or    more halo group preferably bromo, chloro or fluoro, cyano, methyl,    phenyl or methoxy, further more preferably Ar¹ is phenyl,    cyclohexyl, isobutyl, 2-chlorophenyl, 2-tolyl, 2-methoxyphenyl,    3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,    4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2-cyanophenyl,    3,5-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, 1,1′-biphenyl-2-yl, 4-cyanophenyl, even more    preferably Ar¹ is isobutyl, cyclohexyl, phenyl, 2-chlorophenyl,    2-tolyl, 2-methoxyphenyl, 3-chlorophenyl, 4-chlorophenyl,    2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, still even more preferably Ar¹ is isobutyl,    2-chlorophenyl, 2-tolyl, 2-methoxyphenyl, 2-fluorophenyl,    2,4-difluorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl;-   L¹ is as defined above in respect to formula I, preferably L¹ is a    single bond or a methylene optionally being substituted by one or    more substituents selected from fluoro or methyl, more preferably L¹    is a single bond drawn as a solid or dotted wedge, even more    preferably a single bond drawn as a solid wedge;-   R¹ is as defined above in respect to formula I, preferably R¹ is H    or methyl, more preferably R¹ is H;-   E is as defined above in respect to formula I, preferably E is N;-   D is as defined above in respect of formula I, preferably D is CO;-   L² is as defined above in respect to formula I, preferably L² is a    single bond, C₁-C₃ alkylene optionally being substituted by one or    more substituents selected from fluoro or methyl, more preferably L²    is a single bond;-   Ar² is as defined above in respect to formula I, preferably Ar² is    an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl    group, each of which being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, benzoxazol-2-yl, heteroarylalkyl, hydroxyl,    hydroxyalkyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂,    alkoxyalkoxy, cycloalkyloxy, heterocyclyloxy, aryloxy,    heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, cycloalkylalkyloxy,    arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,    arylcarbonyl, alkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, oxo, or two    substituents form an alkylenedioxy group or a haloalkylenedioxy    group, or two substituents form a cycloalkyl or heterocycloalkyl    moiety together with the cycloalkyl or heterocyclyl group they are    attached to, or fused to the aryl, heteroaryl, cycloalkyl or    heterocyclyl group may be one or more cycloalkyl, aryl, hetcrocyclyl    or heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, preferably phenyl, 4-chlorophenyl, 4-tolyl,    heteroaryl, cycloalkylalkyl, heteroalkyl, aralkyl, heteroarylalkyl,    hydroxyl, alkoxy, alkoxyalkyl preferably methoxymethyl,    alkoxyalkoxy, haloalkoxy haloalkoxy preferably trifluoromethoxy,    1,1,1-trifluoroethyloxy, cycloalkyloxy, cycloalkylalkyloxy    preferably cyclopropylmethyloxy, aryloxy, aralkyloxy optionally    substituted by one fluoro, alkoxyalkyl, haloalkoxyalkyl, amino,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy    preferably carbamoylmethyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl    preferably (piperidin-1-yl)sulfonyl, (morpholin-4-yl)sulfonyl,    arylsulfonyl preferably phenylsulfonyl, sulfamoyl, alkylsulfamoyl,    alkylsulfonylamino, cycloalkylsulfonylamino, haloalkylsulfonylamino,    oxo, more preferably Ar² is an aryl or heteroaryl preferably    pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl group,    each of each of said aryl, heteroaryl, cycloalkyl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl,    haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl, aralkyl,    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy preferably    OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy, alkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, cycloalkylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, arylcarbonyl, or two substituents form an    alkylenedioxy group or a haloalkylenedioxy group, or fused to the    cycloalkyl or heterocycloalkyl group may be one aryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro or alkyl or cycloalkyl, amino, alkylcarbonylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino,    still more preferably Ar² is an aryl preferably phenyl, heteroaryl    preferably pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl    group preferably isobutyl, each of said aryl, heteroaryl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, preferably methyl, heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, aryl preferably phenyl,    heteroaryl preferably pyridinyl, pyrimidinyl, pyrazinyl,    pyridazinyl, alkoxy preferably methoxy, ethoxy or isopropyloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy,    phenethyloxy or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy    preferably pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl    preferably phenoxymethyl, heteroaryloxyalkyl preferably    pyridinyloxymethyl, arylcarbonyl preferably phenylacetyl, or two    substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, nitro, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted by one    fluoro, preferably benzyloxy or 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonyl, alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, further more preferably Ar² is a    biaryl consisting of two 6-membered aryl moieties preferably    biphenyl, more preferably a biphenyl linked to L² at position 4′ and    monosubstituted at position 2, or Ar² is a heterobiaryl consisting    of one 6-membered aryl moiety and one 6-membered heteroaryl moiety    or two 6-membered heteroaryl moieties, said heterobiaryl being    linked to L² either on the aryl or on the heteroaryl moiety and    being preferably phenylpyridyl, pyrimidinylphenyl,    pyridazinylphenyl, pyrazinylphenyl, or Ar² is an aryl or heteroaryl    optionally substituted by one group selected from arylalkyloxy,    aryloxyalkyl, arylcarbonyl, each of said biaryl, heterobiaryl, aryl    and heteroaryl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, cyano,    nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy, aryloxy preferably phenoxy, aralkyloxy    optionally substituted by one fluoro preferably benzyloxy or    4-fluorobenzyloxy, amino, alkylcarbonylamino preferably acetylamino,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, or Ar² is a piperidinyl ring    linked to L² at position 4 and N substituted with a phenyl,    4-(4-chlorophenyl)thiazol-2-yl or benzoxazol-2-yl moiety, said    phenyl moiety being further substituted by one or more substituents    selected from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, haloalkyl preferably CF₃, alkoxy preferably    methoxy, heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    methylsulfonylamino, diethylaminosulfonyl, even more preferably Ar²    is 4′-(2-methoxy-1,1′-biphenyl), 4′-(2-methyl-1,1′-biphenyl),    4′-(2-fluoro-1,1′-biphenyl), 4′-(4-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl), 4′-(2-chloro-2′-methoxy-1,1′-biphenyl),    4′-(2-(2-methoxyethoxy)-1,1′-biphenyl),    4′-(2-(methoxymethyl)-1,1′-biphenyl), 4′-(4-methoxy-1,1′-biphenyl),    4′-(4-cyano-1,1′-biphenyl), 4′-(3-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl),    4′-(4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-trifluoromethoxy-1,1′-biphenyl),    4′-(2-isopropoxy-1,1′-biphenyl),    4′-(2-cyclopropylmethyloxy-1,1′-biphenyl),    4′-(2-cyano-1,1′-biphenyl), 4′-(2,6-dimethoxy-1,1′-biphenyl),    4′-(2,4-dichloro-1,1′-biphenyl),    4′-(2-trifluoromethyl-1,1′-biphenyl),    4′-(2-methoxy-4-chloro-1,1′-biphenyl),    4′-(2,4-dimethoxy-1,1′-biphenyl), 4-(2,2′-dimethoxy-1,1′-biphenyl),    4-(naphtalen-2-yl)phenyl, 5-(2-phenyl)pyridyl, 4-cyclohexylphenyl,    4-benzylphenyl, 4-(3-thienyl)phenyl, 4-(pyridin-3-yl)phenyl,    4-(2-methoxypyridin-3-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(2-(2-methoxyethoxy)-pyridin-3-yl)phenyl,    4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-5-yl)phenyl,    4-(2-methoxypyrimidin-5-yl)-3-methoxyphenyl,    4-(2,4-dimethoxypyrimidin-6-yl)phenyl,    4-(2,4-dimethoxypyrimidin-5-yl)phenyl, (4-benzyloxy)phenyl,    4-phenoxyphenyl, (3-phenethyloxy)phenyl, (4-phenethyloxy)phenyl,    (4-phenoxymethyl)phenyl, optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, more    preferably fluoro, alkyl preferably methyl, alkoxy preferably    methoxy, or Ar² is 4′-(2,4-difluoro-1,1′-biphenyl),    4′-(3′-methyl-1,1′-biphenyl), 4′-(3′-fluoro-1,1′-biphenyl),    4′-(2-fluoro-4-methoxy-1,1′-biphenyl),    4′-(4-fluoro-2-methoxy-1,1′-biphenyl),    4′-(2,3-dimethoxy-1,1′-biphenyl), 4′-(3,4-dimethoxy-1,1′-biphenyl),    4′-(2,3,4-trimethoxy-1,1′-biphenyl),    4′-(2,3,6-trimethoxy-1,1′-biphenyl),    4′-(3,5-dimethoxy-1,1′-biphenyl), 4′-(2,5-dimethoxy-1,1′-biphenyl),    4′-(2-isopropyl-1,1′-biphenyl), 4′-(2,2′-dimethoxy-1,1′-biphenyl),    4′-(2′-fluoro,2-dimethoxy-1,1′-biphenyl),    4′-(2-ethyl-1,1′-biphenyl), 4′-(4-propyl-1,1′-biphenyl),    4′-(4-tert-butyl-1,1′-biphenyl),    4′-(2-methoxy-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methoxy-4-acetylamino-1,1′-biphenyl),    4′-(3-hydroxycarbamimidoyl-1,1′-biphenyl),    4′-(4-amino-2-methoxy-1,1′-biphenyl),    4′-(3-carbamoyl-1,1′-biphenyl),    4′-(5-cyano-2,3-dimethoxy-1,1′-biphenyl),    4′-(2-cyano-4,5-dimethoxy-1,1′-biphenyl),    4′-(3,4,5-trimethoxy-1,1′-biphenyl),    4′-(2-cyanomethyl-4,5-dimethoxy-1,1′-biphenyl),    4′-(2-fluoro-5-cyano-1,1′-biphenyl),    4′-(2′-fluoro-3,4-dimethoxy-1,1′-biphenyl),    4′-(3-carbamoyl-4-cyano-1,1′-biphenyl),    4′-(2-cyano-4-methoxy-1,1′-biphenyl),    4′-(2′-fluoro-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2′-fluoro-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-cyano-2′-fluoro-1,1′-biphenyl),    4′-(2-chloro-5-cyano-1,1′-biphenyl),    4′-(2-cyano-4-trifluoromethyl-1,1′-biphenyl),    4′-(2-methyl-3-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(2-methyl-4-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(4-methylsulfonyl-1,1′-biphenyl),    4′-(3-methylsulfonylamino-1,1′-biphenyl),    4′-(4-amino-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methoxy-1,1′-biphenyl), 4′-(3-cyano-1,1′-biphenyl),    4′-(2-cyano-3-methoxy-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methyl-3-acetylamino-1,1′-biphenyl),    4-(2-chloro-6-methoxypyrimidin-5-yl)phenyl,    4-(2-ethoxypyridin-5-yl)phenyl, 4-(2-isopropoxypyridin-5-yl)phenyl,    4-(2-methoxy-6-methylpyridin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-4-yl)-3-chlorophenyl,    4-(2,6-dimethylpyridin-5-yl)phenyl,    4-(2,6dimethoxy-pyrimidin-5-yl)-3-chlorophenyl,    4-(4-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-chlorophenyl,    4-(4,6-dimethoxy-pyridin-3-yl)phenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(5-methoxy-pyridin-3-yl)-3-methoxyphenyl,    dimethoxy-pyridin-3-yl)-3-fluorophenyl,    4-(6-methoxy-pyridin-3-yl)-3-fluorophenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)-3-fluorophenyl,    4-(4,6-dimethoxy-pyrimidin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-5-yl)-3-methoxyphenyl,    4-(3-methoxy-pyridin-4-yl)phenyl, 4-(4-methoxy-pyridin-3-yl)phenyl,    4-(2-methoxy-pyrimidin-3-yl)phenyl,    3-methoxy-2-(2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(5-cyano-2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(2,4-dimethoxyphenyl)pyridin-5-yl,    2-(2,4-dimethoxyphenyl)pyridin-5-yl,    1-(2-cyano-4-trifluoromethyl)piperidin-4-yl,    1-(2-nitro-4-trifluoromethyl)piperidin-4-yl,    1-(2-methoxy-4-trifluoromethyl)piperidin-4-yl;-   R² is H;-   L³ is as defined above in respect to formula I, preferably L³ is a    single bond, C₁-C₃ alkylene optionally substituted by one or more    group(s) selected from chloro, fluoro, alkyl preferably methyl,    alkoxy preferably methoxy, or haloalkyl, preferably L³ is a single    bond, more preferably L³ is a single bond drawn as a solid wedge;-   Z is as defined above in respect to formula I, preferably Z is COOR    where R is as defined above in respect of formula I, more preferably    Z is COOH;-   R³ is as defined above in respect to formula I, preferably R³ is H,    cyano, alkyl, preferably methyl, aralkyl, preferably benzyl,    hydroxyalkyl preferably hydroxymethyl, alkoxyalkyl preferably    methoxymethyl, acetyl linked to the E containing ring by a bond    drawn as a dotted wedge, arylsulfonyl preferably phenylsulfonyl,    more preferably R³ is H;-   R^(3′) is as defined above in respect of formula I, preferably    R^(3′) is H or methyl, more preferably R^(3′) is H;-   R⁴ is as defined above in respect to formula I, preferably R⁴ is H,    cyano or methyl, more preferably R⁴ is H;-   R^(4′) is as defined above in respect to formula I, preferably    R^(4′) is H or methyl, more preferably R^(4′) is H;-   the bond represented by the dotted line is either absent or present,    preferably the dotted line is absent.-   Particularly preferred compounds of formula Ib are those of formula    Ib-1a

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein Ar¹, Ar², R¹, R², R³, R^(3′), R⁴, R^(4′), L², L³, D and Z are asdefined above in respect of formula Ib.

Preferred compounds of formula Ib-1a are those of formula Ib-1b

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein Ar¹, Ar², R¹, R², R³, R^(3′), R⁴, R^(4′), L² and D are asdefined above in respect of formula Ib and R is as defined above inrespect of formula I.

Preferred compounds of formula Ib-1b are those of formula Ib-1c

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein Ar¹, Ar², R¹, R², L² and D are as defined above in respect offormula Ib and R is as defined above in respect of formula I.

Other preferred compounds of formula Ib-1b are those of formula Ib-1b′

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R² is as defined above in respect of formula Ib and R is as defined    above in respect of formula I;-   R¹ is H;-   D is C═O;-   L² is single bond;-   A¹ is a 5- to 6-membered aryl or heteroaryl group, 3- to 6-membered    cycloalkyl group, or a linear or branched C₃-C₆ alkyl group, each of    which being optionally substituted by one or more group(s) selected    from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl,    hydroxyl, alkoxy, haloalkoxy, amino, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, or two substituents form an alkylenedioxy    group or a haloalkylenedioxy group, each of said aryl or heteroaryl    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, preferably Ar¹ is a 5- to 6-membered aryl    preferably phenyl, 5- to 6-membered heteroaryl group preferably    pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl, isopropyl,    isobutyl or isopentyl each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    alkoxy preferably methoxy, aryl preferably phenyl, still more    preferably Ar¹ is aryl preferably phenyl, cyclohexyl, isobutyl or    isopentyl, said phenyl group being optionally substituted by one or    more halo group preferably bromo, chloro or fluoro, cyano, methyl,    phenyl or methoxy, further more preferably Ar¹ is phenyl,    cyclohexyl, isobutyl, 2-chlorophenyl, 2-tolyl, 2-methoxyphenyl,    3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,    4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2-cyanophenyl,    3,5-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, 1,1′-biphenyl-2-yl, 4-cyanophenyl, even more    preferably Ar¹ is isobutyl, cyclohexyl, phenyl, 2-chlorophenyl,    2-tolyl, 2-methoxyphenyl, 3-chlorophenyl, 4-chlorophenyl,    2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, still even more preferably Ar¹ is isobutyl,    2-chlorophenyl, 2-tolyl, 2-methoxyphenyl, 2-fluorophenyl,    2,4-difluorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl;-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo, cyano, nitro, alkyl, haloalkyl,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl, aralkyl, heteroaryl, benzoxazol-2-yl    heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy,    alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy,    aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy,    hetcroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, amino,    alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl,    heteroaryloxycarbonyl, alkylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,    alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl,    alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, oxo,    or two substituents form an alkylenedioxy group or a    haloalkylenedioxy group, or fused to the aryl, heteroaryl,    cycloalkyl or heterocyclyl group may be one or more aryl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, heteroaryl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by a    fluoro or alkyl or cycloalkyl group, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, oxo, alkoxyalkoxy, alkoxyalkyl, and    haloalkoxyalkyl; preferably Ar² is an aryl or heteroaryl preferably    pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl group,    each of each of said aryl, heteroaryl, cycloalkyl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl,    haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl, aralkyl,    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy preferably    OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy, alkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, cycloalkylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, arylcarbonyl, or two substituents form an    alkylenedioxy group or a haloalkylenedioxy group, or fused to the    cycloalkyl or heterocycloalkyl group may be one aryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro or alkyl or cycloalkyl, amino, alkylcarbonylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino,    still more preferably Ar² is an aryl preferably phenyl, heteroaryl    preferably pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl    group preferably isobutyl, each of said aryl, heteroaryl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, preferably methyl, heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, aryl preferably phenyl,    heteroaryl preferably pyridinyl, pyrimidinyl, pyrazinyl,    pyridazinyl, alkoxy preferably methoxy, ethoxy or isopropyloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy,    phenethyloxy or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy    preferably pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl    preferably phenoxymethyl, heteroaryloxyalkyl preferably    pyridinyloxymethyl, arylcarbonyl preferably phenylacetyl, or two    substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, nitro, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted by one    fluoro, preferably benzyloxy or 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonylalkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, further more preferably Ar² is a    biaryl consisting of two 6-membered aryl moieties preferably    biphenyl, more preferably a biphenyl linked to L² at position 4′ and    monosubstituted at position 2, or Ar² is a heterobiaryl consisting    of one 6-membered aryl moiety and one 6-membered heteroaryl moiety    or two 6-membered heteroaryl moieties, said heterobiaryl being    linked to L² either on the aryl or on the heteroaryl moiety and    being preferably phenylpyridyl, pyrimidinylphenyl,    pyridazinylphenyl, pyrazinylphenyl, or Ar² is an aryl or heteroaryl    optionally substituted by one group selected from arylalkyloxy,    aryloxyalkyl, arylcarbonyl, each of said biaryl, heterobiaryl, aryl    and heteroaryl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, cyano,    nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy, aryloxy preferably phenoxy, aralkyloxy    optionally substituted by one fluoro preferably benzyloxy or    4-fluorobenzyloxy, amino, alkylcarbonylamino preferably acetylamino,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, or Ar² is a piperidinyl ring    linked to L² at position 4 and N substituted with a phenyl,    4-(4-chlorophenyl)thiazol-2-yl or benzoxazol-2-yl moiety, said    phenyl moiety being further substituted by one or more substituents    selected from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, haloalkyl preferably CF₃, alkoxy preferably    methoxy, heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    methylsulfonylamino, diethylaminosulfonyl, even more preferably Ar²    is 4′-(2-methoxy-1,1′-biphenyl), 4′-(2-methyl-1,1′-biphenyl),    4′-(2-fluoro-1,1′-biphenyl), 4′-(4-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl), 4′-(2-chloro-2′-methoxy-1,1′-biphenyl),    4′-(2-(2-methoxyethoxy)-1,1′-biphenyl),    4′-(2-(methoxymethyl)-1,1′-biphenyl), 4′-(4-methoxy-1,1′-biphenyl),    4′-(4-cyano-1,1′-biphenyl), 4′-(3-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl),    4′-(4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-trifluoromethoxy-1,1′-biphenyl),    4′-(2-isopropoxy-1,1′-biphenyl),    4′-(2-cyclopropylmethyloxy-1,1′-biphenyl),    4′-(2-cyano-1,1′-biphenyl), 4′-(2,6-dimethoxy-1,1′-biphenyl),    4′-(2,4-dichloro-1,1′-biphenyl),    4′-(2-trifluoromethyl-1,1′-biphenyl),    4′-(2-methoxy-4-chloro-1,1′-biphenyl),    4′-(2,4-dimethoxy-1,1′-biphenyl), 4-(2,2′-dimethoxy-1,1′-biphenyl),    4-(naphtalen-2-yl)phenyl, 5-(2-phenyl)pyridyl, 4-cyclohexylphenyl,    4-benzylphenyl, 4-(3-thienyl)phenyl, 4-(pyridin-3-yl)phenyl,    4-(2-methoxypyridin-3-yl)phenyl, dimethoxy-pyridin-3-yl)phenyl,    4-(2-(2-methoxyethoxy)-pyridin-3-yl)phenyl,    4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-5-yl)phenyl,    4-(2-methoxypyrimidin-5-yl)-3-methoxyphenyl,    4-(2,4-dimethoxypyrimidin-6-yl)phenyl,    4-(2,4-dimethoxypyrimidin-5-yl)phenyl, (4-benzyloxy)phenyl,    4-phenoxyphenyl, (3-phenethyloxy)phenyl, (4-phenethyloxy)phenyl,    (4-phenoxymethyl)phenyl, optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, more    preferably fluoro, alkyl preferably methyl, alkoxy preferably    methoxy, or Ar² is 4′-(2,4-difluoro-1,1′-biphenyl),    4′-(3′-methyl-1,1′-biphenyl), 4′-(3′-fluoro-1,1′-biphenyl),    4′-(2-fluoro-4-methoxy-1,1′-biphenyl),    4′-(4-fluoro-2-methoxy-1,1′-biphenyl),    4′-(2,3-dimethoxy-1,1′-biphenyl), 4′-(3,4-dimethoxy-1,1′-biphenyl),    4′-(2,3,4-trimethoxy-1,1′-biphenyl),    4′-(2,3,6-trimethoxy-1,1′-biphenyl),    4′-(3,5-dimethoxy-1,1′-biphenyl), 4′-(2,5-dimethoxy-1,1′-biphenyl),    4′-(2-isopropyl-1,1′-biphenyl), 4′-(2,2′-dimethoxy-1,1′-biphenyl),    4′-(2′-fluoro,2-dimethoxy-1,1′-biphenyl),    4′-(2-ethyl-1,1′-biphenyl), 4′-(4-propyl-1,1′-biphenyl),    4′-(4-tert-butyl-1,1′-biphenyl),    4′-(2-methoxy-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methoxy-4-acetylamino-1,1′-biphenyl),    4′-(3-hydroxycarbamimidoyl-1,1′-biphenyl),    4′-(4-amino-2-methoxy-1,1′-biphenyl),    4′-(3-carbamoyl-1,1′-biphenyl),    4′-(5-cyano-2,3-dimethoxy-1,1′-biphenyl),    4′-(2-cyano-4,5-dimethoxy-1,1′-biphenyl),    4′-(3,4,5-trimethoxy-1,1′-biphenyl),    4′-(2-cyanomethyl-4,5-dimethoxy-1,1′-biphenyl),    4′-(2-fluoro-5-cyano-1,1′-biphenyl),    4′-(2′-fluoro-3,4-dimethoxy-1,1′-biphenyl),    4′-(3-carbamoyl-4-cyano-1,1′-biphenyl),    4′-(2-cyano-4-methoxy-1,1′-biphenyl),    4′-(2′-fluoro-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2′-fluoro-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-cyano-2′-fluoro-1,1′-biphenyl),    4′-(2-chloro-5-cyano-1,1′-biphenyl),    4′-(2-cyano-4-trifluoromethyl-1,1′-biphenyl),    4′-(2-methyl-3-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(2-methyl-4-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(4-methylsulfonyl-1,1′-biphenyl),    4′-(3-methylsulfonylamino-1,1′-biphenyl),    4′-(4-amino-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methoxy-1,1′-biphenyl), 4′-(3-cyano-1,1′-biphenyl),    4′-(2-cyano-3-methoxy-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methyl-3-acetylamino-1,1′-biphenyl),    4-(2-chloro-6-methoxypyrimidin-5-yl)phenyl,    4-(2-ethoxypyridin-5-yl)phenyl, 4-(2-isopropoxypyridin-5-yl)phenyl,    4-(2-methoxy-6-methylpyridin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-4-yl)-3-chlorophenyl,    4-(2,6-dimethylpyridin-5-yl)phenyl,    4-(2,6-dimethoxy-pyrimidin-5-yl)-3-chlorophenyl,    4-(4-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-chlorophenyl,    4-(4,6-dimethoxy-pyridin-3-yl)phenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(5-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(2,6-dimethoxy-pyridin-3-yl)-3-fluorophenyl,    4-(6-methoxy-pyridin-3-yl)-3-fluorophenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)-3-fluorophenyl,    4-(4,6-dimethoxy-pyrimidin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-5-yl)-3-methoxyphenyl,    4-(3-methoxy-pyridin-4-yl)phenyl, 4-(4-methoxy-pyridin-3-yl)phenyl,    4-(2-methoxy-pyrimidin-3-yl)phenyl,    3-methoxy-2-(2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(5-cyano-2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(2,4-dimethoxyphenyl)pyridin-5-yl,    2-(2,4-dimethoxyphenyl)pyridin-5-yl,    1-(2-cyano-4-trifluoromethyl)piperidin-4-yl,    1-(2-nitro-4-trifluoromethyl)piperidin-4-yl,    1-(2-methoxy-4-trifluoromethyl)piperidin-4-yl;-   R³ is H, cyano, alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl,    arylsulfonyl;-   R^(3′) is H or C₁-C₄ alkyl;-   R⁴ is H, cyano, C₁-C₄ alkyl.

Preferred compounds of formula Ib-1c or Ib-1b′ are those of formulaIb-1d

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein Ar¹, Ar², R¹ and R² are as defined above in respect of formulaIb in case of preferred compounds of formula Ib-1c, or Ib-1b′ in case ofpreferred compounds of formula Ib-1b′, and R is as defined above inrespect of formula I.

Preferred compounds of formula Ib-1d are those of formula Ib-1e

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar², R¹ and R² are as defined above in respect of formula Ib or    Ib-1b′;-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are independently selected from H,    halo preferably fluoro, chloro, bromo, cyano, alkyl, hydroxyalkyl,    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl preferably    phenyl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, heterocyclyloxy, alkylamino,    alkoxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl,    aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, heterocyclylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, arylalkyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′)    form an alkylenedioxy group or a haloalkylenedioxy group together    with the phenyl group they are attached to, or one or more of R⁸ and    R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′) form    together a cycloalkyl, aryl, heterocycloalyl or heteroaryl moiety    fused to the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy, cycloalkyloxy, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, preferably R⁸, R^(8′), R⁹, R^(9′) and    R¹⁰ are independently selected from H, halo preferably fluoro,    chloro, bromo, cyano, alkyl, haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, aryl preferably phenyl, heteroaryl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, alkylamino, alkoxycarbonyl,    alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or one    or more of R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′)    and R^(8′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, more preferably R⁸, R^(8′), R⁹, R^(9′) and R¹⁰    are independently selected from H, halo preferably bromo, fluoro or    chloro, cyano, C₁-C₄ alkyl preferably methyl, aryl preferably    phenyl, alkoxy preferably methoxy, still more preferably R⁸, R^(8′),    R⁹, R^(9′) and R¹⁰ are independently selected from H, halo    preferably bromo, fluoro or chloro, alkyl preferably methyl, still    more preferably R⁸ is Br, Cl or F, preferably Cl and R^(8′), R⁹,    R^(9′) and R¹⁰ are independently selected from H or F, or R⁹ is Cl    or F and R⁸, R^(8′), R^(9′) and R¹⁰ are H, or R⁹ and R^(9′) are F    and R⁸, R^(8′) and R¹⁰ are H, or R¹⁰ is Cl or F and R⁸, R^(8′), R⁹    and R^(9′) are H, even more preferably R⁸ is Br, Cl or F and R^(8′),    R⁹, R^(9′) and R¹⁰ are H, or R⁸ and R⁹ are F and R^(8′), R^(9′) and    R¹⁰ are H, or R⁸ and R¹⁰ are F and R^(8′), R⁹ and R^(9′) are H.

Preferred compounds of formula Ib-1e are those of formula Ib-1f

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar² is as defined above in respect of formula Ib or Ib-1b′;-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1e.

Preferred compounds of formula Ib-1f are those of formula Ib-1g

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1e;-   R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cyclo alkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkyloxycarbonyl, aminoalkylalkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, or one or more    of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form together a cycloalkyl, aryl, heterocycloalkyl or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl,    cyanomethyl, cycloalkyl, heterocyclyl, aryl optionally substituted    by one a chloro or methyl group, heteroaryl, cycloalkylalkyl,    aralkyl, heteroarylalkyl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkoxy, haloalkoxy preferably trifluoromethoxt,    1,1,1-trifluoroethyloxy, alkoxyalkyl, haloalkoxyalkyl,    cycloalkyloxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aryloxy, aralkyloxy optionally substituted by one fluoro, amino,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy    preferably carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino and oxo, preferably    R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, or one or more of R¹¹ and R¹², or R¹² and    R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form an    alkylenedioxy group or a haloalkylenedioxy group together with the    phenyl group they are attached to, or one or more of R¹¹ and R¹², or    R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form    together an aryl or heteroaryl moiety fused to the phenyl group they    are attached to, each of said substituents being optionally    substituted by one or more further substituents selected from halo    preferably chloro or fluoro, cyano, alkyl, hydroxyalkyl,    alkoxyalkyl, haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, aryl    optionally substituted by one a chloro or methyl group, heteroaryl,    heteroalkyl, hydroxyl, alkoxy, alkoxyalkoxy, haloalkoxy preferably    1,1,1-trifluoroethyloxy, alkoxyalkyl, cycloalkyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy,    aralkyloxy optionally substituted by one fluoro, amino, alkylamino,    carboxy, alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy preferably    carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino and oxo, more preferably R¹¹, R^(11′), R¹²,    R^(12′) and R¹⁶ are independently selected from H, halo preferably    chloro and fluoro, cyano, nitro, alkyl, haloalkyl preferably CF₃ or    CHF₂, heterocyclyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,    hydroxyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    aryloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy,    alkoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl, or one    or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or    R^(12′) and R^(11′) form an alkylenedioxy group or a    haloalkylenedioxy group together with the phenyl group they are    attached to, or one or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶    and R^(12′), or R^(12′) and R^(11′) form together an aryl, or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, cyanomethyl, cycloalkyl, heterocyclyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro, amino, alkylamino, alkylcarbonylamino, carbamoyl,    hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino, still more    preferably R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently    selected from H, halo preferably chloro and fluoro, cyano, nitro,    alkyl preferably methyl, ethyl, isopropyl or isobutyl, haloalkyl    preferably CF₃ or CHF₂, cycloalkyl preferably cyclohexyl,    heterocyclyl preferably pyrrolidin-1-yl, 4-methylpiperidin-1-yl,    aryl preferably phenyl, heteroaryl preferably thiophenyl, pyridinyl,    pyrimidinyl, pyrazinyl, pyridazinyl, aralkyl preferably benzyl,    alkoxy preferably methoxy, ethoxy or isopropyloxy,    cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy, phenethyloxy    or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy preferably    pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl preferably    phenoxymethyl, heteroaryloxyalkyl preferably pyridyloxymethyl, or    two substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, cyano,    alkyl preferably methyl, haloalkyl preferably trifluoromethyl,    alkoxy preferably methoxy, isopropyloxy, isobutyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy    preferably phenoxy, aralkyloxy optionally substituted by one fluoro,    preferably benzyloxy, 4-fluorobenzyloxy, amino, alkylcarbonylamino    preferably acetylamino, alkylsulfonyl preferably methylsulfonyl,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino.

Preferred compounds of formula Ib-1g are those of formula Ib-1g1

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1c;-   R¹⁶ is as defined above in respect to formula Ib-1g, preferably R¹⁶    is selected from halo preferably chloro, alkyl preferably methyl or    isobutyl, cycloalkyl preferably cyclohexyl, aryl preferably phenyl,    heteroaryl preferably pyridyl, thiophen-3-yl, pyrimidinyl,    pyrazinyl, pyridazinyl, aralkyl preferably benzyl, alkoxy preferably    methoxy, isopropyloxy more preferably isopropyloxy, haloalkoxy,    preferably OCF₃, OCHF₂, more preferably OCF₃, cycloalkylalkyloxy    preferably cyclopropylmethyloxy, arylalkyloxy preferably    phenethyloxy or benzyloxy, heteroarylalkyloxy preferably    pyridylethyloxy, aryloxyalkyl preferably phenoxymethyl,    heteroaryloxyalkyl preferably pyridyloxymethyl, arylcarbonyl    preferably phenylcarbonyl, each of said substituents being    optionally substituted by one or more further substituents selected    from halo preferably chloro or fluoro, more preferably fluoro,    cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, trifluoromethyl, cyanomethyl, cycloalkyl, aryl    optionally substituted by a chloro or methyl group, hydroxyl, alkoxy    preferably methoxy, ethoxy, isopropoxy, haloalkoxy preferably    trifluoromethoxy, 1,1,1-trifluoroethyloxy, aryloxy preferably    phenoxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aralkyloxy optionally substituted by one fluoro preferably    benzyloxy, 4-fluorobenzyloxy, alkoxyalkyl preferably methoxymethyl,    alkoxyalkoxy preferably 2-methoxyethoxy, amino, alkylcarbonylamino    preferably acetylamino, carbamoyl, carbamoylmethyloxy,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, oxo, more    preferably R¹⁶ is selected from alkyl preferably isobutyl, or R¹⁶ is    alkoxy preferably isopropyloxy, or R¹⁶ is heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, or R¹⁶ is aryl preferably a    phenyl, preferably a phenyl monosubstituted at position 2 by one    group selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, alkyl preferably methyl, alkoxy preferably    methoxy, alkoxyalkyl preferably methoxymethyl, alkoxyalkoxy    preferably 2-methoxyethoxy, or R¹⁶ is 2,4-difluorophenyl,    2-fluoro-4-methoxyphenyl, 4-fluoro-2-methoxyphenyl,    2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl,    2,5-dimethoxyphenyl, 2-methoxy-4-methylsulfonylaminophenyl,    4-acetylamino-2-methoxyphenyl, 4-amino-2-methoxyhenyl,    5-cyano-2,3-dimethoxyphenyl, 2-cyano-4,5-dimethoxyphenyl,    3,4,5-trimethoxyphenyl, 2-cyano-4-methoxyphenyl,    3-methylsulfonylaminophenyl, 4-methylsulfonylaminophenyl,    2-chloro-5-cyanophenyl, 2-cyano-4-trifluoromethylphenyl,    2-methyl-3-(N-methyl-N-methylsulfonyl)aminophenyl,    2-methoxy-4-(N-methyl-N-methylsulfonyl)aminophenyl,    4-methylsulfonylphenyl, 3-methylsulfonylaminophenyl,    4-methylsulfonylaminophenyl, 3-amino-2-methyl,    5-cyano-2-methylphenyl, 5-cyano-2-methoxyphenyl,    2-methyl-3-methylsulfonylamino, 3-cyano-2-methoxyphenyl, or R¹⁶ is    aralkyl preferably benzyl, or R¹⁶ is heteroaryl preferably    4,6-dimethoxypyrimidin-2-yl, 2-methoxypyrimidin-3-yl,    2,4-dimethoxypyrimidin-5-yl, 2-methoxypyridin-3-yl,    2,6-dimethoxy-pyridin-3-yl, 2-(2-methoxyethoxy)-pyridin-3-yl,    2-methoxypyrimidin-5-yl, 2,4-dimethoxypyrimidin-6-yl, preferably    2-methoxypyrimidin-3-yl, (2,4-dimethoxy)pyrimidin-5-yl,    2-methoxypyrimidin-5-yl, 2,6-dimethoxy-pyridin-3-yl, more preferably    (2,4-dimethoxy)pyrimidin-5-yl, 2,6-dimethoxy-pyridin-3-yl,    2-chloro-6-methoxypyrimidin-5-yl, 2-methoxy-6-methylpyridin-5-yl,    2,6-dimethylpyridin-5-yl, 2,6-dimethoxypyrimidin-5-yl,    4-methoxypyridin-3-yl, 2-methoxypyridin-5-yl,    2,4-dimethoxypyridin-5-yl, 2,6-dimethoxypyridazin-5-yl,    2,6-dimethoxypyridin-5-yl, 5-methoxypyridin-3-yl,    4,6-dimethoxypyrimidin-5-yl, 3-methoxypyridin-4-yl,    4-methoxypyridin-3-yl, or R¹⁶ is, arylalkyloxy preferably    phenethyloxy, benzyloxy, 2-fluorobenzyloxy, more preferably    2-fluorobenzyloxy, or R¹⁶ is aryloxyalkyl preferably phenoxymethyl.

Preferred compounds of formula Ib-1g1 are those of formula Ib-1g1a

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1e;-   R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected from H,    halo preferably chloro and fluoro more preferably fluoro, cyano,    alkyl preferably methyl, haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy    preferably methoxy, ethoxy, isopropyloxy, haloalkoxy preferably OCF₃    or OCHF₂, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl,    cycloalkylalkyloxy, aryloxy, aralkyloxy, haloalkoxyalkyl,    alkylamino, alkylsulfonyl preferably methylsulfonyl,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino, preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are    independently selected from H, halo preferably chloro and fluoro    more preferably fluoro, cyano, alkyl preferably methyl, haloalkyl    preferably CF₃ or CHF₂, cycloalkyl, heteroalkyl, heterocyclyl, aryl,    heteroaryl, hydroxyl, alkoxy preferably methoxy, ethoxy,    isopropyloxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    cycloalkyloxy, alkoxyalkyl, cycloalkylalkyloxy, aryloxy, aralkyloxy,    alkylamino, alkylsulfonyl preferably methylsulfonyl,    alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, haloalkylsulfonyl, cycloalkylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino, more preferably    R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected from H,    halo preferably chloro and fluoro more preferably chloro, cyano,    alkyl preferably methyl, haloalkyl preferably CF₃ or CHF₇, alkoxy    preferably methoxy, haloalkoxy preferably OCF₃ or OCHF₂,    alkoxyalkoxy preferably (2-methoxy)ethoxy, alkylamino preferably    dimethylamino, more preferably R^(17′), R^(18′) and R¹⁹ are H and    R¹⁷ is methoxy, (2-methoxy)ethoxy or R¹⁷, R^(18′) and R¹⁹ are H and    R^(17′) is methoxy, or R¹⁷, R^(17′) and R^(18′) are H and R¹⁹ is    chloro, methyl, methoxy, dimethylamino, or R^(17′) and R^(18′) are H    and: a) both R¹⁷ and R¹⁹ are methyl or methoxy, or b) R¹⁷ is methyl    and R¹⁹ is methoxy, or R^(17′), R^(18′) and R¹⁹ are H and R^(18′) is    methoxy even more preferably R^(17′), R^(18′) and R¹⁹ are H and R¹⁷    is methoxy, or R^(17′) and R^(18′) are H and: a) both R¹⁷ and R¹⁹    are methyl or methoxy, or b) R¹⁷ is methyl and R¹⁹ is methoxy, or    R¹⁷, R^(17′) and R¹⁹ are H and R^(18′) is methoxy.

Other preferred compounds of formula Ib-1g are those of formula Ib-1g2

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ib-1c;-   R¹² and R^(12′) are as defined above in respect to formula Ib-1g,    preferably R¹² and R^(12′) are independently selected from H, halo    preferably chloro, cyano, nitro, alkyl preferably ethyl, isopropyl,    haloalkyl preferably CF₃ or CHF₂, aryl preferably phenyl, hydroxyl,    alkoxy preferably methoxy or ethoxy, haloalkoxy preferably OCF₃ or    OCHF₂, alkoxyalkoxy, aryloxy, arylalkyloxy preferably phenethyloxy    or benzyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, alkoxy, alkyl, cycloalkyl, alkylsulfonyl preferably    methylsulfonyl, more preferably R¹² is H or alkoxy preferably    methoxy or ethoxy, more preferably methoxy and R^(12′) is halo    preferably chloro, alkoxy preferably methoxy or ethoxy, more    preferably methoxy, arylalkyloxy preferably phenethyloxy, benzyloxy    or 3,3-diphenylpropan-1-oxy, optionally substituted by halo    preferably chloro or fluoro, alkoxy, alkyl, alkylsulfonyl preferably    methylsulfonyl, even more preferably R¹² is methoxy and R^(12′) is    methoxy, chloro, benzyloxy, (4-chlorobenzyl)oxy,    (4-methylsulfonylbenzyl)oxy.

Other preferred compounds of formula Ib-1g are those of formula Ib-1h

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ib-1e;-   L⁴ is a single bond, —C(O)—, —O—, —O—C₁-C₃-alkylene or    —C₁-C₃-alkylene-O— optionally substituted by one or more group    selected from fluoro or methyl, preferably L⁴ is a single bond, —O—,    —O—C₁-C₂-alkylene, —C₁-alkylene-O— optionally substituted by one or    more group selected from fluoro or methyl, more preferably L⁴ is a    single bond, —OCH₂, —O(CH₂)₂— or —CH₂O—;-   R¹¹, R^(11′), R¹² and R^(12′) are as defined above in respect to    formula Ib-1g, preferably R¹¹ and R^(11′) are H and R¹² and R^(12′)    are independently selected from H, halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, isopropyl, haloalkyl    preferably CF₃ or CHF₂, hydroxyl, alkoxy preferably methoxy or    ethoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy, more    preferably R¹¹ and R^(11′) are H, R¹² is H, fluoro, chloro, methyl,    —CF₃, alkoxy preferably methoxy or ethoxy, more preferably methoxy    and R^(12′) is halo preferably chloro, alkoxy preferably methoxy or    ethoxy, more preferably methoxy, or R¹¹, R^(11′) and R^(12′) are H    and R¹² is fluoro, chloro, methyl, CF₃, methoxy, even more    preferably R¹¹ and R^(11′) are H, R¹² is H or methoxy and R^(12′) is    methoxy,chloro, or R¹¹, R^(11′) and R^(12′) are H and R¹² is fluoro,    chloro, methyl, CF₃, methoxy;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are independently selected from    H, halo preferably chloro and fluoro more preferably fluoro, cyano,    alkyl preferably methyl, ethyl, propyl, isopropyl, tert-butyl,    haloalkyl preferably CF₃ or CHF₂, cyanomethyl, cycloalkyl,    heteroalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, hydroxyalkyl,    alkoxy preferably methoxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl,    cycloalkylalkyloxy, aralkyloxy optionally substituted by one fluoro,    haloalkoxyalkyl, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy,    alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl,    alkylsulfonyl preferably methylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino, preferably R¹³,    R^(13′), R¹⁴, R^(14′) and R¹⁵ are independently selected from H,    halo preferably chloro and fluoro more preferably fluoro, cyano,    alkyl preferably methyl, ethyl, propyl, isopropyl, tert-butyl,    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, aryl, aralkyl, heteroaryl,    heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy preferably methoxy,    haloalkoxy preferably OCF₃, OCHF₂, or 1,1,1-trifluoroethyloxy,    alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl, cycloalkylalkyloxy,    aralkyloxy optionally substituted by one fluoro, haloalkoxyalkyl,    amino, alkylamino, alkylcarbonylamino, haloalkylcarbonylamino,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy,    carbamoylamino, alkylcarbamoylamino, carbamimidoyl,    hydroxycarbamimidoyl, alkylsulfonyl preferably methylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl, alkylsulfamoyl,    alkylsulfonylamino, cycloalkylsulfonylamino, haloalkylsulfonylamino,    more preferably R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are independently    selected from H, halo preferably chloro and fluoro more preferably    fluoro, cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably —CF₃ or CHF₂, hydroxyl,    hydroxyalkyl, alkoxy preferably methoxy, haloalkoxy preferably OCF₃    or OCHF₂, alkoxyalkoxy preferably 2-methoxyethoxy, cycloalkyloxy,    cycloalkylalkyloxy, alkoxyalkyl preferably methoxymethyl,    haloalkoxyalkyl, amino, alkylcarbonylamino preferably acetylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl preferably    methylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, still more preferably R¹³,    R^(13′), R¹⁴, R^(14′) and R¹⁵ are independently selected from H,    halo preferably chloro and fluoro, more preferably fluoro, cyano,    nitro, alkyl preferably methyl, haloalkyl preferably —CF₃ or —CHF₂,    alkoxyalkyl preferably methoxymethyl, alkoxy preferably methoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, haloalkoxy    preferably OCF₃ or OCHF₂, alkoxyalkoxy preferably 2-methoxyethoxy,    amino, alkylcarbonylamino preferably acetylamino, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, even more    preferably R¹³, R^(13′), R¹⁴ and R^(14′) are H and R¹⁵ is H, chloro,    methyl or methoxy, methylsulfonyl, methylsulfonylamino, preferably    H, methylsulfonyl, methylsulfonylamino, or R^(13′), R¹⁴, R^(14′) and    R¹⁵ are H and R¹³ is methoxy or chloro, preferably chloro, or R¹³,    R^(13′), R^(14′) and R¹⁵ are H and R¹⁴ is methylsulfonylamino, or    R^(13′), R¹⁴ and R^(14′) are H and R¹³ and R¹⁵ are a) both F, or b)    R¹³ is F and R¹⁵ is methoxy, or c) R¹³ is methoxy and R¹⁵ is F,    or d) R¹³ is methoxy and R¹⁵ is acetylamino, or e) R¹³ is methoxy    and R¹⁵ is amino, or f) R¹³ is cyano and R¹⁵ is methoxy, or g) R¹³    is chloro and R¹⁵ is cyano, or h) R¹³ is cyano and R¹⁵ is    trifluoromethyl, or i) R¹³ is methoxy and R¹⁵ is    (N-methyl-N-methylsulfonyl)amino, or R^(13′), R^(14′) and R¹⁵ are H    and R¹³ and R¹⁴ are a) both methoxy, or b) R¹³ is methyl and R¹⁴ is    methylsulfonylamino, or c) R¹³ is methoxy and R¹⁴ is cyano, or d)    R¹³ is methyl and R¹⁴ is amino, or R¹³, R^(13′) and R^(14′) are H    and R¹⁴ and R¹⁵ are both methoxy, or R^(13′), R¹⁴ and R¹⁵ are H and    R¹³ and R^(14′) are a) both methoxy, or b) R¹⁴ is methoxy and    R^(14′) is cyano, or c) R¹⁴ is methyl and R^(14′) is cyano, or R¹³,    R^(13′) and R¹⁵ are H and R¹⁴ and R^(14′) are both methoxy, or R¹³    and R¹⁴ are H and R^(13′), R^(14′) and R¹⁵ are methoxy, or R¹⁴ and    R¹⁵ are H and R¹³, R^(13′) and R^(14′) are methoxy, or R¹³ and R¹⁴    are methoxy and R^(13′) and R¹⁵ are H and R^(14′) is cyano, or R¹⁴    and R¹⁵ are methoxy and R¹³ and R^(14′) are H and R^(13′) is cyano,    or R¹³ and R^(13′) are H and R¹⁴, R¹⁴′ and R¹⁵ are methoxy.

Preferred compounds of formula Ib-1h are those of formula Ib-1h1

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ib-1e;-   R¹² is as defined above in respect to formula Ib-1h, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, nitro, cyano, methoxy or    cyclopropylmethyloxy;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are as defined above in respect    to formula Ib-1h, preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and    R¹³ is chloro, cyano, hydroxyl, methyl, trifluoromethyl,    cyanomethyl, methoxy, isopropoxy, isobutyloxy, OCF₃,    cyclopropylmethyloxy, phenoxy, cyclopropylmethyloxy, benzyloxy,    (4-fluorobenzyl)oxy, methoxymethyl, 2-methoxyethoxy,    carbamoylmethyloxy, or R¹³, R^(13′), R^(14′) and R^(15′) are H and    R¹⁴ is chloro, methylsulfonylamino, or R¹³, R^(13′), R¹⁴ and R^(14′)    are H and R¹⁵ is chloro, methylsulfonylamino, R^(13′), R¹⁴ and    R^(14′) are H and R¹³ and R¹⁵ are a) independently selected from    chloro or methoxy, or b) both F, or c) R¹³ is F and R¹⁵ is methoxy,    or d) R¹³ is methoxy and R¹⁵ is F, or e) R¹³ is methoxy and R¹⁵ is    acetylamino, or f) R¹³ is methoxy and R¹⁵ is amino, or g) R¹³ is    cyano and R¹⁵ is methoxy, or h) R¹³ is chloro and R¹⁵ is cyano,    or i) R¹³ is cyano and R¹⁵ is trifluoromethyl, or j) R¹³ is methoxy    and R¹⁵ is (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵    are H and both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R¹⁵    are H and both R¹⁴ and R^(14′) are fluoro, methoxy, or R¹³, R^(13′)    and R^(14′) are H and a) R¹⁴ forms together with R¹⁵ a phenyl moiety    fused to the phenyl ring they are attached to, or b) both R¹⁴ and    R¹⁵ are methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴    are a) both methoxy, or b) R¹³ is methyl and R¹⁴ is    methylsulfonylamino, or c) R¹³ is methoxy and R¹⁴ is cyano, or d)    R¹³ is methyl and R¹⁴ is amino, or R^(13′), R¹⁴ and R¹⁵ are H and    R¹³ and R^(14′) are a) both methoxy, or b) R¹³ is methoxy and    R^(14′) is cyano, or c) R¹³ is methyl and R^(14′) is cyano, or R¹³    and R¹⁴ are H and R^(13′), R^(14′) and R¹⁵ are methoxy, or R¹⁴ and    R¹⁵ are H and R¹³, R^(13′) and R^(14′) are methoxy, or R¹³ and R¹⁴    are methoxy and R^(13′) and R¹⁵ are H and R^(14′) is cyano, or R¹⁴    and R¹⁵ are methoxy and R¹³ and R^(14′) are H and R^(13′) is cyano,    or R¹³ and R^(13′) are H and R¹⁴, R^(14′) and R¹⁵ are methoxy, more    preferably R13′, R¹⁴, R^(14′) and R¹⁵ are H and R¹³ is chloro,    cyano, trifluoromethyl, methoxy, isopropoxy, cyclopropylmethyloxy,    or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴ is chloro, or R¹³,    R^(13′), R¹⁴ and R^(14′) are H and R¹⁵ is chloro,    methylsulfonylamino, or R^(13′), R¹⁴ and R^(14′) are H and R¹³ and    R¹⁵ are a) independently selected from chloro or methoxy, or b) both    F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³ is methoxy and R¹⁵    is F, or e) R¹³ is methoxy and R¹⁵ is acetylamino, or f) R¹³ is    methoxy and R¹⁵ is amino, or g) R¹³ is cyano and R¹⁵ is methoxy,    or h) R¹³ is chloro and R¹⁵ is cyano, or i) R¹³ is cyano and R¹⁵ is    trifluoromethyl, or j) R¹³ is methoxy and R¹⁵ is    (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵ are H and    both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R^(14′) are H    and a) R¹⁴ forms together with R¹⁵ a phenyl moiety fused to the    phenyl ring they are attached to, or b) both R¹⁴ and R¹⁵ are    methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴ are a)    both methoxy, or b) R¹³ is methyl and R¹⁴ is methylsulfonylamino,    or c) R¹³ is methoxy and R¹⁴ is cyano, or d) R¹³ is methyl and R¹⁴    is amino, or R^(13′), R¹⁴ and R¹⁵ are H and R¹³ and R^(14′) are a)    both methoxy, or b) R¹³ is methoxy and R^(14′) is cyano, or c) R¹³    is methyl and R¹⁴′ is cyano, or R¹³ and R¹⁴ are H and R^(13′),    R^(14′) and R¹⁵ are methoxy, or R¹⁴ and R¹⁵ are H and R¹³, R^(13′)    and R^(14′) are methoxy, or R¹³ and R¹⁴ are methoxy and R^(13′) and    R¹⁵ are H and R^(14′) is cyano, or R¹⁴ and R¹⁵ are methoxy and R¹³    and R^(14′) are H and R^(13′) is cyano, or R¹³ and R^(13′) are H and    R¹⁴, R^(14′) and R¹⁵ are methoxy.

Other preferred compounds of formula Ib-1g are those of formula Ib-1h′

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ib-1e;-   R¹² is as defined above in respect to formula Ib-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, or methoxy more preferably R¹² is    H or methoxy;-   R¹⁶ is selected from the group of heteroaryl moieties consisting of:

wherein

-   the arrow marks the attachment point to the phenyl ring;-   R¹⁷, R^(17′), R¹⁸, R^(18′) and R¹⁹ are independently selected from    H, halo preferably chloro and fluoro, cyano, alkyl preferably    methyl, ethyl, propyl, isopropyl, tert-butyl, haloalkyl preferably    CF₃ or CHF₂, hydroxyl, hydroxyalkyl, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl    preferably methoxymethyl, cycloalkylalkyloxy preferably    cyclopropylmethyloxy, aralkyloxy preferably benzyloxy,    haloalkoxyalkyl, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl,    alkylsulfonyl preferably methylsulfonyl, haloalkylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino,    haloalkylsulfonylamino, preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are    independently selected from H, halo preferably chloro and fluoro,    cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkyl preferably methoxymethyl,    aralkyloxy preferably benzyloxy, amino, alkylcarbonylamino,    carbamoyl, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy, even more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy;-   Preferred compounds of formula Ib-1h′ are those wherein R¹⁰ is    selected from 2-2-methoxypyrimidin-4-yl,    2,4-dibenzyloxypyrimidin-5-yl, 2,4-dimethoxypyrimidin-5-yl,    3,6-dimethoxypyridazin-5-yl, 2-methoxypyrimidin-5-yl,    2-methoxypyrimidin-3-yl.

Still other preferred compounds of formula Ib-1g are those of formulaIb-1h″

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R⁸ is F or Cl and R⁹ is H, or both R⁸ and R⁹ are F;-   R is H, methyl, ethyl or tert-butyl;-   A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations    1 to 24:

Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CH C—NHSO₂CH₃CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CH CH CH 4 CHCH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CH C—OCH₃ N NC—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CH C—CN CH 9 C—FCH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CH CH CH CHC—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH N C—OCH₃ NC—OCH₃ 14 N C—OCH₃ CH CH CH CH CH 15 CH CH C—OCH₃ N CH N CH 16 CH C—OCH₃C—OCH₃ CH CH CH CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CH C—OCH₃ NC—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CH C—OCH₃C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 22 N CH C—OCH₃ CHC—OCH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CH

Still other preferred compounds of formula Ib-1g are those of formulaIb-1i

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ib-1f;-   L⁴, R¹¹, R^(11′), R^(12′), R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ is as    defined above in respect to formula Ib-1h;-   R¹⁶ is as defined above in respect to formula Ib-1g, preferably R¹⁶    is selected from H, halo preferably chloro or fluoro more preferably    chloro, alkyl, haloalkyl preferably CF₃ or CHF₂, aryl, hydroxyl,    alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, or R¹⁶ forms together with R^(12′) an    alkylenedioxy group or a haloalkylenedioxy group, each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, alkoxy,    alkyl, alkylsulfonyl, more preferably R¹⁶ is selected from H, halo    preferably chloro and fluoro more preferably chloro, alkyl,    haloalkyl preferably CF₃ or CHF₂, hydroxyl, alkoxy, haloalkoxy    preferably OCF₃ or OCHF₂, alkoxyalkoxy, haloalkoxyalkyl, or R¹⁶    forms together with R^(12′) an alkylenedioxy group or a    haloalkylenedioxy group, each of said substituents being optionally    substituted by one or more further substituents selected from halo    preferably chloro or fluoro, alkoxy, alkyl, cycloalkyl,    alkylsulfonyl.

Other preferred compounds of formula Ib-1f are those of formula Ib-1j

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1f;-   L⁴ is as defined above in respect to formula Ib-1h, preferably L⁴ is    a single bond;-   R¹¹ and R^(11′) are as defined above in respect to formula Ib-1h,    preferably and R^(11′) are H;-   R^(12′) is as defined above in respect to formula Ib-1h, preferably    R^(12′) is H or methoxy, more preferably R^(12′) is H;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are as defined above in respect    to formula Ib-1h, preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and    R¹³ is chloro, fluoro, methoxy, or R¹³ R^(13′), R^(14′) and R¹⁵ are    H and R¹⁴ is methoxy, or R^(13′), R¹⁴ and R¹⁵ are H and a) both R¹³    and R^(14′) are chloro or b) R¹³ is methoxy and R^(14′) is cyano, or    R^(13′), R¹⁴ and R^(14′) are H and both R¹³ and R¹⁵ are methoxy more    preferably R^(13′), R¹⁴, R14′ and R¹⁵ are H and R¹³ is chloro, or    R^(13′), R¹⁴ and R¹⁵ are H and both R¹³ and R^(14′) are chloro.

Other preferred compounds of formula Ib-1f are those of formula Ib-1k

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1e;-   R^(12′) is H, fluoro, chloro, CF₃, methyl or methoxy, preferably    R^(12′) is H or methoxy, more preferably R^(12′) is methoxy;-   R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected from H,    halo preferably chloro and fluoro, more preferably fluoro, cyano,    nitro, alkyl preferably methyl, haloalkyl preferably CF₃ or CHF₂,    alkoxyalkyl preferably methoxymethy, alkoxy preferably methoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, haloalkoxy    preferably OCF₃ or OCHF₂, alkoxyalkoxy preferably 2-methoxyethoxy,    amino, alkylcarbonylamino preferably acetylamino, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, preferably    R^(17′) and R^(18′) are H and both R¹⁷ and R¹⁹ are methoxy.

Other preferred compounds of formula Ib-1f are those of formula Ib-1l

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect of    formula Ib-1e;-   R²⁰ is an aryl or heteroaryl, each of said aryl or heteroaryl being    optionally substituted by one or more substituent(s) selected from    halo, alkyl, haloalkyl, cyano, nitro, phenyl optionally substituted    by one chloro, alkoxy, heterocyclylsulfonyl, alkylsulfamoyl or    alkylsulfonylamino, preferably R²⁰ is a phenyl optionally    substituted by one or more substituent(s) selected from halo    preferably chloro or fluoro, alkyl preferably methyl, haloalkyl    preferably CF₃, cyano, nitro, alkoxy preferably methoxy,    heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    diethylaminosulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, or R²⁰ is 4-(4-chlorophenyl)thiazol-2-yl, or    R²⁰ is a benzoxazol-2-yl, more preferably R²⁰ is 2-methoxyphenyl,    2-cyano-4-trifluoromethylphenyl, 2-chloro-4-trifluoromethylphenyl,    2-nitro-4-trifluoromethylphenyl, 2-nitro-4-(piperidin-1-yl)sulfonyl    phenyl, 4-(morpholin-4-yl)sulfonylphenyl,    2-nitro-4-diethylaminosulfonyl phenyl, 2-nitro-4-tolyl,    2-cyano-4-nitrophenyl, 4-nitrophenyl, 2-fluoro-4-nitrophenyl,    3-methoxy-4-nitrophenyl, 5-chloro-2-nitrophenyl,    2-cyano-4-methylsulfonylaminophenyl, 2-cyano-4-methoxyphenyl,    2-methylsulfonylamino-4-trifluoromethylphenyl, 2-nitrophenyl,    4-cyanophenyl, 2-methoxy-4-trifluoromethylphenyl, or R²⁰ is    4-(4-chlorophenyl)thiazol-2-yl, or R²⁰ is a benzoxazol-2-yl, even    more preferably R²⁰ is 2-cyano-4-trifluoromethylphenyl,    2-nitro-4-trifluoromethylphenyl, 2-methoxy-4-trifluoromethylphenyl.

Other preferred compounds of formula Ib are those of formula Ib-2

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², R¹, R², R³, R^(3′), R⁴, R^(4′), L², L³, D, E and Z are as    defined above in respect of formula Ib; and-   the bond represented by the dotted line is either absent or present.-   Preferred compounds of formula Ib-2 and pharmaceutically acceptable    salts, solvates and prodrugs thereof are those wherein the dotted    line is absent.

Further preferred compounds of formula Ib are those of formula Ib-3

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², R¹, R², R³, R^(3′), R⁴, R^(4′), L¹, L², D and E are as    defined above in respect of formula Ib,-   R is as defined above in respect of formula I; and-   the bond represented by the dotted line is either absent or present.-   Preferred compounds of formula Ib-3 and pharmaceutically acceptable    salts, solvates and prodrugs thereof are those wherein dotted line    is absent.

Yet other preferred compounds of formula Ib are those of formula Ib-4

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², R¹, R², L¹, L², L³, D, E and Z are as defined above in    respect of formula Ib; and-   the bond represented by the dotted line is either absent or present.-   Preferred compounds of formula Ib-4 and pharmaceutically acceptable    salts, solvates and prodrugs thereof are those wherein the dotted    line is absent.

Further preferred compounds of formula Ib are those of formula Ib-5

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², L¹, L³, R¹, R², R³, R^(3′), R⁴, R^(4′) and Z are as    defined above in respect of formula Ib; and-   the bond represented by the dotted line is either absent or present.-   Preferred compounds of formula Ib-5 and pharmaceutically acceptable    salts, oleates and prodrugs thereof are those wherein the dotted    line is absent.

Further preferred compounds of formula Ib are those of formula Ib-6

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², L¹, L², L³, R³, R^(3′), R⁴, R^(4′), D, E and Z are as    defined above in respect of formula Ib; and-   the bond represented by the dotted line is either absent or present.-   Preferred compounds of formula Ib-6 and pharmaceutically acceptable    salts, solvates and prodrugs thereof are those wherein the dotted    line is absent.

In yet another embodiment, preferred compounds of Formula I are those offormula Ic:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², L¹, L², L³, R¹, R², R³, R^(3′), R⁴, R^(4′), D, E and Z are    as defined above in respect of formula I; and-   the bond represented by the dotted line is either absent or present.

Preferred compounds of formula Ic and pharmaceutically acceptable salts,solvates and prodrugs thereof are those wherein the dotted line isabsent.

Other preferred compounds of formula Ic are those of formula Ic-1b′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R² is as defined above in respect of formula Ic and R is as defined    above in respect of formula I;-   R¹ is H;-   D is C═O;-   L² is single bond;-   Ar¹ is a 5- to 6-membered aryl or heteroaryl group, 3- to 6-membered    cycloalkyl group, or a linear or branched C₃-C₆ alkyl group, each of    which being optionally substituted by one or more group(s) selected    from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl,    hydroxyl, alkoxy, haloalkoxy, amino, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, or two substituents form an alkylenedioxy    group or a haloalkylenedioxy group, each of said aryl or heteroaryl    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, preferably Ar¹ is a 5- to 6-membered aryl    preferably phenyl, 5- to 6-membered heteroaryl group preferably    pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl, isopropyl,    isobutyl or isopentyl each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    alkoxy preferably methoxy, aryl preferably phenyl, still more    preferably Ar¹ is aryl preferably phenyl, cyclohexyl, isobutyl or    isopentyl, said phenyl group being optionally substituted by one or    more halo group preferably bromo, chloro or fluoro, cyano, methyl,    phenyl or methoxy, further more preferably Ar¹ is phenyl,    cyclohexyl, isobutyl, 2-chlorophenyl, 2-tolyl, 2-methoxyphenyl,    3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,    4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2-cyanophenyl,    3,5-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, 1,1′-biphenyl-2-yl, 4-cyanophenyl, even more    preferably Ar¹ is isobutyl, cyclohexyl, phenyl, 2-chlorophenyl,    2-tolyl, 2-methoxyphenyl, 3-chlorophenyl, 4-chlorophenyl,    2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, still even more preferably Ar¹ is isobutyl,    2-chlorophenyl, 2-tolyl, 2-methoxyphenyl, 2-fluorophenyl,    2,4-difluorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl;-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo, cyano, nitro, alkyl, haloalkyl,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl, aralkyl, heteroaryl, benzoxazol-2-yl    heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy,    alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy,    aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, amino,    alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl,    heteroaryloxycarbonyl, alkylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,    alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl,    alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, oxo,    or two substituents form an alkylenedioxy group or a    haloalkylenedioxy group, or fused to the aryl, heteroaryl,    cycloalkyl or heterocyclyl group may be one or more aryl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, heteroaryl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by a    fluoro or alkyl or cycloalkyl group, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, oxo, alkoxyalkoxy, alkoxyalkyl, and    haloalkoxyalkyl; preferably Ar² is an aryl or heteroaryl preferably    pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl group,    each of each of said aryl, heteroaryl, cycloalkyl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl,    haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl, aralkyl,    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy preferably    OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy, alkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, cycloalkylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, arylcarbonyl, or two substituents form an    alkylenedioxy group or a haloalkylenedioxy group, or fused to the    cycloalkyl or heterocycloalkyl group may be one aryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro or alkyl or cycloalkyl, amino, alkylcarbonylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino,    still more preferably Ar² is an aryl preferably phenyl, heteroaryl    preferably pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl    group preferably isobutyl, each of said aryl, heteroaryl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, preferably methyl, heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, aryl preferably phenyl,    heteroaryl preferably pyridinyl, pyrimidinyl, pyrazinyl,    pyridazinyl, alkoxy preferably methoxy, ethoxy or isopropyloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy,    phenethyloxy or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy    preferably pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl    preferably phenoxymethyl, heteroaryloxyalkyl preferably    pyridinyloxymethyl, arylcarbonyl preferably phenyl acetyl, or two    substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, nitro, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted by one    fluoro, preferably benzyloxy or 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonylalkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, further more preferably Ar² is a    biaryl consisting of two 6-membered aryl moieties preferably    biphenyl, more preferably a biphenyl linked to L² at position 4′ and    monosubstituted at position 2, or Ar² is a heterobiaryl consisting    of one 6-membered aryl moiety and one 6-membered heteroaryl moiety    or two 6-membered heteroaryl moieties, said heterobiaryl being    linked to L² either on the aryl or on the heteroaryl moiety and    being preferably phenylpyridyl, pyrimidinylphenyl,    pyridazinylphenyl, pyrazinylphenyl, or Ar² is an aryl or heteroaryl    optionally substituted by one group selected from arylalkyloxy,    aryloxyalkyl, arylcarbonyl, each of said biaryl, heterobiaryl, aryl    and heteroaryl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, cyano,    nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy, aryloxy preferably phenoxy, aralkyloxy    optionally substituted by one fluoro preferably benzyloxy or    4-fluorobenzyloxy, amino, alkylcarbonylamino preferably acetylamino,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, or Ar² is a piperidinyl ring    linked to L² at position 4 and N substituted with a phenyl,    4-(4-chlorophenyl)thiazol-2-yl or benzoxazol-2-yl moiety, said    phenyl moiety being further substituted by one or more substituents    selected from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, haloalkyl preferably CF₃, alkoxy preferably    methoxy, heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    methylsulfonylamino, diethylaminosulfonyl, even more preferably Ar²    is 4′-(2-methoxy-1,1′-biphenyl), 4′-(2-methyl-1,1′-biphenyl),    4′-(2-fluoro-1,1′-biphenyl), 4′-(4-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl), 4′-(2-chloro-2′-methoxy-1,1′-biphenyl),    4′-(2-(2-methoxyethoxy)-1,1′-biphenyl),    4′-(2-(methoxymethyl)-1,1′-biphenyl), 4′-(4-methoxy-1,1′-biphenyl),    4′-(4-cyano-1,1′-biphenyl), 4′-(3-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl),    4′-(4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-trifluoromethoxy-1,1′-biphenyl),    4′-(2-isopropoxy-1,1′-biphenyl),    4′-(2-cyclopropylmethyloxy-1,1′-biphenyl),    4′-(2-cyano-1,1′-biphenyl), 4′-(2,6-dimethoxy-1,1′-biphenyl),    4′-(2,4-dichloro-1,1′-biphenyl),    4′-(2-trifluoromethyl-1,1′-biphenyl),    4′-(2-methoxy-4-chloro-1,1′-biphenyl),    4′-(2,4-dimethoxy-1,1′-biphenyl), 4-(2,2′-dimethoxy-1,1′-biphenyl),    4-(naphtalen-2-yl)phenyl, 5-(2-phenyl)pyridyl, 4-cyclohexylphenyl,    4-benzylphenyl, 4-(3-thienyl)phenyl, 4-(pyridin-3-yl)phenyl,    4-(2-methoxypyridin-3-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(2-(2-methoxyethoxy)-pyridin-3-yl)phenyl,    4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-5-yl)phenyl,    4-(2-methoxypyrimidin-5-yl)-3-methoxyphenyl,    4-(2,4-dimethoxypyrimidin-6-yl)phenyl,    4-(2,4-dimethoxypyrimidin-5-yl)phenyl, (4-benzyloxy)phenyl,    4-phenoxyphenyl, (3-phenethyloxy)phenyl, (4-phenethyloxy)phenyl,    (4-phenoxymethyl)phenyl, optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, more    preferably fluoro, alkyl preferably methyl, alkoxy preferably    methoxy, or Ar² is 4′-(2,4-difluoro-1,1′-biphenyl),    4′-(3′-methyl-1,1′-biphenyl), 4′-(3′-fluoro-1,1′-biphenyl),    4′-(2-fluoro-4-methoxy-1,1′-biphenyl),    4′-(4-fluoro-2-methoxy-1,1′-biphenyl),    4′-(2,3-dimethoxy-1,1′-biphenyl), 4′-(3,4-dimethoxy-1,1′-biphenyl),    4′-(2,3,4-trimethoxy-1,1′-biphenyl),    4′-(2,3,6-trimethoxy-1,1′-biphenyl),    4′-(3,5-dimethoxy-1,1′-biphenyl), 4′-(2,5-dimethoxy-1,1′-biphenyl),    4′-(2-isopropyl-1,1′-biphenyl), 4′-(2,2′-dimethoxy-1,1′-biphenyl),    4′-(2′-fluoro,2-dimethoxy-1,1′-biphenyl),    4′-(2-ethyl-1,1′-biphenyl), 4′-(4-propyl-1,1′-biphenyl),    4′-(4-tert-butyl-1,1′-biphenyl),    4′-(2-methoxy-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methoxy-4-acetylamino-1,1′-biphenyl),    4′-(3-hydroxycarbamimidoyl-1,1′-biphenyl),    4′-(4-amino-2-methoxy-1,1′-biphenyl),    4′-(3-carbamoyl-1,1′-biphenyl),    4′-(5-cyano-2,3-dimethoxy-1,1′-biphenyl),    4′-(2-cyano-4,5-dimethoxy-1,1′-biphenyl),    4′-(3,4,5-trimethoxy-1,1′-biphenyl),    4′-(2-cyanomethyl-4,5-dimethoxy-1,1′-biphenyl),    4′-(2-fluoro-5-cyano-1,1′-biphenyl),    4′-(2′-fluoro-3,4-dimethoxy-1,1′-biphenyl),    4′-(3-carbamoyl-4-cyano-1,1′-biphenyl),    4′-(2-cyano-4-methoxy-1,1′-biphenyl),    4′-(2′-fluoro-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2′-fluoro-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-cyano-2′-fluoro-1,1′-biphenyl),    4′-(2-chloro-5-cyano-1,1′-biphenyl),    4′-(2-cyano-4-trifluoromethyl-1,1′-biphenyl),    4′-(2-methyl-3-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(2-methyl-4-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(4-methylsulfonyl-1,1′-biphenyl),    4′-(3-methylsulfonylamino-1,1′-biphenyl),    4′-(4-amino-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methoxy-1,1′-biphenyl), 4′-(3-cyano-1,1′-biphenyl),    4′-(2-cyano-3-methoxy-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methyl-3-acetylamino-1,1′-biphenyl),    4-(2-chloro-6-methoxypyrimidin-5-yl)phenyl,    4-(2-ethoxypyridin-5-yl)phenyl, 4-(2-isopropoxypyridin-5-yl)phenyl,    4-(2-methoxy-6-methylpyridin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-4-yl)-3-chlorophenyl,    4-(2,6-dimethylpyridin-5-yl)phenyl,    4-(2,6-dimethoxy-pyrimidin-5-yl)-3-chlorophenyl,    4-(4-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-chlorophenyl,    4-(4,6-dimethoxy-pyridin-3-yl)phenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(5-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(2,6-dimethoxy-pyridin-3-yl)-3-fluorophenyl,    4-(6-methoxy-pyridin-3-yl)-3-fluorophenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)-3-fluorophenyl,    dimethoxy-pyrimidin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-5-yl)-3-methoxyphenyl,    4-(3-methoxy-pyridin-4-yl)phenyl, 4-(4-methoxy-pyridin-3-yl)phenyl,    4-(2-methoxy-pyrimidin-3-yl)phenyl,    3-methoxy-2-(2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(5-cyano-2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(2,4-dimethoxyphenyl)pyridin-5-yl,    2-(2,4-dimethoxyphenyl)pyridin-5-yl,    1-(2-cyano-4-trifluoromethyl)piperidin-4-yl,    1-(2-nitro-4-trifluoromethyl)piperidin-4-yl,    1-(2-methoxy-4-trifluoromethyl)piperidin-4-yl;-   R³ is H, cyano, alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl,    arylsulfonyl;-   R^(3′) is H or C₁-C₄ alkyl;-   R⁴ is H, cyano, C₁-C₄ alkyl.

Preferred compounds of formula Ic-1b′ are those of formula Ic-1g:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are independently selected from H,    halo preferably fluoro, chloro, bromo, cyano, alkyl, hydroxyalkyl,    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl preferably    phenyl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, heterocyclyloxy, alkylamino,    alkoxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl,    aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, heterocyclylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, arylalkyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′)    form an alkylenedioxy group or a haloalkylenedioxy group together    with the phenyl group they are attached to, or one or more of R⁸ and    R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′) form    together a cycloalkyl, aryl, heterocycloalyl or heteroaryl moiety    fused to the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy, cycloalkyloxy, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, preferably R⁸, R^(8′), R⁹, R^(9′) and    R¹⁰ are independently selected from H, halo preferably fluoro,    chloro, bromo, cyano, alkyl, haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, aryl preferably phenyl, heteroaryl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, alkylamino, alkoxycarbonyl,    alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or one    or more of R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′)    and R^(8′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, more preferably R⁸, R^(8′), R⁹, R^(9′) and R¹⁰    are independently selected from H, halo preferably bromo, fluoro or    chloro, cyano, C₁-C₄ alkyl preferably methyl, aryl preferably    phenyl, alkoxy preferably methoxy, still more preferably R⁸, R^(8′),    R⁹, R^(9′) and R¹⁰ are independently selected from H, halo    preferably bromo, fluoro or chloro, alkyl preferably methyl, still    more preferably R⁸ is Br, Cl or F, preferably Cl and R^(8′), R⁹,    R^(9′) and R¹⁰ are independently selected from H or F, or R⁹ is Cl    or F and R⁸, R^(8′), R^(9′) and R¹⁰ are H, or R⁹ and R^(9′) are F    and R⁸, R^(8′) and R¹⁰ are H, or R¹⁰ is Cl or F and R⁸, R^(8′), R⁹    and R^(9′) are H, even more preferably R⁸ is Br, Cl or F and R^(8′),    R⁹, R^(9′) and R¹⁰ are H, or R⁸ and R⁹ are F and R^(8′), R^(9′) and    R¹⁰ are H, or R⁸ and R¹⁰ are F and R^(8′), R⁹ and R^(9′) are H;-   R¹⁰, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkyloxycarbonyl, aminoalkylalkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, aryl carbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, eye lo alkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, or one or more    of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form together a cycloalkyl, aryl, heterocycloalkyl or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl,    cyanomethyl, cycloalkyl, heterocyclyl, aryl optionally substituted    by one a chloro or methyl group, heteroaryl, cycloalkylalkyl,    aralkyl, heteroarylalkyl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkoxy, haloalkoxy preferably trifluoromethoxt,    1,1,1-trifluoroethyloxy, alkoxyalkyl, haloalkoxyalkyl,    cycloalkyloxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aryloxy, aralkyloxy optionally substituted by one fluoro, amino,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy    preferably carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, cyclo    alkylsulfonylamino, haloalkylsulfonylamino and oxo, preferably R¹¹,    R^(11′), R¹², R^(12′) and R¹⁶ are, independently selected from H,    halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, aryl carbonyl,    alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, or one or more of R¹¹ and R¹², or R¹² and    R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form an    alkylenedioxy group or a haloalkylenedioxy group together with the    phenyl group they are attached to, or one or more of R¹¹ and R¹², or    R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form    together an aryl or heteroaryl moiety fused to the phenyl group they    are attached to, each of said substituents being optionally    substituted by one or more further substituents selected from halo    preferably chloro or fluoro, cyano, alkyl, hydroxyalkyl,    alkoxyalkyl, haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, aryl    optionally substituted by one a chloro or methyl group, heteroaryl,    heteroalkyl, hydroxyl, alkoxy, alkoxyalkoxy, haloalkoxy preferably    1,1,1-trifluoroethyloxy, alkoxyalkyl, cycloalkyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy,    aralkyloxy optionally substituted by one fluoro, amino, alkylamino,    carboxy, alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy preferably    carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino and oxo, more preferably R¹¹, R^(11′), R¹²,    R^(12′) and R¹⁶ are independently selected from H, halo preferably    chloro and fluoro, cyano, nitro, alkyl, haloalkyl preferably CF₃ or    CHF₂, heterocyclyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,    hydroxyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    aryloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy,    alkoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl, or one    or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or    R^(12′) and R^(11′) form an alkylenedioxy group or a    haloalkylenedioxy group together with the phenyl group they are    attached to, or one or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶    and R^(12′), or R^(12′) and R^(11′) form together an aryl, or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, cyanomethyl, cycloalkyl, heterocyclyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro, amino, alkylamino, alkylcarbonylamino, carbamoyl,    hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino, still more    preferably R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently    selected from H, halo preferably chloro and fluoro, cyano, nitro,    alkyl preferably methyl, ethyl, isopropyl or isobutyl, haloalkyl    preferably CF₃ or CHF₂, cycloalkyl preferably cyclohexyl,    heterocyclyl preferably pyrrolidin-1-yl, 4-methylpiperidin-1-yl,    aryl preferably phenyl, heteroaryl preferably thiophenyl, pyridinyl,    pyrimidinyl, pyrazinyl, pyridazinyl, aralkyl preferably benzyl,    alkoxy preferably methoxy, ethoxy or isopropyloxy,    cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy, phenethyloxy    or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy preferably    pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl preferably    phenoxymethyl, heteroaryloxyalkyl preferably pyridyloxymethyl, or    two substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, cyano,    alkyl preferably methyl, haloalkyl preferably trifluoromethyl,    alkoxy preferably methoxy, isopropyloxy, isobutyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy    preferably phenoxy, aralkyloxy optionally substituted by one fluoro,    preferably benzyloxy, 4-fluorobenzyloxy, amino, alkylcarbonylamino    preferably acetylamino, alkylsulfonyl preferably methylsulfonyl,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino.

Preferred compounds of formula Ic-1g are those of formula Ic-1h1:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ic-1g;-   R¹² is as defined above in respect to formula Ic-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, nitro, cyano, methoxy or    cyclopropylmethyloxy;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are as defined above in respect    to formula Ic-1g, preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and    R¹³ is chloro, cyano, hydroxyl, methyl, trifluoromethyl,    cyanomethyl, methoxy, isopropoxy, isobutyloxy, OCF₃,    cyclopropylmethyloxy, phenoxy, cyclopropylmethyloxy, benzyloxy,    (4-fluorobenzyl)oxy, methoxymethyl, 2-methoxyethoxy,    carbamoylmethyloxy, or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴    is chloro, methylsulfonylamino, or R¹³, R^(13′), R¹⁴ and R^(14′) are    H and R¹⁵ is chloro, methylsulfonylamino, R^(13′), R¹⁴ and R^(14′)    are H and R¹³ and R¹⁵ are a) independently selected from chloro or    methoxy, or b) both F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³    is methoxy and R¹⁵ is F, or e) R¹³ is methoxy and R¹⁵ is    acetylamino, or f) R¹³ is methoxy and R¹⁵ is amino, or g) R¹³ is    cyano and R¹⁵ is methoxy, or h) R¹³ is chloro and R¹⁵ is cyano,    or i) R¹³ is cyano and R¹⁵ is trifluoromethyl, or j) R¹³ is methoxy    and R¹⁵ is (N-methyl-N-methylsulfonyl)amino, or R¹³, R^(13′) and R¹⁵    are H and both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R¹⁵    are H and both R¹⁴ and R^(14′) are fluoro, methoxy, or R¹³, R^(13′)    and R^(14′) are H and a) R¹⁴ forms together with R¹⁵ a phenyl moiety    fused to the phenyl ring they are attached to, or b) both R¹⁴ and    R¹⁵ are methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴    are a) both methoxy, or b) R¹³ is methyl and R¹⁴ is    methylsulfonylamino, or c) R¹³ is methoxy and R¹⁴ is cyano, or d)    R¹³ is methyl and R¹⁴ is amino, or R^(13′), R¹⁴ and R¹⁵ are H and    R¹³ and R^(14′) are a) both methoxy, or b) R¹³ is methoxy and    R^(14′) is cyano, or c) R¹³ is methyl and R^(14′) is cyano, or R¹³    and R¹⁴ are H and R^(13′), R^(14′) and R¹⁵ are methoxy, or R¹⁴ and    R¹⁵ are H and R¹³, R^(13′) and R^(14′) are methoxy, or R¹³ and R¹⁴    are methoxy and R^(13′) and R¹⁵ are H and R^(14′) is cyano, or R¹⁴    and R¹⁵ are methoxy and R¹³ and R^(14′) are H and R^(13′) is cyano,    or R¹³ and R^(13′) are H and R¹⁴, R^(14′) and R¹⁵ are methoxy, more    preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and R¹³ is chloro,    cyano, trifluoromethyl, methoxy, isopropoxy, cyclopropylmethyloxy,    or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴ is chloro, or R¹³,    R^(13′), R¹⁴ and R^(14′) are H and R¹⁵ is chloro,    methylsulfonylamino, or R^(13′), R¹⁴ and R^(14′) are H and R¹³ and    R¹⁵ are a) independently selected from chloro or methoxy, or b) both    F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³ is methoxy and R¹⁵    is F, or e) R¹³ is methoxy and R¹⁵ is acetylamino, or f) R¹³ is    methoxy and R¹⁵ is amino, or g) R¹³ is cyano and R¹⁵ is methoxy,    or h) R¹³ is chloro and R¹⁵ is cyano, or i) R¹³ is cyano and R¹⁵ is    trifluoromethyl, or j) R¹³ is methoxy and R¹⁵ is    (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵ are H and    both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R^(14′) are H    and a) R¹⁴ forms together with R¹⁵ a phenyl moiety fused to the    phenyl ring they are attached to, or b) both R¹⁴ and R¹⁵ are    methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴ are a)    both methoxy, or b) R¹³ is methyl and R¹⁴ is methylsulfonylamino,    or c) R¹³ is methoxy and R¹⁴ is cyano, or d) R¹³ is methyl and R¹⁴    is amino, or R^(13′), R¹⁴ and R¹⁵ are H and R¹³ and R^(14′) are a)    both methoxy, or h) R¹³ is methoxy and R^(14′) is cyano, or c) R¹³    is methyl and R^(14′) is cyano, or R¹³ and R¹⁴ are H and R^(13′),    R^(14′) and R¹⁵ are methoxy, or R¹⁴ and R¹⁵ are H and R¹³, R^(13′)    and R^(14′) are methoxy, or R¹³ and R¹⁴ are methoxy and R^(13′) and    R¹⁵ are H and R^(14′) is cyano, or R¹⁴ and R¹⁵ are methoxy and R¹³    and R^(14′) are H and R^(13′) is cyano, or R¹³ and R^(13′) are H and    R¹⁴, R^(14′) and R¹⁵ are methoxy.

Other preferred compounds of formula Ic-1g are those of formula Ic-1h′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ic-1g;-   R¹² is as defined above in respect to formula Ic-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, or methoxy more preferably R¹² is    H or methoxy;-   R¹⁶ is selected from the group of heteroaryl moieties consisting of:

wherein

-   the arrow marks the attachment point to the phenyl ring;-   R¹⁷, R^(17′), R¹⁸, R^(18′) and R¹⁹ are independently selected from    H, halo preferably chloro and fluoro, cyano, alkyl preferably    methyl, ethyl, propyl, isopropyl, tert-butyl, haloalkyl preferably    CF₃ or CHF₂, hydroxyl, hydroxyalkyl, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl    preferably methoxymethyl, cycloalkylalkyloxy preferably    cyclopropylmethyloxy, aralkyloxy preferably benzyloxy,    haloalkoxyalkyl, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl,    alkylsulfonyl preferably methylsulfonyl, haloalkylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino,    haloalkylsulfonylamino, preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are    independently selected from H, halo preferably chloro and fluoro,    cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkyl preferably methoxymethyl,    aralkyloxy preferably benzyloxy, amino, alkylcarbonylamino,    carbamoyl, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, more    preferably R¹⁷, R^(17′), R^(18′), and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy, even more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy;

Preferred compounds of formula Ic-1h′ are those wherein R¹⁶ is selectedfrom 2-2-methoxypyrimidin-4-yl, 2,4-dibenzyloxypyrimidin-5-yl,2,4-dimethoxypyrimidin-5-yl, 3,6-dimethoxypyridazin-5-yl,2-methoxypyrimidin-5-yl, 2-methoxypyrimidin-3-yl.

In yet another embodiment, preferred compounds of Formula I are those offormula Id:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   Ar¹, Ar², L¹, L², L³, R¹, R², R³, R^(3′), R⁴, R^(4′), D, E and Z are    as defined above in respect of formula I; and-   the bond represented by the dotted line is either absent or present.

Preferred compounds of formula Id and pharmaceutically acceptable salts,solvates and prodrugs thereof are those wherein the dotted line isabsent.

Other preferred compounds of formula Id are those of formula Id-1b′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R² is as defined above in respect of formula Id and R is as defined    above in respect of formula I;-   R¹ is H;-   D is C═O;-   L² is single bond;-   Ar¹ is a 5- to 6-membered aryl or heteroaryl group, 3- to 6-membered    cycloalkyl group, or a linear or branched C₃-C₆ alkyl group, each of    which being optionally substituted by one or more group(s) selected    from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl,    hydroxyl, alkoxy, haloalkoxy, amino, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, or two substituents form an alkylenedioxy    group or a haloalkylenedioxy group, each of said aryl or heteroaryl    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, preferably Ar¹ is a 5- to 6-membered aryl    preferably phenyl, 5- to 6-membered heteroaryl group preferably    pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl, isopropyl,    isobutyl or isopentyl each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    alkoxy preferably methoxy, aryl preferably phenyl, still more    preferably Ar¹ is aryl preferably phenyl, cyclohexyl, isobutyl or    isopentyl, said phenyl group being optionally substituted by one or    more halo group preferably bromo, chloro or fluoro, cyano, methyl,    phenyl or methoxy, further more preferably Ar¹ is phenyl,    cyclohexyl, isobutyl, 2-chlorophenyl, 2-tolyl, 2-methoxyphenyl,    3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,    4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2-cyanophenyl,    3,5-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, 1,1′-biphenyl-2-yl, 4-cyanophenyl, even more    preferably Ar¹ is isobutyl, cyclohexyl, phenyl, 2-chlorophenyl,    2-tolyl, 2-methoxyphenyl, 3-chlorophenyl, 4-chlorophenyl,    2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, still even more preferably Ar¹ is isobutyl,    2-chlorophenyl, 2-tolyl, 2-methoxyphenyl, 2-fluorophenyl,    2,4-difluorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl;-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo, cyano, nitro, alkyl, haloalkyl,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl, aralkyl, heteroaryl, benzoxazol-2-yl    heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy,    alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy,    aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, amino,    alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl,    heteroaryloxycarbonyl, alkylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,    alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl,    alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, oxo,    or two substituents form an alkylenedioxy group or a    haloalkylenedioxy group, or fused to the aryl, heteroaryl,    cycloalkyl or heterocyclyl group may be one or more aryl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, heteroaryl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by a    fluoro or alkyl or cycloalkyl group, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, oxo, alkoxyalkoxy, alkoxyalkyl, and    haloalkoxyalkyl; preferably Ar² is an aryl or heteroaryl preferably    pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl group,    each of each of said aryl, heteroaryl, cycloalkyl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl,    haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl, aralkyl,    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy preferably    OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy, alkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, cycloalkylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, arylcarbonyl, or two substituents form an    alkylenedioxy group or a haloalkylenedioxy group, or fused to the    cycloalkyl or heterocycloalkyl group may be one aryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro or alkyl or cycloalkyl, amino, alkylcarbonylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino,    still more preferably Ar² is an aryl preferably phenyl, heteroaryl    preferably pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl    group preferably isobutyl, each of said aryl, heteroaryl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, preferably methyl, heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, aryl preferably phenyl,    heteroaryl preferably pyridinyl, pyrimidinyl, pyrazinyl,    pyridazinyl, alkoxy preferably methoxy, ethoxy or isopropyloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy,    phenethyloxy or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy    preferably pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl    preferably phenoxymethyl, heteroaryloxyalkyl preferably    pyridinyloxymethyl, arylcarbonyl preferably phenylacetyl, or two    substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, nitro, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted by one    fluoro, preferably benzyloxy or 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonylalkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, further more preferably Ar² is a    biaryl consisting of two 6-membered aryl moieties preferably    biphenyl, more preferably a biphenyl linked to L² at position 4′ and    monosubstituted at position 2, or Ar² is a heterobiaryl consisting    of one 6-membered aryl moiety and one 6-membered heteroaryl moiety    or two 6-membered heteroaryl moieties, said heterobiaryl being    linked to L² either on the aryl or on the heteroaryl moiety and    being preferably phenylpyridyl, pyrimidinylphenyl,    pyridazinylphenyl, pyrazinylphenyl, or Ar² is an aryl or heteroaryl    optionally substituted by one group selected from arylalkyloxy,    aryloxyalkyl, arylcarbonyl, each of said biaryl, heterobiaryl, aryl    and heteroaryl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, cyano,    nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy, aryloxy preferably phenoxy, aralkyloxy    optionally substituted by one fluoro preferably benzyloxy or    4-fluorobenzyloxy, amino, alkylcarbonylamino preferably acetylamino,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, or Ar² is a piperidinyl ring    linked to L² at position 4 and N substituted with a phenyl,    4-(4-chlorophenyl)thiazol-2-yl or benzoxazol-2-yl moiety, said    phenyl moiety being further substituted by one or more substituents    selected from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, haloalkyl preferably CF₃, alkoxy preferably    methoxy, heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    methylsulfonylamino, diethylaminosulfonyl, even more preferably Ar²    is 4′-(2-methoxy-1,1′-biphenyl), 4′-(2-methyl-1,1′-biphenyl),    4′-(2-fluoro-1,1′-biphenyl), 4′-(4-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl), 4′-(2-chloro-2′-methoxy-1,1′-biphenyl),    4′-(2-(2-methoxyethoxy)-1,1′-biphenyl),    4′-(2-(methoxymethyl)-1,1′-biphenyl), 4′-(4-methoxy-1,1′-biphenyl),    4′-(4-cyano-1,1′-biphenyl), 4′-(3-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl),    4′-(4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-trifluoromethoxy-1,1′-biphenyl),    4′-(2-isopropoxy-1,1′-biphenyl),    4′-(2-cyclopropylmethyloxy-1,1′-biphenyl),    4′-(2-cyano-1,1′-biphenyl), 4′-(2,6-dimethoxy-1,1′-biphenyl),    4′-(2,4-dichloro-1,1′-biphenyl),    4′-(2-trifluoromethyl-1,1′-biphenyl),    4′-(2-methoxy-4-chloro-1,1′-biphenyl),    4′-(2,4-dimethoxy-1,1′-biphenyl), 4-(2,2′-dimethoxy-1,1′-biphenyl),    4-(naphtalen-2-yl)phenyl, 5-(2-phenyl)pyridyl, 4-cyclohexylphenyl,    4-benzylphenyl, 4-(3-thienyl)phenyl, 4-(pyridin-3-yl)phenyl,    4-(2-methoxypyridin-3-yl)phenyl, dimethoxy-pyridin-3-yl)phenyl,    4-(2-(2-methoxyethoxy)-pyridin-3-yl)phenyl,    4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-5-yl)phenyl,    4-(2-methoxypyrimidin-5-yl)-3-methoxyphenyl,    4-(2,4-dimethoxypyrimidin-6-yl)phenyl,    4-(2,4-dimethoxypyrimidin-5-yl)phenyl, (4-benzyloxy)phenyl,    4-phenoxyphenyl, (3-phenethyloxy)phenyl, (4-phenethyloxy)phenyl,    (4-phenoxymethyl)phenyl, optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, more    preferably fluoro, alkyl preferably methyl, alkoxy preferably    methoxy, or Ar² is 4′-(2,4-difluoro-1,1′-biphenyl),    4′-(3′-methyl-1,1′-biphenyl), 4′-(3′-fluoro-1,1′-biphenyl),    4′-(2-fluoro-4-methoxy-1,1′-biphenyl),    4′-(4-fluoro-2-methoxy-1,1′-biphenyl),    4′-(2,3-dimethoxy-1,1′-biphenyl), 4′-(3,4-dimethoxy-1,1′-biphenyl),    4′-(2,3,4-trimethoxy-1,1′-biphenyl),    4′-(2,3,6-trimethoxy-1,1′-biphenyl),    4′-(3,5-dimethoxy-1,1′-biphenyl), 4′-(2,5-dimethoxy-1,1′-biphenyl),    4′-(2-isopropyl-1,1′-biphenyl), 4′-(2,2′-dimethoxy-1,1′-biphenyl),    4′-(2′-fluoro,2-dimethoxy-1,1′-biphenyl),    4′-(2-ethyl-1,1′-biphenyl), 4′-(4-propyl-1,1′-biphenyl),    4′-(4-tert-butyl-1,1′-biphenyl),    4′-(2-methoxy-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methoxy-4-acetylamino-1,1′-biphenyl),    4′-(3-hydroxycarbamimidoyl-1,1′-biphenyl),    4′-(4-amino-2-methoxy-1,1′-biphenyl),    4′-(3-carbamoyl-1,1′-biphenyl),    4′-(5-cyano-2,3-dimethoxy-1,1′-biphenyl),    4′-(2-cyano-4,5-dimethoxy-1,1′-biphenyl),    4′-(3,4,5-trimethoxy-1,1′-biphenyl),    4′-(2-cyanomethyl-4,5-dimethoxy-1,1′-biphenyl),    4′-(2-fluoro-5-cyano-1,1′-biphenyl),    4′-(2′-fluoro-3,4-dimethoxy-1,1′-biphenyl),    4′-(3-carbamoyl-4-cyano-1,1′-biphenyl),    4′-(2-cyano-4-methoxy-1,1′-biphenyl),    4′-(2′-fluoro-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2′-fluoro-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-cyano-2′-fluoro-1,1′-biphenyl),    4′-(2-chloro-5-cyano-1,1′-biphenyl),    4′-(2-cyano-4-trifluoromethyl-1,1′-biphenyl),    4′-(2-methyl-3-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(2-methyl-4-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(4-methylsulfonyl-1,1′-biphenyl),    4′-(3-methylsulfonylamino-1,1′-biphenyl),    4′-(4-amino-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methoxy-1,1′-biphenyl), 4′-(3-cyano-1,1′-biphenyl),    4′-(2-cyano-3-methoxy-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methyl-3-acetylamino-1,1′-biphenyl),    4-(2-chloro-6-methoxypyrimidin-5-yl)phenyl,    4-(2-ethoxypyridin-5-yl)phenyl, 4-(2-isopropoxypyridin-5-yl)phenyl,    4-(2-methoxy-6-methylpyridin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-4-yl)-3-chlorophenyl,    4-(2,6-dimethylpyridin-5-yl)phenyl,    4-(2,6-dimethoxy-pyrimidin-5-yl)-3-chlorophenyl,    4-(4-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-chlorophenyl,    4-(4,6-dimethoxy-pyridin-3-yl)phenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(5-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(2,6-dimethoxy-pyridin-3-yl)-3-fluorophenyl,    4-(6-methoxy-pyridin-3-yl)-3-fluorophenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)-3-fluorophenyl,    dimethoxy-pyrimidin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-5-yl)-3-methoxyphenyl,    4-(3-methoxy-pyridin-4-yl)phenyl, 4-(4-methoxy-pyridin-3-yl)phenyl,    4-(2-methoxy-pyrimidin-3-yl)phenyl,    3-methoxy-2-(2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(5-cyano-2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(2,4-dimethoxyphenyl)pyridin-5-yl,    2-(2,4-dimethoxyphenyl)pyridin-5-yl,    1-(2-cyano-4-trifluoromethyl)piperidin-4-yl,    1-(2-nitro-4-trifluoromethyl)piperidin-4-yl,    1-(2-methoxy-4-trifluoromethyl)piperidin-4-yl;-   R³ is H, cyano, alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl,    arylsulfonyl;-   R^(3′) is H or C₁-C₄ alkyl;-   R⁴ is H, cyano, C₁-C₄ alkyl.

Preferred compounds of formula Id-1b′ are those of formula Id-1g:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are independently selected from H,    halo preferably fluoro, chloro, bromo, cyano, alkyl, hydroxyalkyl,    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl preferably    phenyl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, heterocyclyloxy, alkylamino,    alkoxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl,    aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, heterocyclylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, arylalkyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′)    form an alkylenedioxy group or a haloalkylenedioxy group together    with the phenyl group they are attached to, or one or more of R⁸ and    R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′) form    together a cycloalkyl, aryl, heterocycloalyl or heteroaryl moiety    fused to the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy, cycloalkyloxy, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, preferably R⁸, R^(8′), R⁹, R^(9′) and    R¹⁰ are independently selected from H, halo preferably fluoro,    chloro, bromo, cyano, alkyl, haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, aryl preferably phenyl, heteroaryl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, alkylamino, alkoxycarbonyl,    alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or one    or more of R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′)    and R^(8′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, more preferably R⁸, R^(8′), R⁹, R^(9′) and R¹⁰    are independently selected from H, halo preferably bromo, fluoro or    chloro, cyano, C₁-C₄ alkyl preferably methyl, aryl preferably    phenyl, alkoxy preferably methoxy, still more preferably R⁸, R^(8′),    R⁹, R^(9′) and R¹⁰ are independently selected from H, halo    preferably bromo, fluoro or chloro, alkyl preferably methyl, still    more preferably R⁸ is Br, Cl or F, preferably Cl and R^(8′), R⁹,    R^(9,) and R¹⁰ are independently selected from H or F, or R⁹ is Cl    or F and R⁸, R^(8′), R^(9′) and R¹⁰ are H, or R⁹ and R^(9′) are F    and R⁸, R^(8′) and R¹⁰ are H, or R¹⁰ is Cl or F and R⁸, R^(8′), R⁹    and R^(9′) are H, even more preferably R⁸ is Br, Cl or F and R^(8′),    R⁹, R^(9′) and R¹⁰ are H, or R⁸ and R⁹ are F and R^(8′), R^(9′) and    R¹⁰ are H, or R⁸ and R¹⁰ are F and R^(8′), R⁹ and R^(9′) are H;    R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cyclo alkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkyloxycarbonyl, aminoalkylalkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, or one or more    of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form together a cycloalkyl, aryl, heterocycloalkyl or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl,    cyanomethyl, cycloalkyl, heterocyclyl, aryl optionally substituted    by one a chloro or methyl group, heteroaryl, cycloalkylalkyl,    aralkyl, heteroarylalkyl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkoxy, haloalkoxy preferably trifluoromethoxt,    1,1,1-trifluoroethyloxy, alkoxyalkyl, haloalkoxyalkyl,    cycloalkyloxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aryloxy, aralkyloxy optionally substituted by one fluoro, amino,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy    preferably carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino and oxo, preferably    R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, or one or more of R¹¹ and R¹², or R¹² and    R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form an    alkylenedioxy group or a haloalkylenedioxy group together with the    phenyl group they are attached to, or one or more of R¹¹ and R¹², or    R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form    together an aryl or heteroaryl moiety fused to the phenyl group they    are attached to, each of said substituents being optionally    substituted by one or more further substituents selected from halo    preferably chloro or fluoro, cyano, alkyl, hydroxyalkyl,    alkoxyalkyl, haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, aryl    optionally substituted by one a chloro or methyl group, heteroaryl,    heteroalkyl, hydroxyl, alkoxy, alkoxyalkoxy, haloalkoxy preferably    1,1,1-trifluoroethyloxy, alkoxyalkyl, cycloalkyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy,    aralkyloxy optionally substituted by one fluoro, amino, alkylamino,    carboxy, alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino , carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy preferably    carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino and oxo, more preferably R¹¹, R^(11′), R¹²,    R^(12′) and R¹⁶ are independently selected from H, halo preferably    chloro and fluoro, cyano, nitro, alkyl, haloalkyl preferably CF₃ or    CHF₂, heterocyclyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,    hydroxyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    aryloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy,    alkoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl, or one    or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or    R^(12′) and R^(11′) form an alkylenedioxy group or a    haloalkylenedioxy group together with the phenyl group they are    attached to, or one or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶    and R^(12′), or R^(12′) and R^(11′) form together an aryl, or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, cyanomethyl, cycloalkyl, heterocyclyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro, amino, alkylamino, alkylcarbonylamino, carbamoyl,    hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino, still more    preferably R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently    selected from H, halo preferably chloro and fluoro, cyano, nitro,    alkyl preferably methyl, ethyl, isopropyl or isobutyl, haloalkyl    preferably CF₃ or CHF₂, cycloalkyl preferably cyclohexyl,    heterocyclyl preferably pyrrolidin-1-yl, 4-methylpiperidin-1-yl,    aryl preferably phenyl, heteroaryl preferably thiophenyl, pyridinyl,    pyrimidinyl, pyrazinyl, pyridazinyl, aralkyl preferably benzyl,    alkoxy preferably methoxy, ethoxy or isopropyloxy,    cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy, phenethyloxy    or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy preferably    pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl preferably    phenoxymethyl, heteroaryloxyalkyl preferably pyridyloxymethyl, or    two substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, cyano,    alkyl preferably methyl, haloalkyl preferably trifluoromethyl,    alkoxy preferably methoxy, isopropyloxy, isobutyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy    preferably phenoxy, aralkyloxy optionally substituted by one fluoro,    preferably benzyloxy, 4-fluorobenzyloxy, amino, alkylcarbonylamino    preferably acetylamino, alkylsulfonyl preferably methylsulfonyl,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino.

Preferred compounds of formula Id-1g are those of formula Id-1h1:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Id-1g;-   R¹² is as defined above in respect to formula Id-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, nitro, cyano, methoxy or    cyclopropylmethyloxy;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are as defined above in respect    to formula Id-1g, preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and    R¹³ is chloro, cyano, hydroxyl, methyl, trifluoromethyl,    cyanomethyl, methoxy, isopropoxy, isobutyloxy, OCF₃,    cyclopropylmethyloxy, phenoxy, cyclopropylmethyloxy, benzyloxy,    (4-fluorobenzyl)oxy, methoxymethyl, 2-methoxyethoxy,    carbamoylmethyloxy, or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴    is chloro, methylsulfonylamino, or R¹³, R^(13′), R¹⁴ and R^(14′) are    H and R¹⁵ is chloro, methylsulfonylamino, R^(13′), R¹⁴ and R^(14′)    are H and R¹³ and R¹⁵ are a) independently selected from chloro or    methoxy, or b) both F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³    is methoxy and R¹⁵ is F, or e) R¹³ is methoxy and R¹⁵ is    acetylamino, or f) R¹³ is methoxy and R¹⁵ is amino, or g) R¹³ is    cyano and R¹⁵ is methoxy, or h) R¹³ is chloro and R¹⁵ is cyano,    or i) R¹³ is cyano and R¹⁵ is trifluoromethyl, or j) R¹³ is methoxy    and R¹⁵ is (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵    are H and both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R¹⁵    are H and both R¹⁴ and R^(14′) are fluoro, methoxy, or R¹³, R^(13′)    and R^(14′) are H and a) R¹⁴ forms together with R¹⁵ a phenyl moiety    fused to the phenyl ring they are attached to, or b) both R¹⁴ and    R¹⁵ are methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴    are a) both methoxy, or b) R¹³ is methyl and R¹⁴ is    methylsulfonylamino, or c) R¹³ is methoxy and R¹⁴ is cyano, or d)    R¹³ is methyl and R¹⁴ is amino, or R^(13′), R¹⁴ and R¹⁵ are H and    R¹³ and R^(14′) are a) both methoxy, or b) R¹³ is methoxy and    R^(14′) is cyano, or c) R¹³ is methyl and R^(14′) is cyano, or R¹³    and R¹⁴ are H and R^(13′), R^(14′) and R¹⁵ are methoxy, or R¹⁴ and    R¹⁵ are H and R¹³, R^(13′) and R^(14′) are methoxy, or R¹³ and R¹⁴    are methoxy and R^(13′) and R¹⁵ are H and R^(14′) is cyano, or R¹⁴    and R¹⁵ are methoxy and R¹³ and R^(14′) are H and R^(13′) is cyano,    or R¹³ and R^(13′) are H and R¹⁴, R^(14′) and R¹⁵ are methoxy, more    preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and R¹³ is chloro,    cyano, trifluoromethyl, methoxy, isopropoxy, cyclopropylmethyloxy,    or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴ is chloro, or R¹³,    R^(13′), R¹⁴ and R^(14′) are H and R¹⁵ is chloro,    methylsulfonylamino, or R^(13′), R¹⁴ and R^(14′) are H and R¹³ and    R¹⁵ are a) independently selected from chloro or methoxy, or b) both    F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³ is methoxy and R¹⁵    is F, or e) R¹³ is methoxy and R¹⁵ is acetylamino, or f) R¹³ is    methoxy and R¹⁵ is amino, or g) R¹³ is cyano and R¹⁵ is methoxy,    or h) R¹³ is chloro and R¹⁵ is cyano, or i) R¹³ is cyano and R¹⁵ is    trifluoromethyl, or j) R¹³ is methoxy and R¹⁵ is    (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵ are H and    both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R^(14′) are H    and a) R¹⁴ forms together with R¹⁵ a phenyl moiety fused to the    phenyl ring they are attached to, or b) both R¹⁴ and R¹⁵ are    methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴ are a)    both methoxy, or b) R¹³ is methyl and R¹⁴ is methylsulfonylamino,    or c) R¹³ is methoxy and R¹⁴ is cyano, or d) R¹³ is methyl and R¹⁴    is amino, or R^(13′), R¹⁴ and R¹⁵ are H and R¹³ and R^(14′) are a)    both methoxy, or b) R¹³ is methoxy and R^(14′) is cyano, or c) R¹³    is methyl and R^(14′) is cyano, or R¹³ and R¹⁴ are H and R^(13′),    R^(14′) and R¹⁵ are methoxy, or R¹⁴ and R¹⁵ are H and R¹³, R^(13′)    and R^(14′) are methoxy, or R¹³ and R¹⁴ are methoxy and R^(13′) and    R¹⁵ are H and R^(14′) is cyano, or R¹⁴ and R¹⁵ are methoxy and R¹³    and R^(14′) are H and R^(13′) is cyano, or R¹³ and R^(13′) are H and    R¹⁴, R^(14′) and R¹⁵ are methoxy.

Other preferred compounds of formula Id-1g are those of formula Id-1h′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Id-1g;-   R¹² is as defined above in respect to formula Id-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, or methoxy more preferably R¹² is    H or methoxy;-   R¹⁶ is selected from the group of heteroaryl moieties consisting of:

wherein

-   the arrow marks the attachment point to the phenyl ring;-   R¹⁷, R^(17′), R¹⁸, R^(18′) and R¹⁹ are independently selected from    H, halo preferably chloro and fluoro, cyano, alkyl preferably    methyl, ethyl, propyl, isopropyl, tert-butyl, haloalkyl preferably    CF₃ or CHF₂, hydroxyl, hydroxyalkyl, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl    preferably methoxymethyl, cycloalkylalkyloxy preferably    cyclopropylmethyloxy, aralkyloxy preferably benzyloxy,    haloalkoxyalkyl, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl,    alkylsulfonyl preferably methylsulfonyl, haloalkylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino,    haloalkylsulfonylamino, preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are    independently selected from H, halo preferably chloro and fluoro,    cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkyl preferably methoxymethyl,    aralkyloxy preferably benzyloxy, amino, alkylcarbonylamino,    carbamoyl, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, more    preferably R¹⁷, R^(17′), R^(18′), and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy, even more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy;

Preferred compounds of formula Id-1h′ are those wherein R¹⁶ is selectedfrom 2-2-methoxypyrimidin-4-yl, 2,4-dibenzyloxypyrimidin-5-yl,2,4-dimethoxypyrimidin-5-yl, 3,6-dimethoxypyridazin-5-yl,2-methoxypyrimidin-5-yl, 2-methoxypyrimidin-3-yl.

In yet another embodiment, preferred compounds of Formula I are those offormula Ie:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   A¹, Ar², L¹, L², L³, R¹, R², R³, R^(3′), R⁴, R^(4′), D, E and Z are    as defined above in respect of formula I; and-   the bond represented by the dotted line is either absent or present.

Preferred compounds of formula Ie and pharmaceutically acceptable salts,solvates and prodrugs thereof are those wherein the dotted line isabsent.

Other preferred compounds of formula Ie are those of formula Ie-1b′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R² is as defined above in respect of formula Ie and R is as defined    above in respect of formula I;-   R¹ is H;-   D is C═O;-   L² is single bond;-   Ar¹ is a 5- to 6-membered aryl or heteroaryl group, 3- to 6-membered    cycloalkyl group, or a linear or branched C₃-C₆ alkyl group, each of    which being optionally substituted by one or more group(s) selected    from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl,    hydroxyl, alkoxy, haloalkoxy, amino, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,    haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, or two substituents form an alkylenedioxy    group or a haloalkylenedioxy group, each of said aryl or heteroaryl    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, preferably Ar¹ is a 5- to 6-membered aryl    preferably phenyl, 5- to 6-membered heteroaryl group preferably    pyridin-2-yl, pyridin-3-yl, cyclohexyl, cyclopentyl, isopropyl,    isobutyl or isopentyl each of said phenyl, pyridin-2-yl,    pyridin-3-yl, cyclohexyl or cyclopentyl group being optionally    substituted by one or more group(s) selected from halo preferably    bromo, chloro or fluoro, cyano, C₁-C₄ alkyl preferably methyl, C₁-C₄    alkoxy preferably methoxy, aryl preferably phenyl, still more    preferably Ar¹ is aryl preferably phenyl, cyclohexyl, isobutyl or    isopentyl, said phenyl group being optionally substituted by one or    more halo group preferably bromo, chloro or fluoro, cyano, methyl,    phenyl or methoxy, further more preferably Ar¹ is phenyl,    cyclohexyl, isobutyl, 2-chlorophenyl, 2-tolyl, 2-methoxyphenyl,    3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl,    4-fluorophenyl, 2,6-difluorophenyl, 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2-cyanophenyl,    3,5-difluorophenyl, 3,4-difluorophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, 1,1′-biphenyl-2-yl, 4-cyanophenyl, even more    preferably Ar¹ is isobutyl, cyclohexyl, phenyl, 2-chlorophenyl,    2-tolyl, 2-methoxyphenyl, 3-chlorophenyl, 4-chlorophenyl,    2-fluorophenyl, 3-fluorophenyl, 4-fluoropheny 2,4-difluorophenyl,    2,4-dichlorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl, still even more preferably Ar¹ is isobutyl,    2-chlorophenyl, 2-tolyl, 2-methoxyphenyl, 2-fluorophenyl,    2,4-difluorophenyl, 2-bromophenyl, 2,3-difluorophenyl,    2,5-difluorophenyl;-   Ar² is an aryl or heteroaryl, cycloalkyl, heterocyclyl or C₂-C₆    alkyl group, each of which being optionally substituted by one or    more group(s) selected from halo, cyano, nitro, alkyl, haloalkyl,    cycloalkyl, cycloalkylalkyl, heteroalkyl, heterocyclyl,    heterocyclylalkyl, aryl, aralkyl, heteroaryl, benzoxazol-2-yl    heteroarylalkyl, hydroxyl, hydroxyalkyl, alkoxy, haloalkoxy,    alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy, heterocyclyloxy,    aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, amino,    alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl,    heteroaryloxycarbonyl, alkylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,    alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl,    alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, oxo,    or two substituents form an alkylenedioxy group or a    haloalkylenedioxy group, or fused to the aryl, heteroaryl,    cycloalkyl or heterocyclyl group may be one or more aryl or    heteroaryl moiety, each of said substituents being optionally    substituted by one or more further substituents selected from halo,    cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl,    cycloalkyl, heterocyclyl, aryl optionally substituted by a chloro or    methyl group, heteroaryl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by a    fluoro or alkyl or cycloalkyl group, carboxy, alkoxycarbonyl,    alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,    arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino, oxo, alkoxyalkoxy, alkoxyalkyl, and    haloalkoxyalkyl; preferably Ar² is an aryl or heteroaryl preferably    pyridyl, pyrazinyl, cycloalkyl, heterocyclyl or C₂-C₆ alkyl group,    each of each of said aryl, heteroaryl, cycloalkyl and heterocyclyl    groups being optionally substituted by one or more group(s) selected    from halo preferably chloro and fluoro, cyano, nitro, alkyl,    haloalkyl preferably CF₃ or CHF₂, heterocyclyl, aryl, aralkyl,    heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy preferably    OCF₃ or OCHF₂, alkoxyalkoxy, aryloxy, alkoxyalkyl, arylalkyloxy,    heteroarylalkyloxy, cycloalkylalkyloxy, aryloxyalkyl,    heteroaryloxyalkyl, arylcarbonyl, or two substituents form an    alkylenedioxy group or a haloalkylenedioxy group, or fused to the    cycloalkyl or heterocycloalkyl group may be one aryl moiety, each of    said substituents being optionally substituted by one or more    further substituents selected from halo preferably chloro or fluoro,    cyano, nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, cyanomethyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro or alkyl or cycloalkyl, amino, alkylcarbonylamino,    carbamoyl, hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino,    still more preferably Ar² is an aryl preferably phenyl, heteroaryl    preferably pyridyl, heterocyclyl preferably piperidinyl, C₂-C₆ alkyl    group preferably isobutyl, each of said aryl, heteroaryl and    heterocyclyl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro and fluoro, cyano,    nitro, alkyl, preferably methyl, heterocyclyl preferably    pyrrolidin-1-yl, 4-methylpiperidin-1-yl, aryl preferably phenyl,    heteroaryl preferably pyridinyl, pyrimidinyl, pyrazinyl,    pyridazinyl, alkoxy preferably methoxy, ethoxy or isopropyloxy,    alkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy,    phenethyloxy or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy    preferably pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl    preferably phenoxymethyl, heteroaryloxyalkyl preferably    pyridinyloxymethyl, arylcarbonyl preferably phenylacetyl, or two    substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, more    preferably fluoro, cyano, nitro, alkyl preferably methyl,    cycloalkyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    aryloxy preferably phenoxy, aralkyloxy optionally substituted by one    fluoro, preferably benzyloxy or 4-fluorobenzyloxy, amino,    alkylcarbonylamino preferably acetylamino, alkylsulfonyl preferably    methylsulfonylalkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, further more preferably Ar² is a    biaryl consisting of two 6-membered aryl moieties preferably    biphenyl, more preferably a biphenyl linked to L² at position 4′ and    monosubstituted at position 2, or Ar² is a heterobiaryl consisting    of one 6-membered aryl moiety and one 6-membered heteroaryl moiety    or two 6-membered heteroaryl moieties, said heterobiaryl being    linked to L² either on the aryl or on the heteroaryl moiety and    being preferably phenylpyridyl, pyrimidinylphenyl,    pyridazinylphenyl, pyrazinylphenyl, or Ar² is an aryl or heteroaryl    optionally substituted by one group selected from arylalkyloxy,    aryloxyalkyl, arylcarbonyl, each of said biaryl, heterobiaryl, aryl    and heteroaryl groups being optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, cyano,    nitro, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, alkoxy preferably methoxy, isopropyloxy, isobutyloxy,    cycloalkylalkyloxy, aryloxy preferably phenoxy, aralkyloxy    optionally substituted by one fluoro preferably benzyloxy or    4-fluorobenzyloxy, amino, alkylcarbonylamino preferably acetylamino,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino, or Ar² is a piperidinyl ring    linked to L² at position 4 and N substituted with a phenyl,    4-(4-chlorophenyl)thiazol-2-yl or benzoxazol-2-yl moiety, said    phenyl moiety being further substituted by one or more substituents    selected from halo preferably chloro and fluoro, cyano, nitro, alkyl    preferably methyl, haloalkyl preferably CF₃, alkoxy preferably    methoxy, heterocyclylsulfonyl preferably (piperidin-1-yl)sulfonyl,    (morpholin-4-yl)sulfonyl, alksulfamoyl preferably    methylsulfonylamino, diethylaminosulfonyl, even more preferably Ar²    is 4′-(2-methoxy-1,1′-biphenyl), 4′-(2-methyl-1,1′-biphenyl),    4′-(2-fluoro-1,1′-biphenyl), 4′-(4-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl), 4′-(2-chloro-2′-methoxy-1,1′-biphenyl),    4′-(2-(2-methoxyethoxy)-1,1′-biphenyl),    4′-(2-(methoxymethyl)-1,1′-biphenyl), 4′-(4-methoxy-1,1′-biphenyl),    4′-(4-cyano-1,1′-biphenyl), 4′-(3-chloro-1,1′-biphenyl),    4′-(2-chloro-1,1′-biphenyl),    4′-(4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-trifluoromethoxy-1,1′-biphenyl),    4′-(2-isopropoxy-1,1′-biphenyl),    4′-(2-cyclopropylmethyloxy-1,1′-biphenyl),    4′-(2-cyano-1,1′-biphenyl), 4′-(2,6-dimethoxy-1,1′-biphenyl),    4′-(2,4-dichloro-1,1′-biphenyl),    4′-(2-trifluoromethyl-1,1′-biphenyl),    4′-(2-methoxy-4-chloro-1,1′-biphenyl),    4′-(2,4-dimethoxy-1,1′-biphenyl), 4-(2,2′-dimethoxy-1,1′-biphenyl),    4-(naphtalen-2-yl)phenyl, 5-(2-phenyl)pyridyl, 4-cyclohexylphenyl,    4-benzylphenyl, 4-(3-thienyl)phenyl, 4-(pyridin-3-yl)phenyl,    4-(2-methoxypyridin-3-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(2-(2-methoxyethoxy)-pyridin-3-yl)phenyl,    4-(pyrimidin-2-yl)phenyl, 4-(pyrimidin-5-yl)phenyl,    4-(2-methoxypyrimidin-5-yl)-3-methoxyphenyl,    4-(2,4-dimethoxypyrimidin-6-yl)phenyl,    4-(2,4-dimethoxypyrimidin-5-yl)phenyl, (4-benzyloxy)phenyl,    4-phenoxyphenyl, (3-phenethyloxy)phenyl, (4-phenethyloxy)phenyl,    (4-phenoxymethyl)phenyl, optionally substituted by one or more    group(s) selected from halo preferably chloro or fluoro, more    preferably fluoro, alkyl preferably methyl, alkoxy preferably    methoxy, or Ar² is 4′-(2,4-difluoro-1,1′-biphenyl),    4′-(3′-methyl-1,1′-biphenyl), 4′-(3′-fluoro-1,1′-biphenyl),    4′-(2-fluoro-4-methoxy-1,1′-biphenyl),    4′-(4-fluoro-2-methoxy-1,1′-biphenyl),    4′-(2,3-dimethoxy-1,1′-biphenyl), 4′-(3,4-dimethoxy-1,1′-biphenyl),    4′-(2,3,4-trimethoxy-1,1′-biphenyl),    4′-(2,3,6-trimethoxy-1,1′-biphenyl),    4′-(3,5-dimethoxy-1,1′-biphenyl), 4′-(2,5-dimethoxy-1,1′-biphenyl),    4′-(2-isopropyl-1,1′-biphenyl), 4′-(2,2′-dimethoxy-1,1′-biphenyl),    4′-(2′-fluoro,2-dimethoxy-1,1′-biphenyl),    4′-(2-ethyl-1,1′-biphenyl), 4′-(4-propyl-1,1′-biphenyl),    4′-(4-tert-butyl-1,1′-biphenyl),    4′-(2-methoxy-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methoxy-4-acetylamino-1,1′-biphenyl),    4′-(3-hydroxycarbamimidoyl-1,1′-biphenyl),    4′-(4-amino-2-methoxy-1,1′-biphenyl),    4′-(3-carbamoyl-1,1′-biphenyl),    4′-(5-cyano-2,3-dimethoxy-1,1′-biphenyl),    4′-(2-cyano-4,5-dimethoxy-1,1′-biphenyl),    4′-(3,4,5-trimethoxy-1,1′-biphenyl), 4′-(2-cyano    methyl-4,5-dimethoxy-1,1′-biphenyl),    4′-(2-fluoro-5-cyano-1,1′-biphenyl),    4′-(2′-fluoro-3,4-dimethoxy-1,1′-biphenyl),    4′-(3-carbamoyl-4-cyano-1,1′-biphenyl),    4′-(2-cyano-4-methoxy-1,1′-biphenyl),    4′-(2′-fluoro-4-methylsulfonylamino-1,1′-biphenyl),    4′-(2′-fluoro-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-cyano-2′-fluoro-1,1′-biphenyl),    4′-(2-chloro-5-cyano-1,1′-biphenyl),    4′-(2-cyano-4-trifluoromethyl-1,1′-biphenyl),    4′-(2-methyl-3-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(2-methyl-4-(N-methyl-N-methylsulfonyl)amino-1,1′-biphenyl),    4′-(4-methylsulfonyl-1,1′-biphenyl),    4′-(3-methylsulfonylamino-1,1′-biphenyl),    4′-(4-amino-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    4′-(5-cyano-2-methoxy-1,1′-biphenyl), 4′-(3-cyano-1,1′-biphenyl),    4′-(2-cyano-3-methoxy-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4′-(2-methyl-3-acetylamino-1,1′-biphenyl),    4-(2-chloro-6-methoxypyrimidin-5-yl)phenyl,    4-(2-ethoxypyridin-5-yl)phenyl, 4-(2-isopropoxypyridin-5-yl)phenyl,    4-(2-methoxy-6-methylpyridin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-4-yl)-3-chlorophenyl,    4-(2,6-dimethylpyridin-5-yl)phenyl,    4-(2,6-dimethoxy-pyrimidin-5-yl)-3-chlorophenyl,    4-(4-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(6-methoxy-pyridin-3-yl)-3-chlorophenyl,    4-(4,6-dimethoxy-pyridin-3-yl)phenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)phenyl,    4-(2,6-dimethoxy-pyridin-3-yl)phenyl,    4-(5-methoxy-pyridin-3-yl)-3-methoxyphenyl,    4-(2,6-dimethoxy-pyridin-3-yl)-3-fluorophenyl,    4-(6-methoxy-pyridin-3-yl)-3-fluorophenyl,    4-(3,6-dimethoxy-pyridazin-5-yl)-3-fluorophenyl,    dimethoxy-pyrimidin-5-yl)phenyl,    4-(2-methoxy-pyrimidin-5-yl)-3-methoxyphenyl,    4-(3-methoxy-pyridin-4-yl)phenyl, 4-(4-methoxy-pyridin-3-yl)phenyl,    4-(2-methoxy-pyrimidin-3-yl)phenyl,    3-methoxy-2-(2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(5-cyano-2-methoxyphenyl)pyridin-5-yl,    3-methoxy-2-(2,4-dimethoxyphenyl)pyridin-5-yl,    2-(2,4-dimethoxyphenyl)pyridin-5-yl,    1-(2-cyano-4-trifluoromethyl)piperidin-4-yl,    1-(2-nitro-4-trifluoromethyl)piperidin-4-yl,    1-(2-methoxy-4-trifluoromethyl)piperidin-4-yl;-   R³ is H, cyano, alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl,    arylsulfonyl;-   R^(3′) is H or C₁-C₄ alkyl;-   R⁴ is H, cyano, C₁-C₄ alkyl.

Preferred compounds of formula Ie-1b′ are those of formula Ie-1g:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect of formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are independently selected from H,    halo preferably fluoro, chloro, bromo, cyano, alkyl, hydroxyalkyl,    haloalkyl preferably CF₃ or CHF₂, cycloalkyl, cycloalkylalkyl,    heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl preferably    phenyl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, heterocyclyloxy, alkylamino,    alkoxycarbonyl, cycloalkyloxycarbonyl, heterocyclyloxycarbonyl,    aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, heterocyclylcarbonyloxy, arylcarbonyloxy,    heteroarylcarbonyloxy, arylalkyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonylsulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R⁸ and R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′)    form an alkylenedioxy group or a haloalkylenedioxy group together    with the phenyl group they are attached to, or one or more of R⁸ and    R⁹, or R⁹ and R¹⁰, or R¹⁰ and R^(9′), or R^(9′) and R^(8′) form    together a cycloalkyl, aryl, heterocycloalyl or heteroaryl moiety    fused to the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, hydroxyalkyl,    haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, hydroxyl,    alkoxy, haloalkoxy, cycloalkyloxy, alkylamino, carboxy,    alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, cycloalkylcarbonylamino,    alkylcarbonylaminoalkyl, carbamoyl, hydroxycarbamoyl,    alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino,    alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    haloalkylsulfonylamino or oxo, preferably R⁸, R^(8′), R⁹, R^(9′) and    R¹⁰ are independently selected from H, halo preferably fluoro,    chloro, bromo, cyano, alkyl, haloalkyl preferably CF₃ or CHF₂,    cycloalkyl, aryl preferably phenyl, heteroaryl, hydroxyl, haloalkoxy    preferably OCF₃ or OCHF₂, alkylamino, alkoxycarbonyl,    alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    carbamoyl, hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl,    alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or one    or more of R⁸ and R⁹, or R⁹ and R¹⁰ , or R¹⁰ and R^(9′), or R^(9′)    and R^(8′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, each of said    substituents being optionally substituted by one or more further    substituents selected from halo, cyano, alkyl, haloalkyl, hydroxyl,    alkoxy, haloalkoxy, more preferably R⁸, R^(8′), R⁹, R^(9′) and R¹⁰    are independently selected from H, halo preferably bromo, fluoro or    chloro, cyano, C₁-C₄ alkyl preferably methyl, aryl preferably    phenyl, alkoxy preferably methoxy, still more preferably R⁸, R^(8′),    R⁹, R^(9′) and R¹⁰ are independently selected from H, halo    preferably bromo, fluoro or chloro, alkyl preferably methyl, still    more preferably R⁸ is Br, Cl or F, preferably Cl and R^(8′), R⁹,    R^(9′) and R¹⁰ are independently selected from H or F, or R⁹ is Cl    or F and R⁸, R^(8′), R^(9′) and R¹⁰ are H, or R⁹ and R^(9′) are F    and R⁸, R^(8′) and R¹⁰ are H, or R¹⁰ is Cl or F and R⁸, R^(8′), R⁹    and R^(9′) are H, even more preferably R⁸ is Br, Cl or F and R^(8′),    R⁹, R^(9′) and R¹⁰ are H, or R⁸ and R⁹ are F and R^(8′), R^(9′) and    R¹⁰ are H, or R⁸ and R¹⁰ are F and R^(8′), R⁹ and R^(9′) are H;-   R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkyloxycarbonyl, aminoalkyl alkoxycarbonyl, cycloalkyloxycarbonyl,    heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, cycloalkylcarbonyloxy, heterocyclylcarbonyloxy,    arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino,    haloalkylcarbonylamino, cycloalkylcarbonylamino,    heterocyclylcarbonylamino arylcarbonylamino,    heteroarylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl,    heteroarylcarbamoyl, carbamoylalkyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,    cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, cycloalkylsulfonylamino,    heterocyclylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, haloalkylsulfonylamino, or one or more of    R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form an alkylenedioxy group or a haloalkylenedioxy group    together with the phenyl group they are attached to, or one or more    of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and    R^(11′) form together a cycloalkyl, aryl, heterocycloalkyl or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl,    cyanomethyl, cycloalkyl, heterocyclyl, aryl optionally substituted    by one a chloro or methyl group, heteroaryl, cycloalkylalkyl,    aralkyl, heteroarylalkyl, heteroalkyl, hydroxyl, alkoxy,    alkoxyalkoxy, haloalkoxy preferably trifluoromethoxt,    1,1,1-trifluoroethyloxy, alkoxyalkyl, haloalkoxyalkyl,    cycloalkyloxy, cycloalkylalkyloxy preferably cyclopropylmethyloxy,    aryloxy, aralkyloxy optionally substituted by one fluoro, amino,    alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,    cycloalkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino,    cycloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyloxy    preferably carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    cycloalkylsulfonylamino, haloalkylsulfonylamino and oxo, preferably    R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently selected from    H, halo preferably chloro and fluoro more preferably chloro, cyano,    nitro, alkyl, haloalkyl preferably CF₃ or CHF₂, cycloalkyl,    cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,    aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, hydroxyalkyl,    alkoxy, haloalkoxy preferably —OCF₃ or —OCHF₂, alkoxyalkoxy,    cycloalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl,    haloalkoxyalkyl, cycloalkylalkyloxy, arylalkyloxy,    heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl,    alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,    alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,    alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,    arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,    heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,    heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,    heteroarylsulfonylamino, or one or more of R¹¹ and R¹², or R¹² and    R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form an    alkylenedioxy group or a haloalkylenedioxy group together with the    phenyl group they are attached to, or one or more of R¹¹ and R¹², or    R¹² and R¹⁶, or R¹⁶ and R^(12′), or R^(12′) and R^(11′) form    together an aryl or heteroaryl moiety fused to the phenyl group they    are attached to, each of said substituents being optionally    substituted by one or more further substituents selected from halo    preferably chloro or fluoro, cyano, alkyl, hydroxyalkyl,    alkoxyalkyl, haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, aryl    optionally substituted by one a chloro or methyl group, heteroaryl,    heteroalkyl, hydroxyl, alkoxy, alkoxyalkoxy, haloalkoxy preferably    1,1,1-trifluoroethyloxy, alkoxyalkyl, cycloalkyloxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy,    aralkyloxy optionally substituted by one fluoro, amino, alkylamino,    carboxy, alkoxycarbonyl, alkylcarbonyloxy, cycloalkylcarbonyloxy,    alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy preferably    carbamoylmethyloxy carbamoylamino, alkylcarbamoylamino,    carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,    haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl preferably    phenylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,    haloalkylsulfonylamino and oxo, more preferably R¹¹, R^(11′), R¹²,    R^(12′) and R¹⁶ are independently selected from H, halo preferably    chloro and fluoro, cyano, nitro, alkyl, haloalkyl preferably CF₃ or    CHF₂, heterocyclyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,    hydroxyl, alkoxy, haloalkoxy preferably OCF₃ or OCHF₂, alkoxyalkoxy,    aryloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy,    alkoxyalkyl, aryloxyalkyl, heteroaryloxyalkyl, arylcarbonyl, or one    or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶ and R^(12′), or    R^(12′) and R^(11′) form an alkylenedioxy group or a    haloalkylenedioxy group together with the phenyl group they are    attached to, or one or more of R¹¹ and R¹², or R¹² and R¹⁶, or R¹⁶    and R^(12′), or R^(12′) and R^(11′) form together an aryl, or    heteroaryl moiety fused to the phenyl group they are attached to,    each of said substituents being optionally substituted by one or    more further substituents selected from halo preferably chloro or    fluoro, cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, cyanomethyl, cycloalkyl, heterocyclyl, alkoxy preferably    methoxy, ethoxy, isopropoxy, alkoxyalkyl, alkoxyalkoxy,    cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by    one fluoro, amino, alkylamino, alkylcarbonylamino, carbamoyl,    hydroxycarbamimidoyl, alkylsulfonyl, alkylsulfonylamino, still more    preferably R¹¹, R^(11′), R¹², R^(12′) and R¹⁶ are independently    selected from H, halo preferably chloro and fluoro, cyano, nitro,    alkyl preferably methyl, ethyl, isopropyl or isobutyl, haloalkyl    preferably CF₃ or CHF₂, cycloalkyl preferably cyclohexyl,    heterocyclyl preferably pyrrolidin-1-yl, 4-methylpiperidin-1-yl,    aryl preferably phenyl, heteroaryl preferably thiophenyl, pyridinyl,    pyrimidinyl, pyrazinyl, pyridazinyl, aralkyl preferably benzyl,    alkoxy preferably methoxy, ethoxy or isopropyloxy,    cycloalkylalkyloxy, arylalkyloxy preferably benzyloxy, phenethyloxy    or 3,3-diphenylpropan-1-oxy, heteroarylalkyloxy preferably    pyridylmethyloxy or pyridylethyloxy, aryloxyalkyl preferably    phenoxymethyl, heteroaryloxyalkyl preferably pyridyloxymethyl, or    two substituents form an haloalkylenedioxy group each of said    substituents being optionally substituted by one or more further    substituents selected from halo preferably chloro or fluoro, cyano,    alkyl preferably methyl, haloalkyl preferably trifluoromethyl,    alkoxy preferably methoxy, isopropyloxy, isobutyloxy, alkoxyalkyl    preferably methoxymethyl, alkoxyalkoxy preferably 2-methoxyethoxy,    cycloalkylalkyloxy preferably cyclopropylmethyloxy, aryloxy    preferably phenoxy, aralkyloxy optionally substituted by one fluoro,    preferably benzyloxy, 4-fluorobenzyloxy, amino, alkylcarbonylamino    preferably acetylamino, alkylsulfonyl preferably methylsulfonyl,    alkylsulfonylamino preferably methylsulfonylamino,    (N-methyl-N-methylsulfonyl)amino.

Preferred compounds of formula Ie-1g are those of formula Ie-1h1:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ie-1g;-   R¹² is as defined above in respect to formula Ie-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, nitro, cyano, methoxy or    cyclopropylmethyloxy;-   R¹³, R^(13′), R¹⁴, R^(14′) and R¹⁵ are as defined above in respect    to formula Ie-1g, preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and    R¹³ is chloro, cyano, hydroxyl, methyl, trifluoromethyl,    cyanomethyl, methoxy, isopropoxy, isobutyloxy, OCF₃,    cyclopropylmethyloxy, phenoxy, cyclopropylmethyloxy, benzyloxy,    (4-fluorobenzyl)oxy, methoxymethyl, 2-methoxyethoxy,    carbamoylmethyloxy, or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴    is chloro, methylsulfonylamino, or R¹³, R^(13′), R¹⁴ and R^(14′) are    H and R¹⁵ is chloro, methylsulfonylamino, R^(13′), R¹⁴ and R^(14′)    are H and R¹³ and R¹⁵ are a) independently selected from chloro or    methoxy, or b) both F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³    is methoxy and R¹⁵ is F, or e) R¹³ is methoxy and R¹⁵ is    acetylamino, or f) R¹³ is methoxy and R¹⁵ is amino, or g) R¹³ is    cyano and R¹⁵ is methoxy, or h) R¹³ is chloro and R¹⁵ is cyano,    or i) R¹³ is cyano and R¹⁵ is trifluoromethyl, or j) R¹³ is methoxy    and R¹⁵ is (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵    are H and both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R¹⁵    are H and both R¹⁴ and R^(14′) are fluoro, methoxy, or R¹³, R^(13′)    and R^(14′) are H and a) R¹⁴ forms together with R¹⁵ a phenyl moiety    fused to the phenyl ring they are attached to, or b) both R¹⁴ and    R¹⁵ are methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴    are a) both methoxy, or b) R¹³ is methyl and R¹⁴ is    methylsulfonylamino, or c) R¹³ is methoxy and R¹⁴ is cyano, or d)    R¹³ is methyl and R¹⁴ is amino, or R^(13′), R¹⁴ and R¹⁵ are H and    R¹³ and R^(14′) are a) both methoxy, or b) R¹³ is methoxy and    R^(14′) is cyano, or c) R¹³ is methyl and R^(14′) is cyano, or R¹³    and R¹⁴ are H and R^(13′), R^(14′) and R¹⁵ are methoxy, or R¹⁴ and    R¹⁵ are H and R¹³, R^(13′) and R^(14′) are methoxy, or R¹³ and R¹⁴    are methoxy and R^(13′) and R¹⁵ are H and R^(14′) is cyano, or R¹⁴    and R¹⁵ are methoxy and R¹³ and R^(14′) are H and R^(13′) is cyano,    or R¹³ and R^(13′) are H and R¹⁴, R^(14′) and R¹⁵ are methoxy, more    preferably R^(13′), R¹⁴, R^(14′) and R¹⁵ are H and R¹³ is chloro,    cyano, trifluoromethyl, methoxy, isopropoxy, cyclopropylmethyloxy,    or R¹³, R^(13′), R^(14′) and R¹⁵ are H and R¹⁴ is chloro, or R¹³,    R^(13′), R¹⁴ and R^(14′) are H and R¹⁵ is chloro,    methylsulfonylamino, or R^(13′), R¹⁴ and R^(14′) are H and R¹³ and    R¹⁵ are a) independently selected from chloro or methoxy, or b) both    F, or c) R¹³ is F and R¹⁵ is methoxy, or d) R¹³ is methoxy and R¹⁵    is F, or e) R¹³ is methoxy and R¹⁵ is acetylamino, or f) R¹³ is    methoxy and R¹⁵ is amino, or g) R¹³ is cyano and R¹⁵ is methoxy,    or h) R¹³ is chloro and R¹⁵ is cyano, or i) R¹³ is cyano and R¹⁵ is    trifluoromethyl, or j) R¹³ is methoxy and R¹⁵ is    (N-methyl-N-methylsulfonyl)amino, or R¹⁴, R^(14′) and R¹⁵ are H and    both R¹³ and R^(13′) are methoxy, or R¹³, R^(13′) and R^(14′) are H    and a) R¹⁴ forms together with R¹⁵ a phenyl moiety fused to the    phenyl ring they are attached to, or b) both R¹⁴ and R¹⁵ are    methoxy, or R^(13′), R^(14′) and R¹⁵ are H and R¹³ and R¹⁴ are a)    both methoxy, or b) R¹³ is methyl and R¹⁴ is methylsulfonylamino,    or c) R¹³ is methoxy and R¹⁴ is cyano, or d) R¹³ is methyl and R¹⁴    is amino, or R^(13′), R¹⁴ and R¹⁵ are H and R¹³ and R^(14′) are a)    both methoxy, or b) R¹³ is methoxy and R^(14′) is cyano, or c) R¹³    is methyl and R^(14′) is cyano, or R¹³ and R¹⁴ are H and R^(13′),    R^(14′) and R¹⁵ are methoxy, or R¹⁴ and R¹⁵ are H and R¹³, R^(13′)    and R^(14′) are methoxy, or R¹³ and R¹⁴ are methoxy and R^(13′) and    R¹⁵ are H and R^(14′) is cyano, or R¹⁴ and R¹⁵ are methoxy and R¹³    and R^(14′) are H and R^(13′) is cyano, or R¹³ and R^(13′) are H and    R¹⁴, R^(14′) and R¹⁵ are methoxy.

Other preferred compounds of formula Ie-1g are those of formula Ie-1h′:

and pharmaceutically acceptable salts, solvates and prodrugs thereof,wherein

-   R is as defined above in respect to formula I;-   R⁸, R^(8′), R⁹, R^(9′) and R¹⁰ are as defined above in respect to    formula Ie-1g;-   R¹² is as defined above in respect to formula Ie-1g, preferably R¹²    is H, fluoro, chloro, methyl, CF₃, or methoxy more preferably R¹² is    H or methoxy;-   R¹⁶ is selected from the group of heteroaryl moieties consisting of:

wherein

-   the arrow marks the attachment point to the phenyl ring;-   R¹⁷, R^(17′), R¹⁸, R^(18′) and R¹⁹ are independently selected from    H, halo preferably chloro and fluoro, cyano, alkyl preferably    methyl, ethyl, propyl, isopropyl, tert-butyl, haloalkyl preferably    CF₃ or CHF₂, hydroxyl, hydroxyalkyl, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkoxy, cycloalkyloxy, alkoxyalkyl    preferably methoxymethyl, cycloalkylalkyloxy preferably    cyclopropylmethyloxy, aralkyloxy preferably benzyloxy,    haloalkoxyalkyl, amino, alkylamino, alkylcarbonylamino,    haloalkylcarbonylamino, alkylcarbonylaminoalkyl, carbamoyl,    hydroxycarbamoyl, alkylcarbamoyl, carbamoylamino,    alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl,    alkylsulfonyl preferably methylsulfonyl, haloalkylsulfonyl,    sulfamoyl, alkylsulfamoyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino,    haloalkylsulfonylamino, preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are    independently selected from H, halo preferably chloro and fluoro,    cyano, alkyl preferably methyl, ethyl, propyl, isopropyl,    tert-butyl, haloalkyl preferably CF₃, alkoxy preferably methoxy,    ethoxy, isopropyloxy, haloalkoxy preferably OCF₃, OCHF₂, or    1,1,1-trifluoroethyloxy, alkoxyalkyl preferably methoxymethyl,    aralkyloxy preferably benzyloxy, amino, alkylcarbonylamino,    carbamoyl, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl    preferably methylsulfonyl, alkylsulfonylamino preferably    methylsulfonylamino, (N-methyl-N-methylsulfonyl)amino, more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy, even more    preferably R¹⁷, R^(17′), R^(18′) and R¹⁹ are independently selected    from H, halo preferably chloro, alkoxy preferably methoxy;

Preferred compounds of formula Ie-1h′ are those wherein R¹⁶ is selectedfrom 2-2-methoxypyrimidin-4-yl, 2,4-dibenzyloxypyrimidin-5-yl,2,4-dimethoxypyrimidin-5-yl, 3,6-dimethoxypyridazin-5-yl,2-methoxypyrimidin-5-yl, 2-methoxypyrimidin-3-yl.

Particularly preferred compounds of the invention are those listed inTable 1 hereafter:

TABLE 1 Compound (M + n^(o) Compound name H)⁺ 1(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 2(2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-[1,1′- 420.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 3(2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5- 501.4methoxybenzoyl)-5-(2-chlorophenyl)pyrrolidine- 2-carboxylic acid 4(2S,5R)-5-(2-chlorophenyl)-1-(2′-fluoro-[1,1′- 424.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 5(2S,5R)-5-(2-chlorophenyl)-1-(4′-methyl-[1,1′- 420.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 6(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5- 481.0phenethoxybenzoyl)pyrrolidine-2-carboxylic acid 8(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(2- 406.9chlorophenyl)pyrrolidine-2-carboxylic acid 9(2S,5R)-5-(2-chlorophenyl)-1-(3-(3,3- 571.1diphenylpropoxy)-5-methoxybenzoyl)pyrrolidine- 2-carboxylic acid 10(2S,5R)-5-(2-chlorophenyl)-1-(3′-fluoro-[1,1′- 424.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 11(2S,5R)-5-(2-chlorophenyl)-1-(3′-methyl-[1,1′- 420.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 12(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-((4- 545.0(methylsulfonyl)benzyl)oxy)benzoyl)pyrrolidine- 2-carboxylic acid 13(2S,5R)-5-(2-chlorophenyl)-1-(3′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 14(2S,5R)-5-(2-chlorophenyl)-1-(3,5- 390.8dimethoxybenzoyl)pyrrolidine-2-carboxylic acid 15(2S,5R)-5-(2-chlorophenyl)-1-(4- 436.9(phenoxymethyl)benzoyl)pyrrolidine-2-carboxylic acid 16(2S,5R)-5-(2-chlorophenyl)-1-(4-((2- 454.9fluorobenzyl)oxy)benzoyl)pyrrolidine-2- carboxylic acid 17(2S,5R)-1-(3-chloro-5-methoxybenzoyl)-5-(2- 395.2chlorophenyl)pyrrolidine-2-carboxylic acid 18(2S,5R)-5-(2-chlorophenyl)-1-(4′-fluoro-[1,1′- 424.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 19(2S,5R)-5-(2-chlorophenyl)-1-(4- 450.9phenethoxybenzoyl)pyrrolidine-2-carboxylic acid 20(2S,5R)-5-(2-chlorophenyl)-1-(chroman-3- 386.8carbonyl)pyrrolidine-2-carboxylic acid 21(2S,5R)-5-(2-chlorophenyl)-1-(3,5- 418.9diethoxybenzoyl)pyrrolidine-2-carboxylic acid 23(2S,5R)-5-(2-chlorophenyl)-1-(3- 450.9phenethoxybenzoyl)pyrrolidine-2-carboxylic acid 24(2S)-1-([1,1′-biphenyl]-4-carbonyl)-4-benzyl-5- 462.6phenylpyrrolidine-2-carboxylic acid 25(2S,5R)-5-(2-chlorophenyl)-1-(1,2,3,4- 384.9tetrahydronaphthalene-2-carbonyl)pyrrolidine-2- carboxylic acid 26(2S,5R)-5-(2-chlorophenyl)-1-(4- 386.9isobutylbenzoyl)pyrrolidine-2-carboxylic acid 27(2S,5R)-5-(2-chlorophenyl)-1-(2,2- 410.8 difluorobenzo[d][1,3]dioxole-6-carbonyl)pyrrolidine-2-carboxylic acid 28(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5- 372.4phenylpyrrolidine-2-carboxylic acid 29(2S,5R)-5-(2-chlorophenyl)-1-(3-fluoro-5- 378.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 30(2S,5R)-5-(2-chlorophenyl)-1-(6- 407.9phenylnicotinoyl)pyrrolidine-2-carboxylic acid 31(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-(2- 434.9methoxyethoxy)benzoyl)pyrrolidine-2-carboxylic acid 32(2S,5R)-5-(2-chlorophenyl)-1-(3′-methoxy-[1,1′- 436.9biphenyl]-3-carbonyl)pyrrolidine-2-carboxylic acid 33(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5- 428.8(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylic acid 34(2S,5R)-5-(2-chlorophenyl)-1-(1-(4- 503.0methoxyphenyl)-5-phenyl-1H-pyrazole-3- carbonyl)pyrrolidine-2-carboxylicacid 35 (2S,5R)-5-(2-chlorophenyl)-1-(4- 388.9isopropoxybenzoyl)pyrrolidine-2-carboxylic acid 36(2S,5R)-5-(2-chlorophenyl)-1-(3-((3,5- 485.9dimethylisoxazol-4-yl)methoxy)-5-methoxybenzoyl)pyrrolidine-2-carboxylic acid 37(2S,5R)-5-(2-chlorophenyl)-1-(2,3-dihydro-1H- 370.8indene-2-carbonyl)pyrrolidine-2-carboxylic acid 38(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5- 428.8(trifluoromethoxy)benzoyl)pyrrolidine-2- carboxylic acid 39(2S,5R)-1-(3-(benzyloxy)benzoyl)-5-(2- 436.9chlorophenyl)pyrrolidine-2-carboxylic acid 40(2S,5R)-5-(2-chlorophenyl)-1-(3- 360.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 41(2S,5R)-5-(2-chlorophenyl)-1-(2- 408.9phenylpyrimidine-5-carbonyl)pyrrolidine-2- carboxylic acid 42(2S,5R)-5-(2-chlorophenyl)-1-(4- 414.8(trifluoromethoxy)benzoyl)pyrrolidine-2- carboxylic acid 43(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-cyclopropyl- 438.91,2,4-oxadiazol-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 444-((2S,5R)-2-carboxy-5-(2- 438.8chlorophenyl)pyrrolidine-1-carbonyl)-2,6- dimethoxypyrimidin-1-iumformate 45 (2S,5R)-5-(2-chlorophenyl)-1-(4- 372.9phenylbutanoyl)pyrrolidine-2-carboxylic acid 46(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5- 412.8(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylic acid 47(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(3- 407.9chloropyridin-2-yl)pyrrolidine-2-carboxylic acid 48(2S,5R)-5-(2-chlorophenyl)-1-(3-hydroxy-5- 414.8(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylic acid 49(2S,5S)-5-(2-chlorophenyl)-1-(3- 360.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 50(2S,5R)-1-(3,5-dimethoxybenzoyl)-5- 356.4 phenylpyrrolidine-2-carboxylicacid 51 (S)-5-([1,1′-biphenyl]-3-yl)-1-(3- 402.5methoxybenzoyl)pyrrolidine-2-carboxylic acid 52(2S,5R)-5-(2-chlorophenyl)-1-(3- 358.8phenylpropanoyl)pyrrolidine-2-carboxylic acid 53(2S,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 54(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(pyridin- 373.42-yl)pyrrolidine-2-carboxylic acid 55 (2S,5R)-5-(2-chlorophenyl)-1-(5-407.9 phenylpicolinoyl)pyrrolidine-2-carboxylic acid 57(2S,5R)-5-(2-fluorophenyl)-1-(3- 344.3methoxybenzoyl)pyrrolidine-2-carboxylic acid 58(2S,5R)-1-(2-([1,1′-biphenyl]-4-yl)acetyl)-5-(2- 420.9chlorophenyl)pyrrolidine-2-carboxylic acid 59(2R,5S)-1-([1,1′-biphenyl]-4-carbonyl)-5- 372.4phenylpyrrolidine-2-carboxylic acid 60(2S,5R)-5-phenyl-1-(2-phenylacetyl)pyrrolidine-2- 310.4 carboxylic acid61 (2R,5S)-5-phenyl-1-(2-phenylacetyl)pyrrolidine-2- 310.4 carboxylicacid 62 (2S,5R)-1-(3-methoxybenzoyl)-5-(2- 356.4methoxyphenyl)pyrrolidine-2-carboxylic acid 63(2R,5S)-5-(2-chlorophenyl)-1-(3- 360.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 64(2R,5R)-5-(2-chlorophenyl)-1-(3- 360.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 65(2S)-5-(4-chlorophenyl)-1-(3- 360.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 66(2S)-5-([1,1′-biphenyl]-4-yl)-1-(3- 402.5methoxybenzoyl)pyrrolidine-2-carboxylic acid 67 (2S,5R)-methyl5-(2-chlorophenyl)-1-(3- 374.8 methoxybenzoyl)pyrrolidine-2-carboxylate68 (2S)-5-(2-chlorobenzyl)-1-(3- 374.8methoxybenzoyl)pyrrolidine-2-carboxylic acid 69 (2S)-5-cyclohexyl-1-(3-332.4 methoxybenzoyl)pyrrolidine-2-carboxylic acid 70(2S,5R)-5-(2-chlorophenyl)-1-(2-(3- 374.8methoxyphenyl)acetyl)pyrrolidine-2-carboxylic acid 71(2S,5S)-5-(2-chlorophenyl)-1-(3,5- 390.8dimethoxybenzoyl)pyrrolidine-2-carboxylic acid 72(2S,5R)-5-([1,1′-biphenyl]-2-yl)-1-(3- 402.5methoxybenzoyl)pyrrolidine-2-carboxylic acid 742-((2S,5R)-5-(2-chlorophenyl)-1-(3- 374.8methoxybenzoyl)pyrrolidin-2-yl)acetic acid 75(2S,5R)-5-(2-chlorophenyl)-1-(6- 408.9phenylpyrimidine-4-carbonyl)pyrrolidine-2- carboxylic acid 76(2S,5R)-5-(2-chlorophenyl)-1-(6-(2- 425.9fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 77(2S,5R)-5-(2-chlorophenyl)-1-(6-(2- 442.3chlorophenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 78(2S,5R)-5-(2-chlorophenyl)-1-(6-(2- 437.9methoxyphenyl)nicotinoyl)pyrrolidine-2- carboxylic acid 79(2S,5R)-5-(2-chlorophenyl)-1-(6-(3- 425.9fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 80(2S,5R)-5-(2-chlorophenyl)-1-(6-(3- 437.9methoxyphenyl)nicotinoyl)pyrrolidine-2- carboxylic acid 81(2S,5R)-5-(2-chlorophenyl)-1-(6-(4- 437.9methoxyphenyl)nicotinoyl)pyrrolidine-2- carboxylic acid 82(2S,5R)-5-(2-chlorophenyl)-1-(6-(4- 425.9fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 83(2S,5R)-5-(2-chlorophenyl)-1-(2-(2- 443.3chlorophenyl)pyrimidine-5-carbonyl)pyrrolidine- 2-carboxylic acid 84(2S,5R)-5-(2-chlorophenyl)-1-(2-methyl-6- 421.9phenylnicotinoyl)pyrrolidine-2-carboxylic acid 85(2S,5R)-1-(4-chloro-2-(pyridin-3-yl)pyrimidine-5- 444.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 86(2S,5R)-1-(4-chloro-2-(pyridin-2-yl)pyrimidine-5- 444.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 87(2S,5R)-1-(4-chloro-2-(pyridin-4-yl)pyrimidine-5- 444.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 88(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-2- 407.9yl)benzoyl)pyrrolidine-2-carboxylic acid 89(2S,5R)-1-(4-((4-chlorophenoxy)methyl)benzoyl)- 471.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 90(2S,5R)-5-(2-chlorophenyl)-1-(4-((4- 454.9fluorophenoxy)methyl)benzoyl)pyrrolidine-2- carboxylic acid 91(2S,5R)-5-(2-chlorophenyl)-1-(4-((4- 466.9methoxyphenoxy)methyl)benzoyl)pyrrolidine-2- carboxylic acid 92(2S,5R)-1-(4-((2-chlorophenoxy)methyl)benzoyl)- 471.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 93(2S,5R)-5-(2-chlorophenyl)-1-(4-((2- 466.9methoxyphenoxy)methyl)benzoyl)pyrrolidine-2- carboxylic acid 94(2S,5R)-5-(2-chlorophenyl)-1-(4-((3- 466.9methoxyphenoxy)methyl)benzoyl)pyrrolidine-2- carboxylic acid 95(2S,5R)-1-(4-((3-chlorophenoxy)methyl)benzoyl)- 471.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 96(2S,5R)-5-(2-chlorophenyl)-1-(4-((p- 450.9tolyloxy)methyl)benzoyl)pyrrolidine-2-carboxylic acid 97(2S,5R)-5-(2-chlorophenyl)-1-(4-((3- 466.9methoxybenzyl)oxy)benzoyl)pyrrolidine-2- carboxylic acid 98(2S,5R)-1-(4-((3-chlorobenzyl)oxy)benzoyl)-5-(2- 471.3chlorophenyl)pyrrolidine-2-carboxylic acid 99(2S,5R)-5-(2-chlorophenyl)-1-(4-((3,5- 455.9 dimethylisoxazol-4-yl)methoxy)benzoyl)pyrrolidine-2-carboxylic acid 100(2S,5R)-5-(2-chlorophenyl)-1-(4-((3,5-dimethyl- 454.91H-pyrazol-1-yl)methoxy)benzoyl)pyrrolidine-2- carboxylic acid 101(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-2- 437.9ylmethoxy)benzoyl)pyrrolidine-2-carboxylic acid 102(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-4- 437.9ylmethoxy)benzoyl)pyrrolidine-2-carboxylic acid 103(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-3- 437.9ylmethoxy)benzoyl)pyrrolidine-2-carboxylic acid 104(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-1H- 410.9pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylic acid 105(2S,5R)-5-(2-chlorophenyl)-1-(4-(isoxazol-5- 397.8yl)benzoyl)pyrrolidine-2-carboxylic acid 106(2S,5R)-1-(4-(4H-1,2,4-triazol-4-yl)benzoyl)-5-(2- 397.8chlorophenyl)pyrrolidine-2-carboxylic acid 107(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-(p-tolyl)-1H- 488.01,2,3-triazol-1-yl)benzoyl)pyrrolidine-2- carboxylic acid 108(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-oxo-3-phenyl- 488.94,5-dihydro-1H-pyrazol-1-yl)benzoyl)pyrrolidine- 2-carboxylic acid 109(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-3- 478.9(trifluoromethyl)-1H-pyrazol-1- yl)benzoyl)pyrrolidine-2-carboxylic acid110 (2S,5R)-1-(4-(1H-pyrazol-1-yl)benzoyl)-5-(2- 396.8chlorophenyl)pyrrolidine-2-carboxylic acid 111(2S,5R)-5-(2-chlorophenyl)-1-(4-(oxazol-5- 397.8yl)benzoyl)pyrrolidine-2-carboxylic acid 112(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,5-dimethyl- 424.91H-pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylic acid 113(2S,5R)-5-(2-chlorophenyl)-1-(2′,5′-dichloro-[1,1′- 475.8biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 114(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyrimidin-5- 408.9yl)benzoyl)pyrrolidine-2-carboxylic acid 115(2S,5R)-5-(2-chlorophenyl)-1-(4-(furan-3- 396.8yl)benzoyl)pyrrolidine-2-carboxylic acid 116(2S,5R)-5-(2-chlorophenyl)-1-(4-(6- 437.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 117(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-fluoropyridin- 425.94-yl)benzoyl)pyrrolidine-2-carboxylic acid 118(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-3- 407.9yl)benzoyl)pyrrolidine-2-carboxylic acid 119(2S,5R)-5-(2-chlorophenyl)-1-(4-(6- 450.9(dimethylamino)pyridin-3-yl)benzoyl)pyrrolidine- 2-carboxylic acid 120(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-4- 407.9yl)benzoyl)pyrrolidine-2-carboxylic acid 121(2S,5R)-5-(2-chlorophenyl)-1-(4-(6- 421.9methylpyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 122(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 437.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 123(2S,5R)-5-(2-chlorophenyl)-1-(4′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 124(2S,5R)-5-(2-chlorophenyl)-1-(4′-cyano-[1,1′- 431.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 125(2S,5R)-5-(2-chlorophenyl)-1-(4-(4- 437.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 126(2S,5R)-1-(4′-chloro-[1,1′-biphenyl]-4-carbonyl)- 441.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 127(2S,5R)-1-(3′-chloro-[1,1′-biphenyl]-4-carbonyl)- 441.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 128(2S,5R)-1-(2′-chloro-[1,1′-biphenyl]-4-carbonyl)- 441.35-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 129(2S,5R)-5-(2-chlorophenyl)-1-(4′- 500.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 130 (2S,5R)-5-(2-chlorophenyl)-1-(3′- 500.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 131 (2S,5R)-5-(2-chlorophenyl)-1-(2′- 500.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 132 (2S,5R)-5-(2-chlorophenyl)-1-(4-(naphthalen-2- 456.9yl)benzoyl)pyrrolidine-2-carboxylic acid 133(2S,5R)-5-(2-chlorophenyl)-1-(3′,5′-difluoro-[1,1′- 442.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 134(2S,5R)-5-(2-chlorophenyl)-1-(2′-hydroxy-[1,1′- 422.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 135(2S,5R)-5-(2-chlorophenyl)-1-(2′- 490.9(trifluoromethoxy)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 136 (2S,5R)-1-(2′-(benzyloxy)-[1,1′-biphenyl]-4- 513.0carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 137(2S,5R)-5-(2-chlorophenyl)-1-(2′-phenoxy-[1,1′- 499.0biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 138(2S,5R)-5-(2-chlorophenyl)-1-(2′-isopropoxy- 465.0[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 139(2S,5R)-5-(2-chlorophenyl)-1-(2′-isobutoxy-[1,1′- 479.0biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 140(2S,5R)-5-(2-chlorophenyl)-1-(2′- 477.0(cyclopropylmethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 141(2S,5R)-5-(2-chlorophenyl)-1-(2′-((4- 531.0fluorobenzyl)oxy)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 142 (2S,5R)-5-(2-chlorophenyl)-1-(4-(6-chloropyridin- 442.33-yl)benzoyl)pyrrolidine-2-carboxylic acid 143(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-fluoropyridin- 425.93-yl)benzoyl)pyrrolidine-2-carboxylic acid 144(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-chloropyridin- 442.34-yl)benzoyl)pyrrolidine-2-carboxylic acid 145(2S,5R)-1-(4-(2-chloro-3-fluoropyridin-4- 460.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 146(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-chloropyridin- 442.33-yl)benzoyl)pyrrolidine-2-carboxylic acid 147(2S,5R)-1-(4-(6-(benzyloxy)pyridin-3-yl)benzoyl)- 514.05-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 148(2S,5R)-1-(4-(1H-pyrazol-4-yl)benzoyl)-5-(2- 396.8chlorophenyl)pyrrolidine-2-carboxylic acid 149(2S,5R)-5-(2-chlorophenyl)-1-(4-(thiophen-3- 412.9yl)benzoyl)pyrrolidine-2-carboxylic acid 150(2S,5R)-5-(2-chlorophenyl)-1-(4- 412.9cyclohexylbenzoyl)pyrrolidine-2-carboxylic acid 151(2S,5R)-5-(2-chlorophenyl)-1-(4′- 485.0(methylsulfonyl)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 152 (2S,5R)-5-(2-chlorophenyl)-1-(9-oxo-9H-fluorene- 432.92-carbonyl)pyrrolidine-2-carboxylic acid 153(2S,5R)-5-(2-chlorophenyl)-1-(2′- 485.0(methylsulfonyl)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 154 (2S,5R)-5-(2-chlorophenyl)-1-(4-(tetrahydro-2H- 414.9pyran-4-yl)benzoyl)pyrrolidine-2-carboxylic acid 155(2S,5R)-5-(2-chlorophenyl)-1-(9-methyl-9H- 433.9carbazole-2-carbonyl)pyrrolidine-2-carboxylic acid 156(2S,5R)-5-(2-chlorophenyl)-1-(4- 422.9phenoxybenzoyl)pyrrolidine-2-carboxylic acid 157(2S,5R)-1-(4-benzylbenzoyl)-5-(2- 420.9chlorophenyl)pyrrolidine-2-carboxylic acid 158(2S,5R)-1-(4-benzoylbenzoyl)-5-(2- 434.9chlorophenyl)pyrrolidine-2-carboxylic acid 159(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyrimidin-2- 408.9yl)benzoyl)pyrrolidine-2-carboxylic acid 160(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6- 468.9dimethoxypyrimidin-2-yl)benzoyl)pyrrolidine-2- carboxylic acid 161(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4- 468.9dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 162(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 438.9methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 163(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 451.9 (dimethylamino)pyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 164(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 494.0morpholinopyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 165(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-(piperidin-1- 492.0yl)pyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 168(2S,5R)-5-(2-chlorophenyl)-1- 336.8(cyclohexanecarbonyl)pyrrolidine-2-carboxylic acid 169(2S,5R)-5-(2-chlorophenyl)-1-(4- 324.8methylpentanoyl)pyrrolidine-2-carboxylic acid 172(2S,5R)-5-(2-chlorophenyl)-1-(4-(4- 472.9methylpiperidin-1-yl)-3-nitrobenzoyl)pyrrolidine-2- carboxylic acid 173(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-oxopiperidin- 427.91-yl)benzoyl)pyrrolidine-2-carboxylic acid 174(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4- 429.9morpholinobenzoyl)pyrrolidine-2-carboxylic acid 175(2S,5R)-5-(2-chlorophenyl)-1-(4-(piperidin-1- 413.9yl)benzoyl)pyrrolidine-2-carboxylic acid 176(2S,5R)-5-(2-chlorophenyl)-1-(4- 415.9morpholinobenzoyl)pyrrolidine-2-carboxylic acid 177(2S,5R)-5-(2-chlorophenyl)-1-(1-(2- 438.9cyanophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 178(2S,5R)-5-(2-chlorophenyl)-1-(4-(4- 447.4chlorophenyl)cyclohexanecarbonyl)pyrrolidine-2- carboxylic acid 179(2S,5R)-5-(2-chlorophenyl)-1-(4- 412.9phenylcyclohexanecarbonyl)pyrrolidine-2- carboxylic acid 183((2R,5S)-2-(2-chlorophenyl)-5-(1H-tetrazol-5- 460.9yl)pyrrolidin-1-yl)(2′-methoxy-[1,1′-biphenyl]-4- yl)methanone 184(2R,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 189(2S,5R)-5-(2-chlorophenyl)-1-(6-(2- 425.9fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 191(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6- 437.9phenylnicotinoyl)pyrrolidine-2-carboxylic acid 192(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 452.9methoxyphenoxy)benzoyl)pyrrolidine-2-carboxylic acid 193(2S,5R)-5-(2-chlorophenyl)-1-(4-(3- 437.9methoxypyridin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 194(2S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 465.0biphenyl]-4-carbonyl)-4,4-dimethylpyrrolidine-2- carboxylic acid 195(2S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 450.9biphenyl]-4-carbonyl)-4-methylpyrrolidine-2- carboxylic acid 196(2S,5R)-5-(2-chlorophenyl)-1-(2-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 197(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-[1,1′- 431.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 198(2S,5R)-5-(2-chlorophenyl)-1-(2′,6′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 199(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-dichloro-[1,1′- 475.8biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 200(2S,5R)-5-(2-chlorophenyl)-1-(2′-(trifluoromethyl)- 474.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 201(2S,5R)-5-(2-chlorophenyl)-1-(2,2′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 202(2S,5R)-1-(4′-chloro-2′-methoxy-[1,1′-biphenyl]-4- 471.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 203(2S,5R)-5-(2-chlorophenyl)-1-(4-(4- 438.9methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 204(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 205(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(pyridin- 373.43-yl)pyrrolidine-2-carboxylic acid 206(2R,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 207(2S,5R)-5-(2-chlorophenyl)-1-(1-phenyl-1H- 446.9benzo[d]imidazole-5-carbonyl)pyrrolidine-2- carboxylic acid 208(2S,5R)-methyl 5-(2-chlorophenyl)-1-(2′-methoxy- 450.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylate 211(2S,4S,5R)-5-(2-chlorophenyl)-4-(hydroxymethyl)- 466.91-(2′-methoxy-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylic acid217 (2S,4S,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 577.1biphenyl]-4-carbonyl)-4- (phenylsulfonyl)pyrrolidine-2-carboxylic acid220 (2S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′- 461.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 221(2S,3R,5R)-5-(2-chlorophenyl)-3-cyano-1-(2′- 461.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 224(2S,5R)-1-(2-chloro-[1,1′-biphenyl]-4-carbonyl)-5- 441.3(2-chlorophenyl)pyrrolidine-2-carboxylic acid 225(2S,5R)-1-(2′-chloro-2-methoxy-[1,1′-biphenyl]-4- 471.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 226(2S,5R)-5-(2-chlorophenyl)-1-(2′-(2- 481.0methoxyethoxy)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylic acid227 (2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 426.9methylthiophen-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 228(2S,5R)-5-(2-chlorophenyl)-1-(2′,6′-dichloro-[1,1′- 475.8biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 229(2S,5R)-1-(2′-chloro-4′-methoxy-[1,1′-biphenyl]-4- 471.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 230(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4- 438.9(pyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 231(2S,5R)-1-(2′-carbamimidoyl-[1,1′-biphenyl]-4- 448.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 232(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 233(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)- 416.55-(o-tolyl)pyrrolidine-2-carboxylic acid 234(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)- 432.55-(2-methoxyphenyl)pyrrolidine-2-carboxylic acid 235(2S,5R)-5-(2-chlorophenyl)-1-(2′- 450.9(methoxymethyl)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 236 (2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6- 467.9dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 237(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(2- 468.9methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 238(2S,5R)-5-(2-chlorophenyl)-1-(4-(5- 438.9methoxypyrazin-2-yl)benzoyl)pyrrolidine-2- carboxylic acid 239(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-(2- 481.9methoxyethoxy)pyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 240(2S,5R)-5-(2-chlorophenyl)-1-(4-(3- 438.9methoxypyrazin-2-yl)benzoyl)pyrrolidine-2- carboxylic acid 241(2S,5R)-1-(4-(2-chloro-4- 486.4(dimethylamino)pyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 242(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6- 468.9dimethoxypyrimidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 243(2S,5R)-5-(2-chlorophenyl)-1-(2′-(dimethylamino)- 449.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 244(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 438.9methoxypyrimidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 245(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(2- 468.9methoxypyrimidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 246(2S,5R)-5-(2-fluorophenyl)-1-(4-(2- 421.4methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 247(2S,5R)-1-(4-(2,4-dimethoxypyrimidin-5- 452.4yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 248(2S,5R)-5-(2-chlorophenyl)-1-(2-methyl-[1,1′- 420.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 249(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 250(2S,5R)-5-(2-chlorophenyl)-1-(2′-(2-oxopyrrolidin- 490.01-yl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 251(2S,5R)-5-(2-chlorophenyl)-1-(5-phenylpyrazine-2- 408.9carbonyl)pyrrolidine-2-carboxylic acid 252(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6-(2- 467.9methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 253(2S,5R)-5-(2-chlorophenyl)-1-(4-(5- 438.9methoxypyrimidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 254(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridazin-4- 408.9yl)benzoyl)pyrrolidine-2-carboxylic acid 255(2S,5R)-1-(4-(1H-1,2,3-triazol-1-yl)benzoyl)-5-(2- 397.8chlorophenyl)pyrrolidine-2-carboxylic acid 256(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-(p-tolyl)-1H- 488.01,2,3-triazol-1-yl)benzoyl)pyrrolidine-2-carboxylic acid 257(2S,5R)-5-(2-chlorophenyl)-1-(1-(2- 443.9methoxyphenyl)piperidine-4-carbonyl)pyrrolidine- 2-carboxylic acid 258(2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 444.9methoxyphenyl)piperazine-1-carbonyl)pyrrolidine- 2-carboxylic acid 259(2S,5R)-5-(2-chlorophenyl)-1-(1-(4- 445.9methoxypyrimidin-5-yl)piperidine-4- carbonyl)pyrrolidine-2-carboxylicacid 260 (2S,5R)-5-(2-chlorophenyl)-1-(4-(4- 446.9methoxypyrimidin-5-yl)piperazine-1- carbonyl)pyrrolidine-2-carboxylicacid 261 (2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(4- 458.0methylpiperidin-1-yl)benzoyl)pyrrolidine-2- carboxylic acid 262(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(1- 458.0methylpiperidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 263(2S,5R)-5-(2-chlorophenyl)-1-(2-cyano-[1,1′- 431.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 264(2S,5R)-5-(2-chlorophenyl)-1-(2-isobutoxy-[1,1′- 479.0biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 265(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4- 477.7dichloropyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 266(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4- 498.9 dimethoxypyrimidin-5-yl)-3-methoxybenzoyl)pyrrolidine-2-carboxylic acid 267(2S,5R)-1-(4-(2-chloro-4-methoxypyrimidin-5- 473.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 268(2S,35,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 450.9biphenyl]-4-carbonyl)-3-methylpyrrolidine-2- carboxylic acid 269(2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)- 451.55-(2-fluorophenyl)pyrrolidine-2-carboxylic acid 270(2S,5R)-1-(2′-(2-amino-2-oxoethoxy)-[1,1′- 479.9biphenyl]-4-carbonyl)-5-(2- chlorophenyl)pyrrolidine-2-carboxylic acid271 (2S,5R)-5-(2-chlorophenyl)-1-(2- 477.0(cyclopropylmethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 272(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)- 402.55-phenylpyrrolidine-2-carboxylic acid 273(2S,5R)-5-(3-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 274(2S,5R)-5-(4-chlorophenyl)-1-(2′-methoxy-[1,1′- 436.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 275(2S,5R)-5-(3-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 276(2S,5R)-5-(4-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 278(2S,5R)-4-acetyl-5-(2-chlorophenyl)-1-(2′- 478.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 279(2S,4S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′- 481.0biphenyl]-4-carbonyl)-4- (methoxymethyl)pyrrolidine-2-carboxylic acid280 (2S,5R)-5-(2-chlorophenyl)-1-(4-(2- 438.9methoxypyrimidin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 281(2S,5R)-5-cyclohexyl-1-(2′-methoxy-[1,1′- 408.5biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 283(2S,5R)-1-(4-(2-chloro-4-methoxypyrimidin-5- 473.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 284(2S,5R)-5-(2-chlorophenyl)-1-(4-(3- 437.9methoxypyridin-2-yl)benzoyl)pyrrolidine-2- carboxylic acid 285(2R,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 286(2S,5S)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 287(2R,5S)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′- 420.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 288(2S,5R)-5-(2-chlorophenyl)-1-(2-(trifluoromethyl)- 474.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 289(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-difluoro-[1,1′- 442.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 290(2S,5R)-5-(2-chlorophenyl)-1-(2-methyl-[1,1′- 420.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 291(2S,5R)-5-(2,6-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 292(2S,5R)-5-(2,4-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 293(2S,5R)-5-(2,4-dichlorophenyl)-1-(2′-methoxy- 471.3[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 294(2S,5R)-5-isobutyl-1-(2′-methoxy-[1,1′-biphenyl]- 382.54-carbonyl)pyrrolidine-2-carboxylic acid 295(2S,5R)-5-isopropyl-1-(2′-methoxy-[1,1′-biphenyl]- 368.44-carbonyl)pyrrolidine-2-carboxylic acid 296(2S,5R)-1-(3-chloro-4-(pyrimidin-4-yl)benzoyl)-5- 443.3(2-chlorophenyl)pyrrolidine-2-carboxylic acid 297(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-[1,1′- 424.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 298(2S,5R)-5-(2-chlorophenyl)-1-(2′-fluoro-4′- 454.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 299(2S,5R)-5-(2-chlorophenyl)-1-(4′-fluoro-2′- 454.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 300(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-ethoxypyridin- 451.93-yl)benzoyl)pyrrolidine-2-carboxylic acid 301(2S,5R)-5-(2-chlorophenyl)-1-(4-(6- 465.9isopropoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 302(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-methoxy-2- 451.9methylpyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 303(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-4- 473.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 304(2S,5R)-1-(3-chloro-4-(pyrimidin-5-yl)benzoyl)-5- 443.3(2-chlorophenyl)pyrrolidine-2-carboxylic acid 305(2S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′- 475.9methoxy-[1,1′-biphenyl]-4-carbonyl)-3- methylpyrrolidine-2-carboxylicacid 306 (2S,4S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′- 475.9methoxy-[1,1′-biphenyl]-4-carbonyl)-4- methylpyrrolidine-2-carboxylicacid 307 (2S,5R)-5-(2-chlorophenyl)-1-(2′,3′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 308(2S,5R)-5-(2-chlorophenyl)-1-(3′,4′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 309(2S,5R)-5-(2-chlorophenyl)-1-(2′,3′,4′-trimethoxy- 497.0[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 310(2S,5R)-5-(2-chlorophenyl)-1-(2′,3′,6′-trimethoxy- 497.0[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 311(2S,5R)-5-(2-chlorophenyl)-1-(3′,5′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 312(2S,5R)-5-(2-chlorophenyl)-1-(2′,5′-dimethoxy- 466.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 313(2S,5R)-5-(2-chlorophenyl)-1-(2′-isopropyl-[1,1′- 449.0biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 314(2S,5R)-1-(2,2′-dimethoxy-[1,1′-biphenyl]-4- 450.5carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 315(2S,5R)-1-(2-fluoro-2′-methoxy-[1,1′-biphenyl]-4- 438.4carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 316(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-2′- 454.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 318(2S,5R)-5-cyclopentyl-1-(2′-methoxy-[1,1′- 394.5biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 319(2S,5R)-5-(2-chlorophenyl)-1-(2′-ethyl-[1,1′- 434.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 320(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6- 435.9dimethylpyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 321(2S,5R)-1-(4-(2,4-bis(benzyloxy)pyrimidin-5- 621.1yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 322(2S,5R)-1-([1,1′:4′,1″-terphenyl]-4-carbonyl)-5-(2- 483.0chlorophenyl)pyrrolidine-2-carboxylic acid 323(2S,5R)-5-(2-chlorophenyl)-1-(4′-propyl-[1,1′- 449.0biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 324(2S,5R)-1-(4′-(tert-butyl)-[1,1′-biphenyl]-4- 463.0carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 325(2S,5R)-1-(3-chloro-4-(2,4-dimethoxypyrimidin-5- 503.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 326(2S,5R)-5-(2-chlorophenyl)-1-(5-(2- 438.9methoxyphenyl)pyrazine-2-carbonyl)pyrrolidine-2- carboxylic acid 327(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(4- 467.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 328(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(6- 467.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 329(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-5- 473.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 330(2S,5R)-1-(3-chloro-4-(6-methoxypyridin-3- 472.3yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 331(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(4- 531.5chlorophenyl)thiazol-2-yl)piperidine-4-carbonyl)pyrrolidine-2-carboxylic acid 332(2S,5R)-5-(2-fluorophenyl)-1-(5-methoxy-6-(2- 451.5methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 333(2S,5R)-1-(1-(benzo[d]oxazol-2-yl)piperidine-4- 454.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 334(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4- 429.9(pyrrolidin-1-yl)benzoyl)pyrrolidine-2-carboxylic acid 335(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6-(2- 467.9methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 336(2S,5R)-5-(2-chlorophenyl)-1-(1-(2- 443.9methoxyphenyl)piperidine-4-carbonyl)pyrrolidine- 2-carboxylic acid 337(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4- 498.9 dimethoxypyrimidin-5-yl)-3-methoxybenzoyl)pyrrolidine-2-carboxylic acid 338(2S,5R)-5-(2-bromophenyl)-1-(2′-methoxy-[1,1′- 481.4biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 339(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-[1,1′- 431.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 340(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-2′- 461.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 341(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-2′,4′- 627.9bis(2,2,2-trifluoroethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 342(2S,5R)-1-(3′-amino-2′-methyl-[1,1′-biphenyl]-4- 435.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 343(2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-3′- 514.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 344 (2S,5R)-1-(3′-acetamido-2′-methyl-[1,1′-biphenyl]- 478.04-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 345(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′- 461.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 346(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-methyl- 445.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 347(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6- 467.9dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 348(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6- 468.9dimethoxypyridazin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 349(2S,5S)-5-isopentyl-1-(2′-methoxy-[1,1′-biphenyl]- 396.54-carbonyl)pyrrolidine-2-carboxylic acid 350(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′- 530.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 351 (2S,5R)-1-(4′-acetamido-2′-methoxy-[1,1′- 494.0biphenyl]-4-carbonyl)-5-(2- chlorophenyl)pyrrolidine-2-carboxylic acid352 (2S,5R)-1-(3′-carbamimidoyl-[1,1′-biphenyl]-4- 448.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 353(2S,5R)-5-(2-chlorophenyl)-1-(3′-((E)—N′- 464.9hydroxycarbamimidoyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 354(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-4′- 513.6(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 355 (2S,5R)-5-(2,4-difluorophenyl)-1-(4-(2,6- 469.4dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 356(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(5- 467.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 357(2S,5R)-1-(4′-amino-2′-methoxy-[1,1′-biphenyl]-4- 451.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 358(2S,5R)-5-(2-chlorophenyl)-1-(2′,3,6′-trimethoxy- 498.9[2,3′-bipyridine]-5-carbonyl)pyrrolidine-2- carboxylic acid 359(2S,5R)-1-(3′-carbamoyl-[1,1′-biphenyl]-4- 449.9carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 360(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′,3′- 491.9dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylic acid 361(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′,5′- 491.9dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylic acid 362(2S,5R)-5-(2-chlorophenyl)-1-(3′,4′,5′-trimethoxy- 497.0[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 363(2S,5R)-5-(2-chlorophenyl)-1-(2′-(cyanomethyl)- 506.04′,5′-dimethoxy-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 364 (2S,5R)-5-(2-chlorophenyl)-1-(3′,4′-dicyano-[1,1′- 456.9biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 365(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-fluoro- 449.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 366(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3′,4′- 484.9dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylic acid 367(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6- 485.9 dimethoxypyridin-3-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylic acid 368(2S,5R)-5-(2-chlorophenyl)-1-(3-fluoro-4-(6- 455.9methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 369(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4- 506.9(trifluoromethyl)phenyl)piperidine-4- carbonyl)pyrrolidine-2-carboxylicacid 370 (2S,5R)-1-(1-(2-chloro-4- 516.4(trifluoromethyl)phenyl)piperidine-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylic acid 371(2S,5R)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4- 445.5carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 372(2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)-3- 469.4fluorobenzoyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 373(2S,5R)-1-(3-fluoro-4-(6-methoxypyridin-3- 439.4yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 374(2S,5R)-1-(4-(3,6-dimethoxypyridazin-4- 452.4yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 375(2S,5R)-1-(3′-carbamoyl-4′-cyano-[1,1′-biphenyl]- 474.94-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 376(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitro-4- 526.9(trifluoromethyl)phenyl)piperidine-4- carbonyl)pyrrolidine-2-carboxylicacid 377 (2S,5R)-5-(2-chlorophenyl)-1-(1-(4- 608.1(morpholinosulfonyl)-2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylic acid 378(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitro-4- 606.1(piperidin-1-ylsulfonyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylic acid 379(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(N,N- 594.1diethylsulfamoyl)-2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylic acid 380(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methyl-2- 472.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 381(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4- 483.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 382(2S,5R)-5-(2-chlorophenyl)-1-(1-(4- 458.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 383(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-fluoro-4- 476.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 384(2S,5R)-5-(2-chlorophenyl)-1-(1-(3-methoxy-4- 488.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 385(2S,5R)-1-(1-(5-chloro-2-nitrophenyl)piperidine-4- 493.4carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 386(2S,5R)-5-(2-cyanophenyl)-1-(2′-methoxy-[1,1′- 427.5biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 387(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′- 461.9methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2- carboxylic acid 388(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-4′- 518.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 389 (2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3′- 518.0(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 390 (2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-2-fluoro- 449.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 391(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4- 532.0(methylsulfonamido)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylic acid 392(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4- 468.9methoxyphenyl)piperidine-4-carbonyl)pyrrolidine- 2-carboxylic acid 393(2S,5R)-5-(2-chlorophenyl)-1-(1-(2- 575.0 (methylsulfonamido)-4-(trifluoromethyl)phenyl)piperidine-4- carbonyl)pyrrolidine-2-carboxylicacid 394 (2S,5R)-5-(2-chlorophenyl)-1-(1-(2- 458.9nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 395(2S,5R)-5-(2-chlorophenyl)-1-(1-(4- 438.9cyanophenyl)piperidine-4-carbonyl)pyrrolidine-2- carboxylic acid 396(2S,5R)-5-(3,5-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 397(2S,5R)-5-(3,4-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 398(2S,5R)-5-(2,3-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 399(2S,5R)-5-(2,5-difluorophenyl)-1-(2′-methoxy- 438.4[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 400(2S,5R)-5-([1,1′-biphenyl]-2-yl)-1-(2′-methoxy- 478.6[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 401(2S,5R)-1-(2′-cyano-4′-methoxy-[1,1′-biphenyl]-4- 445.5carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 402(2S,5R)-5-(4-cyanophenyl)-1-(2′-methoxy-[1,1′- 427.5biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 403(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-4- 552.0(phenylsulfonyl)-1H-1,2,3-triazol-1- yl)benzoyl)pyrrolidine-2-carboxylicacid 404 (2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-4′-fluoro- 449.9[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 405(2S,5R)-1-(2′-chloro-5′-cyano-[1,1′-biphenyl]-4- 466.3carbonyl)-5-(2-chlorophenyl)pyrrolidine-2- carboxylic acid 406(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′- 499.9(trifluoromethyl)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 407 (2S,5R)-5-(2-chlorophenyl)-1-(1-(2-methoxy-4- 511.9(trifluoromethyl)phenyl)piperidine-4- carbonyl)pyrrolidine-2-carboxylicacid 408 (2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-3′-(N- 528.0methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 409(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′-(N- 544.0methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 410(2S,5R)-5-(2-chlorophenyl)-1-(6-(5-cyano-2- 492.9methoxyphenyl)-5-methoxynicotinoyl)pyrrolidine- 2-carboxylic acid 411(2S,5R)-5-(2-chlorophenyl)-1-(6-(2,4- 497.9 dimethoxyphenyl)-5-methoxynicotinoyl)pyrrolidine-2-carboxylic acid 412(2S,5R)-5-(2-chlorophenyl)-1-(6-(2,4- 467.9dimethoxyphenyl)nicotinoyl)pyrrolidine-2- carboxylic acid 413(2S,5R)-1-(2′-cyano-4′-(trifluoromethyl)-[1,1′- 483.4biphenyl]-4-carbonyl)-5-(2- fluorophenyl)pyrrolidine-2-carboxylic acid414 (2S,5R)-1-(3′-cyano-4′-fluoro-[1,1′-biphenyl]-4- 433.4carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 415(2S,5R)-1-(2′-chloro-5′-cyano-[1,1′-biphenyl]-4- 449.9carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 416(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6- 486.9 dimethoxypyridazin-4-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylic acid 417(2S,5R)-5-(2-fluorophenyl)-1-(2′-methyl-3′-(N- 511.6methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 418(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-4′-(N- 527.6methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 419(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6- 468.9dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 420(2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2,4- 470.4dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 421(2S,5R)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4- 447.4carbonyl)-5-(2,3-difluorophenyl)pyrrolidine-2- carboxylic acid 422(2S,5R)-5-(2,3-difluorophenyl)-1-(2′-methoxy-4′- 531.5(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 423 (2S,5R)-5-(2,3-difluorophenyl)-1-(2′-methyl-3′- 515.5(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 424 (2S,5R)-5-(2-fluorophenyl)-1-(2′-methyl-3′- 497.6(methylsulfonamido)-[1,1′-biphenyl]-4- carbonyl)pyrrolidine-2-carboxylicacid 425 (2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2- 439.4methoxypyridin-3-yl)benzoyl)pyrrolidine-2- carboxylic acid 426(2S,5R)-5-(2,3-difluorophenyl)-1-(3-methoxy-4-(2- 470.4methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 427(2S,5R)-5-(2-fluorophenyl)-1-(3-methoxy-4-(2- 452.4methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2- carboxylic acid 428(2S,5R)-5-(2,3-difluorophenyl)-1-(4-(3,6- 470.4dimethoxypyridazin-4-yl)benzoyl)pyrrolidine-2- carboxylic acid 429(2S,5R)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4- 463.4carbonyl)-5-(2,3-difluorophenyl)pyrrolidine-2- carboxylic acid 430(2S,5R)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4- 429.5carbonyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid 431(2S,5R)-5-(2,3-difluorophenyl)-1-(4-(3,6- 488.4dimethoxypyridazin-4-yl)-3- fluorobenzoyl)pyrrolidine-2-carboxylic acid432 (2S,5R)-1-(4-(3,6-dimethoxypyridazin-4-yl)-3- 470.4fluorobenzoyl)-5-(2-fluorophenyl)pyrrolidine-2- carboxylic acid

The compounds of table 1 were named using ChemDraw Ultra 12 purchasedfrom CambridgeSoft (Cambridge, Mass., USA).

The compounds of formula I can be prepared by different ways withreactions known by the person skilled in the art. Reaction schemes asdescribed in the example section illustrate by way of example differentpossible approaches.

The invention further provides processes for the preparation ofcompounds of the invention or a pharmaceutically acceptable salts orsolvates thereof.

In one embodiment, the invention further provides a process for thepreparation of a compound of formula Ib-1b′

wherein Ar² is as defined defined above in respect to formula Ib-1b′;

-   Ar¹ is 2-chlorophenyl, 2-fluorophenyl, 2,3-difluorophenyl;-   R¹, R², R³, R^(3′), R⁴ and R are H;-   D is C═O;-   L² is a single bond;-   which consists of:    -   a) the coupling of a compound of formula A

wherein

-   R⁸ is Cl or F and R⁹ is H, or R⁸ and R⁹ are both F;-   R is methyl, ethyl, tert-butyl, benzyl, allyl, phenacyl,    methoxymethyl, methylthiomethyl, 2-methoxyethoxymethyl,    2-trimethylsilylethyl, tert-butyldiphenylsilyl, preferably R is    methyl, ethyl, or tert-butyl;    -   with a compound of formula B

wherein:

-   Ar² is as defined defined above in respect to formula Ib-1b′;-   R″ is Cl or OL wherein L is a carboxylic acid activating group,    followed by    -   b) a alkaline or acidic treatment, hydrogenolysis or treatment        with fluoride of the ester intermediate obtained in step a);-   step b) being optionally followed by conversion of a compound of    formula Ib-1b′ to a pharmaceutically acceptable salt or solvate    thereof.

In another embodiment the invention further provides a process for thepreparation of a compound of formula Ib-1b′

wherein Ar¹ R³, R^(3′), R⁴ are as defined above in respect to formulaIb-1b′;

-   R¹, R², and R are H;-   D is C═O;-   L² is a single bond;-   Ar² is selected from 4′-(2-methoxy-4-methylsulfonyl-1,1′-biphenyl),    4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),    4-(2-methoxypyridin-3-yl)phenyl,    4-(2,6-dimethoxypyrimidin-5-yl)phenyl,    3-methoxy-4-(2-methoxypyrimidin-5-yl)phenyl,    4-(3,6-dimethoxypyridazin-5-yl)phenyl,    4′-(5-cyano-2-methoxy-1,1′-biphenyl),    4′-(5-cyano-2-methyl-1,1′-biphenyl),    3-fluoro-4-(3,6-dimethoxypyridazin-5-yl)phenyl,    (4-(4-methoxypyridin-3-yl)phenyl),    (4′-(methylsulfonamido)-[1,1′-biphenyl]-4-yl),    (3′-(methylsulfonamido)-[1,1′-biphenyl]-4-yl),    (4-(2,4-dimethoxypyrimidin-5-yl)phenyl),    (5-methoxy-6-phenylpyridin-3-yl),    (4-(4-methoxypyrimidin-5-yl)phenyl),    (2,2′-dimethoxy-[1,1′-biphenyl]-4-yl),    (3-methoxy-4-(4-methoxypyridin-3-yl)phenyl),    (4-(2,4-dimethoxypyrimidin-5-yl)-3-methoxyphenyl),    (4′-acetamido-2′-methoxy-[1,1′-biphenyl]-4-yl),    (2′-cyano-4′,5′-dimethoxy-[1,1′-biphenyl]-4-yl),    (2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-yl),    (6-(2,4-dimethoxyphenyl)pyridin-3-yl),    (4-(4,6-dimethoxypyrimidin-5-yl)phenyl),    (4-(3-methoxypyridin-4-yl)phenyl);    which consists of:    -   a) the coupling of a compound of formula C

wherein:

-   Ar¹, R³, R^(3′) and R⁴ are as defined above in respect to formula    Ib-1b′;-   R is methyl, ethyl, tert-butyl, benzyl, allyl, phenacyl,    methoxymethyl, methylthiomethyl, 2-methoxyethoxymethyl,    2-trimethylsilylethyl, tert-butyldiphenylsilyl, preferably R is    methyl, ethyl, or tert-butyl,    -   with a compound of formula D

wherein

-   R″ is Cl or OL, wherein L is a carboxylic acid activating group;-   A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations    1 to 24:

Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CH C—NHSO₂CH₃CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CH CH CH 4 CHCH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CH C—OCH₃ N NC—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CH C—CN CH 9 C—FCH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CH CH CH CHC—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH N C—OCH₃ NC—OCH₃ 14 N C—OCH₃ CH CH CH CH CH 15 CH CH C—OCH₃ N CH N CH 16 CH C—OCH₃C—OCH₃ CH CH CH CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CH C—OCH₃ NC—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CH C—OCH₃C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 22 N CH C—OCH₃ CHC—OCH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CHfollowed by

-   -   b) an alkaline or acidic treatment, a hydrogenolysis or a        treatment with fluoride of the ester intermediate obtained in        step a);

-   step b) being optionally followed by conversion of a compound of    formula Ib-1b′ to a pharmaceutically acceptable salt or solvate    thereof.

In yet another embodiment, the invention further provides a process forthe preparation of a compound of the formula Ib-1h″

wherein

-   R⁸ is F or Cl and R⁹ is H, or both R⁸ and R⁹ are F;-   R is H;-   A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations    1 to 24:

Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CH C—NHSO₂CH₃CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CH CH CH 4 CHCH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CH C—OCH₃ N NC—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CH C—CN CH 9 C—FCH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CH CH CH CHC—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH N C—OCH₃ NC—OCH₃ 14 N C—OCH₃ CH CH CH CH CH 15 CH CH C—OCH₃ N CH N CH 16 CH C—OCH₃C—OCH₃ CH CH CH CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CH C—OCH₃ NC—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CH C—OCH₃C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 22 N CH C—OCH₃ CHC—OCH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CHwhich consists of:

-   -   a) the coupling of a compound of formula A as defined above with        a compound of formula B as defined above, followed by    -   b) an alkaline or acidic treatment, a hydrogenolysis or a        treatment with fluoride of the ester intermediate obtained in        step a);

-   step b) being optionally followed by conversion of a compound of    formula Ib-1h″ to a pharmaceutically acceptable salt or solvate    thereof.

In one variant of the process for the preparation of a compound offormula Ib-1h″ as described above, the compound of formula Ib-1h″ isselected from:

122 (2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid 125(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid 129(2S,5R)-5-(2-chlorophenyl)-1-(4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 130(2S,5R)-5-(2-chlorophenyl)-1-(3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 161(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 191(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6-phenylnicotinoyl)pyrrolidine-2-carboxylic acid 193(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-methoxypyridin-4-yl)benzoyl)pyrrolidine-2-carboxylic acid 203(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 237(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(2-methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 246(2S,5R)-5-(2-fluorophenyl)-1-(4-(2-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid 247(2S,5R)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid 314(2S,5R)-1-(2,2′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid 327(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(4-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid 337(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)-3-methoxybenzoyl)pyrrolidine-2-carboxylic acid 343(2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylicacid 345 (2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 346(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 348(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyridazin-4-yl)benzoyl)pyrrolidine-2-carboxylic acid 350(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylicacid 351 (2S,5R)-1-(4′-acetamido-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidinc-2-carboxylic acid 354(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine- 2-carboxylicacid 361 (2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′,5′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 371(2S,5R)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid 374(2S,5R)-1-(4-(3,6-dimethoxypyridazin-4-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid 409(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid 412(2S,5R)-5-(2-chlorophenyl)-1-(6-(2,4-dimethoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylic acid 416(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyridazin-4-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylic acid 419(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 420(2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylic acid 421(2S,5R)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4-carbonyl)-5-(2,3-difluorophenyl)pyrrolidine-2-carboxylic acid

Suitable carboxylic acid activating groups L for use in the aboveprocesses are benzotriazol-1-yl, 7-azabenzotriazol-1-yl, imidazol-1-yl,preferably 7-azabenzotriazol-1-yl.

In a typical procedure applicable to all of the aforementionedprocesses, the coupling reactions of a compound of formula B or Dwherein R″ is OL, are done in the presence of a base such astriethylamine, diisopropylethylamine, preferably diisopropylethylamine,in a suitable solvent such as MeCN, DMF, DCM, preferably MeCN, at asuitable temperature ranging from room temperature to the boiling pointof the solvent used, preferably at room temperature. Intermediates offormulae B and D are generated in situ from their correspondingcarboxylic acid precursor which is reacted with HOBt, HOBt hydrate,HATU, CDI, pentafluorophenol, preferably with HATU. Preferably, thecoupling with an activated carboxylic acid is made using HATU and DIEAin MeCN at room temperature.

In a typical procedure applicable to all of the above-mentionedprocesses, the coupling reactions of a compound of formula B or Dwherein R is Cl, are done in the presence of a base such astriethylamine, diisopropylethylamine, preferably triethylamine, in asuitable solvent such as MeCN, DMF, DCM preferably DCM, at a suitabletemperature ranging from room temperature to the boiling point of thesolvent used, preferably at room temperature. Preferably, the couplingwith an acyl chloride is made using triethylamine in DCM at roomtemperature.

In a typical procedure applicable to all of the aforementionedprocesses, the alkaline treatment of the intermediates obtained aftercoupling step a) and wherein R is methyl or ethyl, are done in thepresence of a base such as sodium hydroxide, potassium hydroxide,lithium hydroxide, trimethyltin hydroxide, preferably lithium hydroxide,in a suitable solvent such as a 1/1 (v/v) mixture of water and THF, DCE,at a suitable temperature ranging from room temperature to the boilingpoint of the solvent used, preferably at room temperature.

In a typical procedure applicable to all of the above-mentionedprocesses, the acidic treatment of the intermediates obtained aftercoupling step a) and wherein R is tert-butyl, are done in the presenceof a suitable acid such as HCl or TFA, in a suitable solvent such asDCM, dioxane, or in a miscible mixture of said solvents, at roomtemperature.

Those skilled in the art will appreciate that typical proceduresapplicable to all of the above-mentioned processes for step b) andwherein R is benzyl, allyl, phenacyl, methoxymethyl, methylthio methyl,2-methoxyethoxymethyl, 2-trimethylsilylethyl or tert-butyldiphenylsilylare well known and are indeed reported in Koscienski P. J., ProtectingGroups 3^(rd) edition, Thieme, 2005, 394-450.

In a particular embodiment, useful intermediates for the preparation ofcompounds of the invention are those of formula E:

wherein

-   R⁸ is Cl or F and R⁹ is H, or R⁸ and R⁹ are both F;-   R is methyl, ethyl, benzyl, allyl, phenacyl, methoxymethyl,    methylthiomethyl, 2-methoxyethoxymethyl, 2-trimethylsilyl ethyl,    tert-butyldiphenylsilyl or R is tert-butyl when R⁸ is F.

Preferred compounds of formula E are those wherein R is methyl, ethyl,or R is tert-butyl when R⁸ is F.

In a particular embodiment, useful intermediates for the preparation ofcompounds of the invention are those of formula F:

wherein

-   R′ is OH or Cl;-   A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations    1 to 7, 9, 10, 13 to 15,17 to 21, 23 and 24:

Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CH C—NHSO₂CH₃CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CH CH CH 4 CHCH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CH C—OCH₃ N NC—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 9 C—F CH C—OCH₃ N N C—OCH₃ CH 10CH CH CH N CH CH C—OCH₃ 13 CH CH CH N C—OCH₃ N C—OCH₃ 14 N C—OCH₃ CH CHCH CH CH 15 CH CH C—OCH₃ N CH N CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18C—OCH₃ CH C—OCH₃ N C—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CHCH C—CN CH C—OCH₃ C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 23CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CH

The invention further provides the use of the compounds of the inventionor pharmaceutically acceptable salts, solvates or prodrugs thereof asagonists or partial agonists of G-protein coupled receptor 43 (GPR43).

Accordingly, in a particularly preferred embodiment, the inventionrelates to the use of compounds of formula I and subformulae inparticular those of table 1 above, or pharmaceutically acceptable salts,solvates and prodrugs thereof, as GPR43 agonists or partial agonists.

[Applications]

The compounds of the invention are therefore useful in the preventionand/or treatment of type II diabetes, obesity, dyslipidemia such asmixed or diabetic dyslipidemia, hypercholesterolemia, low HDLcholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia,hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH).

Preferred diseases are type II diabetes, lipid disorders such asdyslipidemia, hypertension, obesity, atherosclerosis and its sequelae.

In a particular preferred embodiment the diseases are type II diabetesand a lipid disorder such as dyslipidemia.

The invention also provides for a method for delaying in patient theonset of type II diabetes, obesity, dyslipidemia such as mixed ordiabetic dyslipidemia, hypercholesterolemia, low HDL cholesterol, highLDL cholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia,hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH)comprising the administration of a pharmaceutically effective amount ofa compound of formula (I) or pharmaceutically acceptable salt thereof toa patient in need thereof.

Preferably, the patient is a warm-blooded animal, more preferably ahuman.

The invention further provides the use of a compound of formula (I) or apharmaceutically acceptable salt or solvates thereof for the manufactureof a medicament for use in treating a patient and/or preventing apatient from developing a disease selected from the group consisting oftype II diabetes, obesity, dyslipidemia such as mixed or diabeticdyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDLcholesterol, hyperlipidemia, hypertriglyccridcmia, hypoglycemia,hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH).

Preferably, the patient is a warm-blooded animal, more preferably ahuman.

According to a further feature of the present invention there isprovided a method for modulating GPR43 receptor activity, in a patient,preferably a warm blooded animal, and even more preferably a human, inneed of such treatment, which comprises administering to said animal aneffective amount of compound of the present invention, or apharmaceutically acceptable salt or solvate thereof

According to one embodiment, the compounds of the invention, theirpharmaceutical acceptable salts, solvates or prodrugs may beadministered as part of a combination therapy. Thus, are included withinthe scope of the present invention embodiments comprisingcoadministration of, and compositions and medicaments which contain, inaddition to a compound of the present invention, a pharmaceuticallyacceptable salt or solvate thereof as active ingredient, additionaltherapeutic agents and/or active ingredients. Such multiple drugregimens, often referred to as combination therapy, may be used in thetreatment and/or prevention of any of the diseases or conditionsmediated by or associated with GPR43 receptor modulation, particularlytype II diabetes, obesity, dyslipidemia such as mixed or diabeticdyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDLcholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia,hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH). Theuse of such combinations of therapeutic agents is especially pertinentwith respect to the treatment of the above-mentioned list of diseaseswithin a patient in need of treatment or one at risk of becoming such apatient.

In addition to the requirement of therapeutic efficacy, which maynecessitate the use of active agents in addition to the GPR43 agonist orpartial agonist compounds of Formula I or their pharmaceuticalacceptable salts, solvates or prodrugs thereof, there may be additionalrationales which compel or highly recommend the use of combinations ofdrugs involving active ingredients which represent adjunct therapy,i.e., which complement and supplement the function performed by theGPR43 receptor agonist or partial agonist compounds of the presentinvention. Suitable supplementary therapeutic agents used for thepurpose of auxiliary treatment include drugs which, instead of directlytreating or preventing a disease or condition mediated by or associatedwith GPR43 receptor modulation, treat diseases or conditions whichdirectly result from or indirectly accompany the basic or underlyingGPR43 receptor modulated disease or condition.

Thus, the methods of treatment and pharmaceutical compositions of thepresent invention may employ the compounds of Formula I or theirpharmaceutical acceptable salts, solvates or prodrugs thereof in theform of monotherapy, but said methods and compositions may also be usedin the form of multiple therapy in which one or more compounds ofFormula I or their pharmaceutically acceptable salts, solvates andprodrugs are coadministered in combination with one or more othertherapeutic agents such as those described in detail further herein.

Examples of other active ingredients that may be administered incombination with a compound of Formula I or a pharmaceuticallyacceptable salt or solvate thereof, and either administered separatelyor in the same pharmaceutical composition, include but are not limitedto:

-   -   (a) PPARγ agonists and partial agonists, including both        glitazones and non-glitazones (e.g. troglitazone, pioglitazone,        englitazone, MCC-555, rosiglitazone, balaglitazone,        netoglitazone, T-131, LY-300512 and LY-818;    -   (b) Biguanides such as metformin and phenformin;    -   (c) Protein tyrosine phosphatase-1B (PTP-1B) inhibitors,    -   (d) Dipeptidyl peptidase IV (DP-IV) inhibitor, such as MK-0431        and LAF-237;    -   (e) Insulin or insulin mimetics;    -   (f) Sulfonylureas such as tolbutamide and glipizide or related        materials;    -   (g) α-glucosidase inhibitors (such as acarbose);    -   (h) agents which improve a patient's lipid profile such as (i)        HMG-CoA reductase inhibitors (lovastatin, simvastatin,        rosuvastatin, pravastatin, fluvastatin, atorvastatin,        rivastatin, itavastatin, ZD-4522 and other statins), (ii) bile        acid sequestrants (cholestyramine, colestipol and        dialkylaminoalkyl derivatives of a cross-linked dextran), (iii)        nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα        agonists such as fenofibric acid derivatives (gemfibrozil,        clofibrate, fenofibrate and bezafibrate), (v) cholesterol        absorption inhibitors such as for example ezetimibe, (vi) acyl        CoA: cholesterol acyltransferase (ACAT)inhibitors such as        avasimibe, (vii) CETP inhibitors such as torcetrapib and (viii)        phenolic anti-oxidants such as probucol;    -   (i) PPARα/γ dual agonists such as muraglitazar, tesaglitazar,        farglitazar and JT-501;    -   (j) PPARδ agonists such those disclosed in WO97/28149;    -   (k) Antiobesity compounds such as fenfluramine, dextenfluramine,        phentiramine, subitramine, orlistat, neuropeptide Y5 inhibitors,        MC4R agonists, cannabinoid receptor 1 antagonists/inverse        agonists and β3 adrenergic receptor agonists;    -   (l) Ileal bile acid transporter inhibitors;    -   (m) Agents intended for use in inflammatory conditions such as        aspirin, non-steroidal, anti-inflammatory drugs,        glucocorticoids, azulfidine and cyclo-oxygenase 2 selective        inhibitors;    -   (n) Glucagon receptor antagonists;    -   (o) GLP-1;    -   (p) GIP-1;    -   (q) GLP-1 analogs, such as exendins, for example exenitide, and    -   (r) Hydroxysterol dehydrogenase-1 (HSD-1) inhibitors.

The above combinations include combinations of a compound of the presentinvention or a pharmaceutically acceptable salt or solvate not only withone other active compound but also with two or more active compounds.Non limiting examples include combinations of compounds having Formula Iwith two or more active compounds selected from biguanides,sulfonylureas, HMG-CoA reductase inhibitors, other PPAR agonists, PTP-1Binhibitors, DP-IV inhibitors and anti-obesity compounds.

In the above-described embodiment combinations of the present invention,the compound of Formula I, a pharmaceutically acceptable salt or solvatethereof and other therapeutic active agents may be administered in termsof dosage forms either separately or in conjunction with each other, andin terms of their time of administration, either serially orsimultaneously. Thus, the administration of one component agent may beprior to, concurrent with, or subsequent to the administration of theother component agent(s).

The invention also provides pharmaceutical compositions comprising acompound of formula I or a pharmaceutically acceptable salt or solvatethereof and at least one pharmaceutically acceptable carrier, diluent,excipient and/or adjuvant. As indicated above, the invention also coverspharmaceutical compositions which contain, in addition to a compound ofthe present invention, a pharmaceutically acceptable salt or solvatethereof as active ingredient, additional therapeutic agents and/oractive ingredients.

Another object of this invention is a medicament comprising at least onecompound of the invention, or a pharmaceutically acceptable salt orsolvate thereof, as active ingredient.

The invention also provides the use of a compound of formula I or apharmaceutically acceptable salt or solvate thereof for the manufactureof a medicament. Preferably, the medicament is used for the treatmentand/or prevention of type II diabetes, obesity, dyslipidemia such asmixed or diabetic dyslipidemia, hypercholesterolemia, low HDLcholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia,hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance,hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolicsyndrome, syndrome X, thrombotic disorders, cardiovascular disease,atherosclerosis and its sequelae including angina, claudication, heartattack, stroke and others, kidney diseases, ketoacidosis, nephropathy,diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liverdiseases such as steatosis or nonalcoholic steatohepatitis (NASH).

Preferred diseases are type II diabetes, lipid disorders such asdyslipidemia, hypertension, obesity, atherosclerosis and its sequelae.

In a particular preferred embodiment the disease are type II diabetesand a lipid disorder such as dyslipidemia.

According to a further feature of the present invention there isprovided the use of a compound of formula I or a pharmaceuticallyacceptable salt or solvate thereof for the manufacture of a medicamentfor modulating GPR43 receptor activity, in a patient, in need of suchtreatment, which comprises administering to said patient an effectiveamount of compound of the present invention, or a pharmaceuticallyacceptable salt or solvate thereof

Preferably, the patient is a warm-blooded animal, more preferably ahuman.

As set forth above, the compounds of the invention, theirpharmaceutically acceptable salts, solvates and prodrugs may be used inmonotherapy or in combination therapy. Thus, according to oneembodiment, the invention provides the use of a compound of theinvention for the manufacture of a medicament for at least one of thepurposes described above, wherein said medicament is administered to apatient in need thereof, preferably a warm-blooded animal, and even morepreferably a human, in combination with at least one additionaltherapeutic agent and/or active ingredient. The benefits and advantagesof such a multiple drug regimen, possible administration regimens aswell as suitable additional therapeutic agents and/or active ingredientsare those described above.

Generally, for pharmaceutical use, the compounds of the inventions maybe formulated as a pharmaceutical preparation comprising at least onecompound of the invention and at least one pharmaceutically acceptablecarrier, diluent, excipient and/or adjuvant, and optionally one or morefurther pharmaceutically active compounds.

By means of non-limiting examples, such a formulation may be in a formsuitable for oral administration, for parenteral administration (such asby intravenous, intramuscular or subcutaneous injection or intravenousinfusion), for topical administration (including ocular), foradministration by inhalation, by a skin patch, by an implant, by asuppository, etc. Such suitable administration forms which may be solid,semi-solid or liquid, depending on the manner of administration—as wellas methods and carriers, diluents and excipients for use in thepreparation thereof, will be clear to the skilled person; reference ismade to the latest edition of Remington's Pharmaceutical Sciences.

Some preferred, but non-limiting examples of such preparations includetablets, pills, powders, lozenges, sachets, cachets, elixirs,suspensions, emulsions, solutions, syrups, aerosols, ointments, cremes,lotions, soft and hard gelatin capsules, suppositories, drops, sterileinjectable solutions and sterile packaged powders (which are usuallyreconstituted prior to use) for administration as a bolus and/or forcontinuous administration, which may be formulated with carriers,excipients, and diluents that are suitable per se for such formulations,such as lactose, dextrose, sucrose, sorbitol, mannitol, starches, gumacacia, calcium phosphate, alginates, tragacanth, gelatin, calciumsilicate, microcrystalline cellulose, polyvinylpyrrolidone, polyethyleneglycol, cellulose, (sterile) water, methylcellulose, methyl- andpropylhydroxybenzoates, talc, magnesium stearate, edible oils, vegetableoils and mineral oils or suitable mixtures thereof. The formulations canoptionally contain other substances that are commonly used inpharmaceutical formulations, such as lubricating agents, wetting agents,emulsifying and suspending agents, dispersing agents, desintegrants,bulking agents, fillers, preserving agents, sweetening agents, flavoringagents, flow regulators, release agents, etc. The compositions may alsobe formulated so as to provide rapid, sustained or delayed release ofthe active compound(s) contained therein.

The pharmaceutical preparations of the invention are preferably in aunit dosage form, and may be suitably packaged, for example in a box,blister, vial, bottle, sachet, ampoule or in any other suitablesingle-dose or multi-dose holder or container (which may be properlylabeled); optionally with one or more leaflets containing productinformation and/or instructions for use. Generally, such unit dosageswill contain between 0.05 and 1000 mg, and usually between 1 and 500 mg,of at least one compound of the invention, e.g. about 10, 25, 50, 100,200, 300 or 400 mg per unit dosage.

Usually, depending on the condition to be prevented or treated and theroute of administration, the active compound of the invention willusually be administered between 0.01 to 100 mg per kilogram, more oftenbetween 0.1 and 50 mg, such as between 1 and 25 mg, for example about0.5, 1, 5, 10, 15, 20 or 25 mg, per kilogram body weight of the patientper day, which may be administered as a single daily dose, divided overone or more daily doses, or essentially continuously, e.g. using a dripinfusion.

[Definitions]

The definitions and explanations below are for the terms as usedthroughout the entire application, including both the specification andthe claims.

When describing the compounds of the invention, the terms used are to beconstrued in accordance with the following definitions, unless indicatedotherwise.

Where groups may be substituted, such groups may be substituted with oneor more substituents, and preferably with one, two or threesubstituents. Substituents may be selected from but not limited to, forexample, the group comprising halogen, hydroxyl, oxo, cyano, nitro,amido, carboxy, amino, cyano haloalkoxy, and haloalkyl.

As used herein the terms such as “alkyl, aryl, or cycloalkyl, each beingoptionally substituted with . . . ” or “alkyl, aryl, or cycloalkyl,optionally substituted with . . . ” encompasses “alkyl optionallysubstituted with . . . ”, “aryl optionally substituted with . . . ” and“cycloalkyl optionally substituted with . . . ”.

The term “halo” or “halogen” means fluoro, chloro, bromo, or iodo.Preferred halo groups are fluoro and chloro.

The term “alkyl” by itself or as part of another substituent refers to ahydrocarbyl radical of Formula C_(n)H_(2n+1) wherein n is a numbergreater than or equal to 1. Generally, alkyl groups of this inventioncomprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms,more preferably from 1 to 3 carbon atoms, still more preferably 1 to 2carbon atoms. Alkyl groups may be linear or branched and may besubstituted as indicated herein. C_(x-y)-alkyl and Cx-Cy-alkyl refer toalkyl groups which comprise from x to y carbon atoms.

Suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl,n-butyl, i-butyl, s-butyl and tert-butyl, pentyl and its isomers (e.g.n-pentyl, iso-pentyl), and hexyl and its isomers (e.g. n-hexyl,iso-hexyl). Preferred alkyl groups include methyl, ethyl, n-propyl,i-propyl, n-butyl, i-butyl, s-butyl and tert-butyl.

When the suffix “ene” (“alkylene”) is used in conjunction with an alkylgroup, this is intended to mean the alkyl group as defined herein havingtwo single bonds as points of attachment to other groups. The term“alkylene” includes methylene, ethylene, methylmethylene, propylene,ethylethylene, and 1,2-dimethylethylene.

The term “alkenyl” as used herein refers to an unsaturated hydrocarbylgroup, which may be linear or branched, comprising one or morecarbon-carbon double bonds. Suitable alkenyl groups comprise between 2and 6 carbon atoms, preferably between 2 and 4 carbon atoms, still morepreferably between 2 and 3 carbon atoms. Examples of alkenyl groups areethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers,2-hexenyl and its isomers, 2,4-pentadienyl and the like.

The term “alkynyl” as used herein refers to a class of monovalentunsaturated hydrocarbyl groups, wherein the unsaturation arises from thepresence of one or more carbon-carbon triple bonds. Alkynyl groupstypically, and preferably, have the same number of carbon atoms asdescribed above in relation to alkenyl groups. Non limiting examples ofalkynyl groups are ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyland its isomers, 2-hexynyl and its isomers-and the like. The terms“alkenylene” and “alkynylene” respectively mean an alkenyl group or analkinyl group as defined above having two single bonds as points ofattachment to other groups.

The term “haloalkyl” alone or in combination, refers to an alkyl radicalhaving the meaning as defined above wherein one or more hydrogens arereplaced with a halogen as defined above. Non-limiting examples of suchhaloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl,difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.

The term “cycloalkyl” as used herein is a cyclic alkyl group, that is tosay, a monovalent, saturated, or unsaturated hydrocarbyl group having 1or 2 cyclic structures. Cycloalkyl includes monocyclic or bicyclichydrocarbyl groups. Cycloalkyl groups may comprise 3 or more carbonatoms in the ring and generally, according to this invention comprisefrom 3 to 10, more preferably from 3 to 8 carbon atoms still morepreferably from 3 to 6 carbon atoms. Examples of cycloalkyl groupsinclude but are not limited to cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, with cyclopropyl being particularly preferred.

When the suffix “ene” is used in conjunction with a cyclic group, thisis intended to mean the cyclic group as defined herein having two singlebonds as points of attachment to other groups.

Therefore, “cycloalkylene” herein refers to a saturated homocyclichydrocarbyl biradical of Formula C_(n)H_(2n−2). Suitable cycloalkylenegroups are C₃₋₆ cycloalkylene group, preferably a C₃₋₅ cycloalkylene(i.e. 1,2cyclopropylene, 1,1-cyclopropylene, 1,1-cyclobutylene,1,2-cyclobutylene, 1,3-cyclobutylene, 1,3-cyclopentylene, or1,1-cyclopentylene), more preferably a C₃₋₄ cycloalkylene (i.e.1,3-cyclopropylene, 1,1-cyclopropylene, 1,1-cyclobutylene,1,2-cyclobutylene).

Where at least one carbon atom in a cycloalkyl group is replaced with aheteroatom, the resultant ring is referred to herein as“heterocycloalkyl” or “heterocyclyl”.

The terms “heterocyclyl”, “heterocycloalkyl” or “heterocyclo” as usedherein by itself or as part of another group refer to non-aromatic,fully saturated or partially unsaturated cyclic groups (for example, 3to 7 member monocyclic, 7 to 11 member bicyclic, or containing a totalof 3 to 10 ring atoms) which have at least one heteroatom in at leastone carbon atom-containing ring. Each ring of the heterocyclic groupcontaining a heteroatom may have 1, 2, 3 or 4 heteroatoms selected fromnitrogen, oxygen and/or sulfur atoms, where the nitrogen and sulfurheteroatoms may optionally be oxidized and the nitrogen heteroatoms mayoptionally be quaternized. Any of the carbon atoms of the heterocyclicgroup may be substituted by oxo (for example piperidone, pyrrolidinone).The heterocyclic group may be attached at any heteroatom or carbon atomof the ring or ring system, where valence allows. The rings ofmulti-ring heterocycles may be fused, bridged and/or joined through oneor more Spiro atoms. Non limiting exemplary heterocyclic groups includeoxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinylimidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl,thiazolidinyl, isothiazolidinyl, piperidinyl, 3H-indolyl, indolinyl,isoindolinyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl,2-pyrazolinyl, 3-pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl,4H-pyranyl, 3,4-dihydro-2H-pyranyl, 3-dioxolanyl, 1,4-dioxanyl,2,5-dioximidazolidinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, indolinyl,tetrahydropyranyl, tetrahydrofuranyl, tetrahydroquinolinyl,tetrahydroisoquinolin-1-yl, tetrahydroisoquinolin-2-yl,tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl,thiomorpholin-4-yl, thiomorpholin-4-ylsulfoxide,thiomorpholin-4-ylsulfone, 1,3-dioxolanyl, 1,4-oxathianyl,1H-pyrrolizinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl,and morpholin-4-yl.

The ring atoms of heterocyclyl and heterocyclylene moieties are numberedbased on scheme below

The term “aryl” as used herein refers to a polyunsaturated, aromatichydrocarbyl group having a single ring (i.e. phenyl) or multiplearomatic rings fused together (e.g. naphtyl) or linked covalently,typically containing 5 to 12 atoms; preferably 6 to 10, wherein at leastone ring is aromatic. The aromatic ring may optionally include one totwo additional rings (either cycloalkyl, heterocyclyl or heteroaryl)fused thereto. Aryl is also intended to include the partiallyhydrogenated derivatives of the carbocyclic systems enumerated herein.Non-limiting examples of aryl comprise phenyl, biphenylyl, biphenylenyl,5- or 6-tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl,1-2-, 3-, 4- or 5-acenaphtylenyl, 3-, 4- or 5-acenaphtenyl, 1- or2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl,1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, 1-, 2-, 3-, 4- or5-pyrenyl.

The term “arylene” as used herein is intended to include divalentcarbocyclic aromatic ring systems such as phenylene, biphenylylene,naphthylene, indenylene, pentalenylene, azulenylene and the like.Arylene is also intended to include the partially hydrogenatedderivatives of the carbocyclic systems enumerated above. Non-limitingexamples of such partially hydrogenated derivatives are1,2,3,4-tetrahydronaphthylene, 1,4-dihydronaphthylene and the like.

The term “arylalkyl” or “aralkyl” refers to a linear or branched alkylgroup where one carbon is attached to an aryl ring. Non limitingexamples of aralkyl comprise benzyl, phenethyl, (naphtalen-1-yl) or(naphtalen-2-yl)methyl. When an aralkyl group is substituted, thesubstituent(s) is/are attached either on the alkyl group or on the arylring. A “x-membered aralkyl” refers to a linear or branched alkyl groupwhere one carbon is attached to a x-membered aryl ring. Where at leastone carbon atom in an aryl group is replaced with a heteroatom, theresultant ring is referred to herein as a heteroaryl ring.

The term “heteroaryl” as used herein by itself or as part of anothergroup refers but is not limited to 5 to 12 carbon-atom aromatic rings orring systems containing 1 to 2 rings which are fused together or linkedcovalently, typically containing 5 to 6 atoms; at least one of which isaromatic, in which one or more carbon atoms in one or more of theserings is replaced by oxygen, nitrogen and/or sulfur atoms where thenitrogen and sulfur heteroatoms may optionally be oxidized and thenitrogen heteroatoms may optionally be quaternized. Such rings may befused to an aryl, cycloalkyl, heteroaryl or heterocyclyl ring.Non-limiting examples of such heteroaryl, include: furanyl, thiophenyl,pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl,triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl,thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl,dioxinyl, thiazinyl, triazinyl, imidazo[2,1-b][1,3]thiazolyl,thieno[3,2-b]furanyl, thieno[3,2-b]thiophenyl,thieno[2,3-d][1,3]thiazolyl, thieno[2,3-d]imidazolyl,tetrazolo[1,5-a]pyridinyl, indolyl, indolizinyl, isoindolyl,benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl,indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2-benzisoxazolyl,2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl,2,1-benzoisothiazolyl, benzotriazolyl, 1,2,3-benzoxadiazolyl,2,1,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl,thienopyridinyl, purinyl, imidazo[1,2-a]pyridinyl,6-oxo-pyridazin-1(6H)-yl, 2-oxopyridin-1(2H)-yl,6-oxo-pyridazin-1(6H)-yl, 2-oxopyridin-1(2H)-yl, 1,3-benzodioxolyl,quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl.

The term “heteroarylene” as used herein means divalent carbocyclicaromatic ring systems including pyridinylene and the like.

The ring atoms of heteroaryl or heteroarylene moieties are numbered onscheme below:

The term “biaryl” as used herein designates two aryl moieties as definedherein linked via a single bond. Non-limiting examples of such biarylmoieties include biphenyl.

The term “heterobiaryl” as used herein designates two heteroarylmoieties as defined herein or a heteroaryl moiety and an aryl moity asdefined herein linked via a single bond. Non-limiting examples of suchheterobiaryl moieties include pyridinylphenyl which is meant to include(2-pyridinyl)phenyl, (3-pyridinyl)phenyl and (4-pyridinyl)phenyl,bipyridinyl.

The term “alkylamino” as used herein means an amino group substitutedwith one or two alkyl groups. This includes monoalkylamino anddialkylamino groups.

The term “carbamoyl” as used herein means a group of formula

wherein the arrow defines the attachment point.

The term “carbamimidoyl” as used herein means a group of formula

wherein the arrow defines the attachment point.

The term “carbamimidoyl” as used herein means a group of formula

wherein the arrow defines the attachment point.

The compounds of Formula I and subformulae thereof contain at least oneasymmetric center and thus may exist as different stereoisomeric forms.Accordingly, the present invention includes all possible stereoisomersand includes not only racemic compounds but the individual enantiomersand their non racemic mixtures as well. When a compound is desired as asingle enantiomer, such may be obtained by stereospecific synthesis, byresolution of the final product or any convenient intermediate, or bychiral chromatographic methods as each are known in the art. Resolutionof the final product, an intermediate, or a starting material may beeffected by any suitable method known in the art. See, for example,Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L.N. Mander (Wiley—Interscience, 1994), incorporated by reference withregard to stereochemistry.

The bonds from an asymmetric carbon in compounds of the presentinvention may be depicted herein using a solid line (—), a zigzag line (

), a solid wedge (

) or a dotted wedge (

), a solid bar (

) or a dotted bar (

). The use of a solid line to depict bonds from an asymmetric carbonatom is meant to indicate that all possible stereoisomers are meant tobe included, unless it is clear from the context that a specificstereoisomer is intended. The use of either a solid or dotted wedge todepict bonds from an asymmetric carbon atom is meant to indicate thatonly the stereoisomer shown is meant to be included.

The compounds of the invention may also contain more than one asymmetriccarbon atom. In those compounds, the use of a solid line to depict bondsfrom asymmetric carbon atoms is meant to indicate that all possiblestereoisomers are meant to be included, unless it is clear from thecontext that a specific stereoisomer is intended. In those compounds,the use of solid or dotted bars is meant to indicate relativestereochemistry. As an example,

The compounds of the invention may be in the form of pharmaceuticallyacceptable salts. Pharmaceutically acceptable salts of the compounds offormula I include the acid addition and base salts thereof. Suitableacid addition salts are formed from acids which form non-toxic salts.Examples include the acetate, adipate, aspartate, benzoate, besylate,bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate,cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate,glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride,hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate,nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate,saccharate, stearate, succinate, tannate, tartrate, tosylate,trifluoroacetate and xinofoate salts. Suitable base salts are formedfrom bases which form non-toxic salts. Examples include the aluminium,arginine, benzathine, calcium, choline, diethylamine, diolamine,glycine, lysine, magnesium, meglumine, olamine, potassium, sodium,tromethamine, 2-(diethylamino)ethanol, ethanolamine, morpholine,4-(2-hydroxyethyl)morpholine and zinc salts. Hemisalts of acids andbases may also be formed, for example, hemisulphate and hemicalciumsalts. Preferred, pharmaceutically acceptable salts includehydrochloride/chloride, hydrobromide/bromide, bisulphate/sulphate,nitrate, citrate, and acetate.

When the compounds of the invention contain an acidic group as well as abasic group the compounds of the invention may also form internal salts,and such compounds are within the scope of the invention. When thecompounds of the invention contain a hydrogen-donating heteroatom (e.g.NH), the invention also covers salts and/or isomers formed by transferof said hydrogen atom to a basic group or atom within the molecule.

Pharmaceutically acceptable salts of compounds of Formula I may beprepared by one or more of these methods:

(i) by reacting the compound of Formula I with the desired acid;

(ii) by reacting the compound of Formula I with the desired base;

(iii) by removing an acid- or base-labile protecting group from asuitable precursor of the compound of Formula I or by ring-opening asuitable cyclic precursor, for example, a lactone or lactam, using thedesired acid; or

(iv) by converting one salt of the compound of Formula I to another byreaction with an appropriate acid or by means of a suitable ion exchangecolumn.

All these reactions are typically carried out in solution. The salt, mayprecipitate from solution and be collected by filtration or may berecovered by evaporation of the solvent. The degree of ionization in thesalt may vary from completely ionized to almost non-ionized.

The term “solvate” is used herein to describe a molecular complexcomprising the compound of the invention and one or morepharmaceutically acceptable solvent molecules, for example, ethanol. Theterm ‘hydrate’ is employed when said solvent is water.

All references to compounds of formula I include references to salts,solvates, multi-component complexes and liquid crystals thereof.

The compounds of the invention include compounds of formula I ashereinbefore defined, including all polymorphs and crystal habitsthereof, prodrugs and isomers thereof (including optical, geometric andtautomeric isomers) and isotopically-labeled compounds of formula I.

In addition, although generally, with respect to the salts of thecompounds of the invention, pharmaceutically acceptable salts arepreferred, it should be noted that the invention in its broadest sensealso included non-pharmaceutically acceptable salts, which may forexample be used in the isolation and/or purification of the compounds ofthe invention. For example, salts formed with optically active acids orbases may be used to form diastereoisomeric salts that can facilitatethe separation of optically active isomers of the compounds of Formula Iabove.

The invention also generally covers all pharmaceutically acceptablepredrugs and prodrugs of the compounds of Formula I.

The term “prodrug” as used herein means the pharmacologically acceptablederivatives of compounds of formula I such as esters whose in vivobiotransformation product is the active drug. Prodrugs are characterizedby increased bio-availability and are readily metabolized into theactive compounds in vivo. Suitable prodrugs for the purpose of theinvention include carboxylic esters, in particular alkyl esters, arylesters, acyloxyalkyl esters, and dioxolene carboxylic esters; ascorbicacid esters as well as compounds of formula I in which Z is asubstituent selected from the table 2 below.

TABLE 2 Z Q —C(O)SQ Alkyl or aryl —C(O)NQ¹Q² Q¹ and Q² independentlyselected from: H, alkyl, aryl, OH or NH₂ —C(O)OCHQ¹O(O)CQ² Q¹ = H orphenyl Q² = alkyl or aryl —C(O)OCHQCl H or aryl —C(OQ)₃ Alkyl—C(O)OC(O)OQ Alkyl or aryl —C(O)CH₂Q SMe, SOMe, SO₂Me

The term “predrug”, as used herein, means any compound that will bemodified to form a drug species, wherein the modification may take placeeither inside or outside of the body, and either before or after thepredrug reaches the area of the body where administration of the drug isindicated.

The term “patient” refers to a warm-blooded animal, more preferably ahuman, who/which is awaiting or receiving medical care or is or will bethe object of a medical procedure.

The term “human” refers to subject of both genders and at any stage ofdevelopment (i.e. neonate, infant, juvenile, adolescent, adult).

The terms “treat”, “treating” and “treatment, as used herein, are meantto include alleviating or abrogating a condition or disease and/or itsattendant symptoms.

The terms “prevent”, “preventing” and “prevention”, as used herein,refer to a method of delaying or precluding the onset of a condition ordisease and/or its attendant symptoms, barring a patient from acquiringa condition or disease, or reducing a patient's risk of acquiring acondition or disease.

The term “therapeutically effective amount” (or more simply an“effective amount”) as used herein means the amount of active agent oractive ingredient (e. g. GPR43 agonist or partial agonist) which issufficient to achieve the desired therapeutic or prophylactic effect inthe individual to which it is administered.

The term “administration”, or a variant thereof (e.g.,“administering”),means providing the active agent or active ingredient (e.g. a GPR43agonist or partial agonist), alone or as part of a pharmaceuticallyacceptable composition, to the patient in whom/which the condition,symptom, or disease is to be treated or prevented.

By “pharmaceutically acceptable” is meant that the ingredients of apharmaceutical composition are compatible with each other and notdeleterious to the patient thereof.

The term “agonist” as used herein means a ligand that activates anintracellular response when it binds to a receptor. An agonist accordingto the invention may promote internalization of a cell surface receptorsuch that the cell surface concentration of a receptor is decreased orremove.

The term “partial agonist” as used herein means an agonist which isunable to induce maximal activation of a receptor, regardless of theamount of compound applied on the receptor.

The term “pharmaceutical vehicle” as used herein means a carrier orinert medium used as solvent or diluent in which the pharmaceuticallyactive agent is formulated and/or administered. Non-limiting examples ofpharmaceutical vehicles include creams, gels, lotions, solutions, andliposomes.

The term “lipid disorder” as used herein means any plasma lipid disorderincluding but not limited to dyslipidemia such as mixed or diabeticdyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDLcholesterol, hyperlipidemia and hypertriglyceridemia.

The present invention will be better understood with reference to thefollowing examples. These examples are intended to representative ofspecific embodiments of the invention, and are not intended as limitingthe scope of the invention.

CHEMISTRY EXAMPLES

All temperatures are expressed in ° C. and all reactions were carriedout at room temperature (RT) unless otherwise stated.

Analytical thin layer chromatography (TLC) was used to monitorreactions, establish flash chromatography conditions and verify purityof intermediates or final products. TLC plates used were Merck TLCaluminium sheet silica gel 60 F₂₅₄. TLC plates were revealed usingultraviolet irradiation (wavelength=254 nm) at RT or bromocresol greenspray reagent at 0.1% in propan-2-ol or KMnO₄ revelator (KMnO₄, Na₂CO₃,NaOH, H₂O) upon heating at 160° C.

HPLC-MS spectra were obtained on Agilent LCMS using Electropsrayionization (ESI). The Agilent instrument includes an Autosampler 1200, abinary pump 1100, a 5 wave length detector 1100 and a 6100 Single Quad.The column used was an XBridge C18.

-   Eluent was a mixture of solution A (0.1% TFA in H₂O) and solution B    (0.1% TFA in ACN). Gradients used are as follows: gradient A    (intermediates characterization): held the initial conditions of 5%    solution B for 1 min, increased linearly to 95% solution B in 4 min,    held at 95% during 1 min, returned to initial conditions in 0.5 min    and maintained for 1 min; gradient B (examples characterization):    held the initial conditions of 5% solution B for 1 min, increased    linearly to 60% in 10 min, increased linearly to 95% in 0.5 min,    held at 95% during 3 min, returned to initial conditions in 0.5 min    and maintained for 1 min.

Determination of enantiomeric excess was performed on an Agilent 1100(binary pump and 5 wavelengths detector) with manual or automatic(Autosampler 1100) injection. Columns used were CHIRALPAK IA CHTRALPAKIB or CHTRALPAK IC in isocratic mode. Mixtures of eluents were selecteddepending on the separation obtained of enantiomers or diastereosiomers.Usual mixtures were:

-   -   Hexane and Ethanol (0.1% TFA)    -   Hexane and Propanol (0.1% TFA)    -   Hexane and Ethyl acetate (0.1% TFA)    -   Hexane and Dichloromethane (0.1% TFA)    -   Hexane and tert-butyl methyl ether (0.1% TFA) 25

Preparative HPLC purifications were carried out on Fractionlynxinstrument, from Waters. This instrument consists of a FractionCollector, a 2767 Sample Manager, a pump control a module II, a 515 HPLCPump, a 2525 Binary Gradient Module, a Switching Valve, a 2996Photodiode Array Detector and a Micromass ZQ. The column used was aWaters Sunfire C18 Eluent was a mixture of solution A (0.1% TFA in H₂O)and solution B (0.1% TFA in ACN). The gradient was adapted depending onimpurities present in samples, to allow sufficient separation betweenimpurities and target compound.

Chiral preparative HPLC purification were performed on an Agilent 1100instrument (binary pump and 5 wavelengths detector) with manualinjection using a CHIRALPAK IA or a CHIRALPAK IB column in isocraticmode. Mixtures of eluents were selected depending on the separation ofenantiomers or diastereosiomers obtained with the analytical method.Usual mixtures were the same as those used for the determination of ee.

¹H and ¹³C NMR spectra were recorded on a Bruker ARX 300 MHz. Chemicalshifts are expressed in parts per million, (ppm, δ units). Couplingconstants are expressed in Hertz units (Hz). Splitting patterns describeapparent multiplicities and are described as s (singlet), d (doublet), t(triplet), q (quintet), m (multiplet), or br (broad).

Solvents, reagents and starting materials were purchased from well knownchemical suppliers such as for example Sigma Aldrich, Acros Organics,VWR Int., Sopachem or Polymer labs and the following abbreviations areused:

-   ACN or MeCN: Acetonitrile,-   DCM: Dichloromethane,-   DCE: 1,2-Dichloroethane,-   EtOAc or AcOEt: Ethyl acetate,-   EtOH: Ethanol,-   MeOH: Methanol,-   IPA: isopropanol,-   PE: Petroleumether,-   NMP: N-methylpyrrolidinone,-   RT: Room temperature,-   DIEA: N,N-diisopropylethylamine,-   HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tretramethyluronium    hexafluorophosphate,-   HOBt: 1-hydroxybenzotriazole or 1-hydroxybenzotriazole hydrate,-   DMAP: N, N-Dimethylaminopyridine-   Y: Yield,-   g: Grams,-   mg: Milligrams,-   L: Liters,-   mL: Milliliters,-   μL: Microliters,-   mol: Moles,-   mmol: Millimoles,-   h: Hours,-   min or mn: Minutes,-   TLC: Thin layer chromatography,-   MW: Molecular weight,-   eq: Equivalent,-   THF: Tetrahydrofuran,-   TFA: Trifluoroacetic acid,-   Ac: Acetyl,-   ee: Enantiomeric excess,-   tBu: tert-Butyl-   P: UV purity at 254 nm determined by HPLC-MS,-   rt: Retention time,-   BuLi: butyllithium,-   CDI: carbonyldiimidazole,-   TBDPS: tert-butyl-diphenylsilyl,-   Boc₂O: di-tert-butyldicarbonate,-   TBAF: tetrabutylammonium fluoride,-   S-Phos: 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl,-   RM: reaction mixture,-   Nu: Nucleophile,-   DMF: N,N-dimethylformamide,-   TMS: trimethylsilyl.

General Synthetic Schemes

-   A general method for the synthesis of most compounds of the    invention is outlined in scheme 1.

-   Pyrrolidine methyl acetate intermediate 1.1 was acylated with acyl    chlorides or carboxylic acids intermediates 1.2 using standard amide    coupling procedures to give epimeric mixture compound 1.3.-   In some cases epimers 1.3a and 1.3b were separated by chromatography    (flash chromatography or preparative HPLC); subsequent    saponification of intermediates 1.3a and 1.3b with lithium hydroxide    afforded the desired carboxylic acid products 1.4 and 1.5    respectively.-   Otherwise intermediate 1.3 was saponified with lithium hydroxide to    give epimeric mixture 1.6 which was purified by chromatography    (flash chromatography or preparative HPLC) to give desired    carboxylic acid products 1.4 and 1.5.

Pyrrolidine ester intermediates 1.1 were synthesized from aryl or alkylGrignard or aryl-lithium reagents as shown in scheme 2.

Addition of aryl or alkyl Grignard or aryl-lithium 2.1 toN-Boc-L-pyroglutamic acid methyl ester 2.2 provided intermediate 2.3, asdescribed by Colandrea et al. in Bioorg. & Med. Chem. Lett. 2006, 16,2905-2908 and Ying-zi Xu et al. in J. Org. Chem. 1999, 64, 4069-4078.One pot Boc deprotection and cyclic imine formation under acidicconditions afforded cyclic imine intermediate 2.4 which could be reducedeither by hydrogenation or by borohydride reagent to give thepyrrolidine ester intermediate 1.1. In some cases epimers 1.1a and 1.1bwere separated by flash chromatography.

-   -   Aryl or alkyl Grignard and aryl-lithium reagents 2.1 were        prepared using the methodologies shown in scheme

Aryl or alkyl Grignard reagents 2.1a were prepared from aryl halideseither by method 1 (isopropyl megnasium chloride/lithium chloride) or bymethod 2 (magnesium) and aryl-lithium reagents 2.1b were synthesized bymethod 3 (n-butyllithium).

N-Boc-L-pyroglutamic acid methyl ester 2.2 was synthesized using themethodology shown in scheme 4

L-pyroglutamic acid 4.1 was converted to the methyl ester 4.2 which uponBoc protection with di-tert-butyl dicarbonate afforded intermediate 2.2.

Biaryl and heterobiaryl carboxylic acid intermediates 1.2a weresynthesized using one of the three routes (a, b or c) shown in scheme 5.

Suzuki coupling between 5.1 and 5.2 provided biaryl ester intermediate5.3, subsequent saponification with lithium hydroxide afforded biarylcarboxylic acid intermediate 1.2a.

Aralkyloxyaryl carboxylic acid intermediates 1.2 were synthesized usingthe methodology shown in scheme 6 for benzyloxybenzoic acidintermediates 1.2b.

Methyl 3,5-dihydroxybenzoate 6.1 was methylated with dimehylsulfate togive intermediate 6.2. Benzylation with benzyl halide reagent 6.3provided ester intermediate 6.4 which upon subsequent saponificationwith lithium hydroxide afforded benzyloxybenzoic acid intermediates 1.2b

Additional Synthetic Schemes

Synthesis of compound n° 24 is depicted in scheme 7.

Synthesis of methyl substituted pyrrolidinone intermediates 2.2 isdepicted in scheme 8.

Dipolar cycloaddition methodology is exemplified with the synthesis ofcompound n° 217 and is depicted in scheme 9.

Synthesis of compound n° 268 is depicted in scheme 10.

Synthesis of intermediate 3-methoxy-4-(4-methylpiperidin-1-yl)benzoicacid used in the preparation of compound n° 261 is depicted in scheme11.

The synthesis of compound n° 393 is depicted in scheme 12.

The synthesis of compound n° 369 is depicted in scheme 13.

Synthesis of compound n° 279 is depicted in scheme

General Methods

General Method A: Synthesis of Pyrrolidine Ester Intermediates 1.1

General method A is examplified with the synthesis of intermediate 1a(2S,5R)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylate, intermediate1b (2S,5S)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylate andintermediate 1f (2S,5R)-methyl 5-(pyridin-2-yl)pyrrolidine-2-carboxylatefrom 2-bromopyridine (route 3, conditions E).

Step 1: Synthesis of (2-chlorophenyl)magnesium chloride: Route 1

To a 2M solution of isopropylmagnesium chloride in anhydrous THF (5.76mmol) was added lithium chloride (5.76 mmol) in distilled THF in aSchlenk tube under Ar atmosphere at RT. The reaction mixture was cooledto −15° C. and 1-bromo-2-chlorobenzene (5.35 mmol) was added and the RMwas stirred at −15° C. for another 3 h. This crude solution of(2-chlorophenyl)magnesium chloride was cooled to −40° C. and used assuch in step 2.

Step 2: Synthesis of (S)-methyl2-((tert-butoxycarbonyl)amino)-5-(2-chlorophenyl)-5-oxopentanoate

To the crude solution of (2-chlorophenyl)magnesium chloride obtained instep 1 was added at −40° C. under Ar a solution of (S)-1-tert-butyl2-methyl 5-oxopyrrolidine-1,2-dicarboxylate (4.11 mmol) in distilled THF(4 mL). The reaction mixture was stirred at −40° C. for 2 h and thenquenched with 10 mL of a saturated aqueous solution of ammoniumchloride. The mixture was extracted three times with AcOEt, combinedorganics were dried over anhydrous MgSO₄ and concentrated in vacuo.Crude was purified by flash chromatography (eluent: cyclohexane/AcOEt)to yield title compound. Y: 425 mg (29%), P: >95%, rt=4.24 min,(M+H)⁺=256.

Step 3: Synthesis of (S)-methyl5-(2-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

TFA (2 mL) was added to a solution of (S)-methyl2-((tert-butoxycarbonyl)amino)-5-(2-chlorophenyl)-5-oxopentanoate (1.08mmol) in DCM (2 mL) and the reaction mixture was stirred at RT for 2 h.The RM was evaporated to dryness to yield title compound. Y: 574 mg(56%), P: >95%, rt=2.85 min, (M+H)⁻=238.

Step 4

Reaction conditions C: synthesis of intermediate 1a (2S,5R)-methyl5-(2-chlorophenyl)pyrrolidine-2-carboxylate and intermediate 1b(2S,5S)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylate.

Sodium triacetoxyborohydride (0.091 mol) was added portionwise to astirred solution of (S)-methyl5-(2-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (0.076 mol) in1,2-dichloroethane (200 mL) at RT under a nitrogen atmosphere. TFA (0.76mol) was added and the reaction mixture was stirred at RT for 1.5 h.LCMS showed starting material still remaining so further TFA (˜10 mL)was added (to give pH 3-4) and stirring continued for a further 1.5 h.All starting material was consumed, water (30 mL) was added followed bysaturated aqueous NaHCO₃ (˜400 mL) until neutral pH. The separatedaqueous layer was extracted with DCM (2×300 ml) and the combinedorganics dried over anhydrous MgSO₄ and evaporated in vacuo to give ayellow oil (17.5 g). Crude was purified by column chromatography(eluent: PE/EtOAc) to give, as colourless oils, intermediate 1a: Y: 12 g(66%), P: >95%, rt=2.73 min, (M+H)⁺=240 and intermediate 1b Y: 3 g(16%), P: >95%, (M+H)⁺=240.

Reaction conditions D: synthesis of Intermediate (2S)-methyl5-(2-chlorophenyl)pyrrolidine-2-carboxylate.

Sodium cyanobrorohydridc (2.9 mmol) was added to a solution of(S)-methyl 5-(2-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (2.42mmol) in anhydrous MeOH (20 mL) and the reaction mixture was stirred atRT for 1 h. The RM was quenched with water and extracted with DCM.Combined organics were dried over anhydrous MgSO₄ and concentrated invacuo to yield title compound. Y: 338 mg (59%), P: >95%, rt=2.73 min,(M+H)⁺=240.

Reaction conditions E: synthesis of intermediate 1f: (2S,5R)-methyl5-(pyridin-2-yl)pyrrolidine-2-carboxylate from 2-bromopyridine (route3).

In a 10 mL round bottomed flask was dissolved (S)-methyl5-(pyridin-2-yl)-3,4-dihydro-2H-pyrrole-2-carboxylate (0.208 mmol) inIPA (550 μL) to give a brown solution. Palladium on carbon (3.95 μmol)(10% w/w) was added, and reaction was stirred under H₂ atmosphere.

-   Reaction mixture was stirred overnight at RT. The mixture was    filtered through celite and concentrated under reduced pressure to    give intermediate if in a quantitative yield. Y: 12 g (66%),    P: >95%, rt=2.34 min, (M+H)⁺=207.

The following intermediates were synthesized from ad-hoc reagents usinggeneral method A:

intermediate 1c: (2S,5R)-methyl5-(3-chloropyridin-2-yl)pyrrolidine-2-carboxylate from2-bromo-3-chloropyridine (route 3, conditions C);

intermediate 1e: (2S)-methyl5-([1,1′-biphenyl]-3-yl)pyrrolidine-2-carboxylate frombiphenyl-3-ylmagnesium bromide (conditions C);

intermediate 1g: (2S)-methyl 5-(2-fluorophenyl)pyrrolidine-2-carboxylatefrom 1-bromo-2-fluorobenzene (route 1, conditions C), rt=2.5 min(gradient A);

intermediate 1i: (2S)-methyl5-(2-methoxyphenyl)pyrrolidine-2-carboxylate 1-bromo-2-methoxybenzene(route 1, conditions D);

intermediate 1j: (2R)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylatefrom 1-bromo-2-chlorobenzene (route 1, conditions D);

intermediate 1k: (2S)-methyl 5-(4-chlorophenyl)pyrrolidine-2-carboxylatefrom 4-chlorophenylmagnesium bromide (conditions C);

intermediate 1l: (2S)-methyl5-([1,1′-biphenyl]-4-yl)pyrrolidine-2-carboxylate from[1,1′-biphenyl]-4-ylmagnesium bromide (conditions C);

intermediate 1m: (2S)-methyl 5-(2-chlorobenzyl)pyrrolidine-2-carboxylatefrom 2-chlorobenzylmagnesium chloride (conditions C);

intermediate 1n: (2S)-methyl 5-cyclohexylpyrrolidine-2-carboxylate fromcyclohexylmagnesium chloride (conditions C);

intermediate 1o: (2S)-methyl5-([1,1′-biphenyl]-2-yl)pyrrolidine-2-carboxylate from[1,1′-biphenyl]-2-ylmagnesium bromide (conditions C);

intermediate 1p: (2S,5R)-methyl5-(2-chlorophenyl)-4,4-dimethylpyrrolidine-2-carboxylate (conditions C),starting from (S)-1-tert-butyl2-methyl-4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate obtained usingthe synthetic route described in scheme 8;

intermediate 1q: (2S,5R)-methyl5-(2-chlorophenyl)-4-methylpyrrolidine-2-carboxylate (conditions C),starting from (S)-1-tert-butyl2-methyl-4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate;

intermediate 1r: (2S,5R)-methyl5-(pyridin-3-yl)pyrrolidine-2-carboxylate;

intermediate 1s: (2S,5R)-methyl 5-(o-tolyl)pyrrolidine-2-carboxylate;

intermediate 1t: (2S,5R)-methyl 5-phenylpyrrolidine-2-carboxylate(condition E);

intermediate 1u: (2S,5R)-methyl5-(3-chlorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1v: (2S,5R)-methyl5-(4-chlorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1w: (2S,5R)-5-(3-fluorophenyl)pyrrolidine-2-carboxylic acid(route 1, conditions E);

intermediate 1x: (2S,5R)-methyl5-(4-fluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions E);

intermediate 1y: (2S,5R)-methyl 5-cyclohexylpyrroldine-2-carboxylate wassynthesized by hydrogenation of intermediate 1t using PtO₂ in MeOH,

intermediate 1z: (2R,5R)-methyl5-(2-fluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1a1: (2S,5S)-methyl5-(2-fluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1b1: (2R,5S)-methyl5-(2-fluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1c1: (2S,5R)-methyl5-(2,6-difluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions E);

intermediate 1d1: (2S,5R)-methyl5-(2,4-difluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions E);

intermediate 1e1: (2S,5R)-methyl5-(2,4-dichlorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1f1: (2S,5R)-methyl 5-isobutylpyrrolidine-2-carboxylate(route 2, conditions E);

intermediate 1g1: (2S,5R)-methyl 5-isopropylpyrrolidine-2-carboxylate(route 1, conditions E);

intermediate 1h1: (2S,5R)-methyl 5-cyclopentylpyrrolidine-2-carboxylate(conditions E);

intermediate 1i1: (2S,5R)-methyl5-(2-bromophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1j1: (2S,5S)-methyl 5-isopentylpyrrolidine-2-carboxylate(route 2, conditions E);

intermediate 1k1: (2S,5R)-methyl5-(2,4-difluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions E);

-   -   intermediate 1l1: (2S,5R)-methyl        5-(3,5-difluorophenyl)pyrrolidine-2-icarboxylate (route 1,        conditions C);

intermediate 1m1: (2S,5R)-methyl5-(3,4-difluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1n1: (2S,5R)-methyl5-(2,3-difluorophenyl)pyrrolidine-2carboxylate (route 1, conditions C),rt=2.6 min (gradient A);

intermediate 1o1: (2S,5R)-methyl5-(2,5-difluorophenyl)pyrrolidine-2-carboxylate (route 1, conditions C);

intermediate 1p1: (2S,5R)-methyl5-(4-cyanophenyl)pyrrolidine-2-carboxylate. (route 1, conditions C).

General Method B: Synthesis of Aryloxyaryl Carboxylic Acid Intermediates1.2b

General method B is examplified with the synthesis of intermediate 2a3-(benzyloxy)-5-methoxybenzoic acid.

Step 1: Synthesis of methyl 3-hydroxy-5-methoxybenzoate

To a solution of methyl 3,5-dihydroxybenzoate (29.76 mmol) in anhydrousacetone (40 mL) was added dimethylsulfate (29.69 mmol),tetrabutylammonium iodide (2.97 mmol) and potassium carbonate (59.42mmol). The reaction mixture was stirred at RT overnight. The RM wasdiluted with water and extracted with AcOEt. Combined organics weredried over anhydrous MgSO₄ and concentrated in vacuo. Crude was purifiedby flash chromatography (eluent: PE/AcOEt) to yield title compound. Y:1.7 g (31%), P: >95%, rt=3.75 min, (M+H)⁺=183.

Step 2: Synthesis of methyl 3-(benzyloxy)-5-methoxybenzoate

To a solution of methyl 3-hydroxy-5-methoxybenzoate (0.55 mmol) inanhydrous acetone (2 mL) was added benzyl bromide (0.55 mmol), potassiumcarbonate (0.66 mmol) and sodium iodide (0.055 mmol). The reactionmixture was stirred at 55° C. for 5 h. The RM was diluted with AcOEt anda 1M aqueous solution of sodium hydroxide. The organic layer wasseparated, dried over anhydrous MgSO₄ and concentrated in vacuo. Crudewas purified by flash chromatography (eluent: PE/AcOEt) to yield titlecompound. Y: 104 mg (69%), P: >95%, rt=4.53 min, (M+H)⁺=273.

Step 3: Synthesis of intermediate 2a 3-(benzyloxy)-5-methoxybenzoic Acid

To a solution of methyl 3-(benzyloxy)-5-methoxybenzoate (0.38 mmol) inTHF (1 mL) was added a solution of lithium hydroxide (1.53 mmol) inwater (1 mL). The reaction mixture was stirred at RT overnight. The RMwas quenched with a 1M HCl aqueous solution and extracted three timeswith DCM. Combined organics were dried over anhydrous MgSO₄ andconcentrated in vacuo to yield title compound. Y: 92 mg (94%), P: >95%,rt=3.95 mn, (M+H)⁺=259.

The following intermediates were synthesized from ad-hoc reagents usinggeneral method B:

intermediate 2b: 3((4-chlorobenzypoxy)-5-methoxybenzoic acid,

intermediate 2c: 3-methoxy-5-phenethoxybenzoic acid,

intermediate 2d: 3-(3,3-diphenylpropoxy)-5-methoxybenzoic acid,

intermediate 2e: 3-methoxy-5-((4-(methylsulfonyl)benzyl)oxy)benzoicacid,

intermediate 2f: 3-methoxy-5-(2-methoxyethoxy)benzoic acid,

intermediate 2g: 34(3,5-dimethylisoxazol-4-yl)methoxy)-5-methoxybenzoicacid,

General Method C: Synthesis of Most Compounds of the Invention

General method C is examplified with the synthesis of Example 1:compound n° 1:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Step 1: Synthesis of (2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylateConditions A:

In a 100 mL round bottom flask, under argon, was dissolved2′-methoxybiphenyl-4-carboxylic acid (15.714 g, 68.8 mmol) in DCM (138mL). A white suspension was obtained to which were successively addedthionyl chloride (7.49 mL, 103 mmol) and DMF (0.107 mL, 1.377 mmol).Reaction mixture was heated at reflux (40° C.) 3 hours. The solution wasallowed to reach spontaneously RT (yellow-orange solution). RM wasconcentrated under reduced pressure. Removal of the excess of thionylchloride was done by two co-evaporation cycles with DCM. The resultingbrown residue was dried under vacuum to afford 17 g of a brown solid.Crude product was used without further purification in the next step.

In a 500 mL, round bottom flask were introduced under argon methyl(2S,5R)-5-(2-chlorophenyl)pyrrolidine-2-carboxylate (15 g, 62.6 mmol),DCM (62.4 mL) and Et₃N (9.59 mL, 68.8 mmol). To this solution cooled to0° C., was added dropwise (via an addition funnel) a solution of2′-methoxybiphenyl-4-carbonyl chloride (16.98 g, 68.8 mmol) in DCM (83mL) (dark brown solution). The RM was stirred from 0° C. to RTovernight. The RM was transferred to a separation funnel and washed with25 mL of HCl 6M diluted with 75 mL water. The organic layer was driedunder stirring with MgSO₄ in the presence of 0.3 g of Norit AS, filteredand concentrated to afford 34 g of a light brown foaming oily residue.Purification by column chromatography (eluent: EtOAc/PE: 1/2) yieldeddesired product as a beige solid. Y: 25.4 g (90%), P>95%.

Conditions B: To a solution of 2′-methoxybiphenyl-4-carboxylic acid 2b(1.1 mmol) in anhydrous ACN (2 mL) was added HATU (1.1 mmol). After 5min was added (2S,5R)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylate1a (1 mmol) and DIEA (1.2 mmol). Reaction mixture was stirred at RT for4 days. Reaction mixture was diluted with AcOEt and washed withsaturated aqueous solution of NaHCO₃ and with water. The organic phasewas dried over MgSO₄ and evaporated. Crude was purified by flashchromatography (eluent: cyclohexane/AcOEt) to yield title compound. Y:300 mg (67%), P>95%, rt=4.85 min (M+H)⁺=451.

Step 2: Synthesis of Example 1: Compound n° 1:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicAcid

To a solution of (2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylate(0.67 mmol) in THF (5 mL) was added a solution of lithium hydroxide(2.67 mmol) in water (5 mL). The reaction mixture was stirred at RTovernight. The RM was quenched with a 1M HCl aqueous solution andextracted twice with AcOEt. Combined organics were dried over anhydrousMgSO₄ and concentrated in vacuo to yield title compound as a colorlesssolid. Y: 250 mg (86%), P: >95%, rt=6.05 min, (M+H)⁺=436.

General Method D: Synthesis of Biaryl Carboxylic Acid Intermediates 1.2a

Three routes (a, b and c) were used in the preparation of biaryl orheterobiaryl intermediates.

Route a is examplified with the synthesis of intermediate 2h2′-methoxy-[1,1′-biphenyl]-4-carboxylic acid.

Step 1: Synthesis of methyl 2′-methoxy-[1,1′-biphenyl]-4-carboxylate

A mixture of methyl-4-iodobenzoate (86.2 g, 0.33 mol) and2-methoxyphenyl boronic acid (50.0 g, 0.33 mol) in toluene (975 mL) andEtOH (525 mL) was degassed with nitrogen bubbling for 30 minutes.Pd(PPh₃)₄ (19.0 g, 16.5 mmol) and 4M aqueous Na₂CO₃ (271.5 mL, 1.09 mol)were added and the mixture stirred at 100° C. under a nitrogenatmosphere overnight. After cooling to room temperature, EtOAc (1.5 L)and water (1.5 L) were added, and the separated organic layer was dried(Na₂SO₄) and evaporated in vacuo to leave a brown oily solid (107 g).The residue was purified by column chromatography using an increasinggradient from 5-50% EtOAc/petrol to give title product as a yellowsolid. Y: 51 g (64%), P>80%.

Step 2: Synthesis of Intermediate 2h2′-methoxy-[1,1′-biphenyl]-4-carboxylic Acid

LiOH.H₂O (89 g, 2.1 mol) was added to a stirred suspension of methyl2′-methoxy-[1,1′-biphenyl]-4-carboxylate(51 g, 0.21 mol) in a mixture ofTHF (500 mL) and H₂O (1 L). Further amounts of THF (˜500 mL) and H₂O (˜1L) were added to dissolve the majority of the solids. After stirringovernight at room temperature, more solids had precipitated and startingmaterial still remained. The mixture was heated to 50° C. for 4 hours,after which time all solids had dissolved and no starting materialremained. After cooling to room temperature, saturated aqueous citricacid was added until pH=6-7, which produced a white precipitate. THF wasremoved by evaporation in vacuo and the resulting suspension filtered.The solid was washed with water several times and dried at 50° C.overnight to give intermediate 2 h as an off-white solid. Y: 43 g (90%),P>90%.

Route b is exemplified with the synthesis of intermediate 2s24-(2-methoxypyrimidin-4-yl)benzoic acid.

Step 1: Synthesis of methyl 4-(2-methoxypyrimidin-4-yl)benzoate

In an oven dried glass tube, were introduced under argon4-methoxycarbonylphenylboronic acid (381 mg, 2.116 mmol) and4-bromo-2-methoxypyrimidine (200mg, 1.058 mmol).Three vacuum/Argoncycles were performed and toluene (5 mL) was added, followed by a 2Maqueous solution of K₂CO₃ (0.106 mmol). The resulting mixture wasdegassed (argon bubbling into the solution for 5-10 minutes).

Tetrakis(triphenylphosphine)palladium(0) (0.1 mmol) was then added andthe mixture was heated to 95° C. overnight. The mixture was cooled downto room temperature and then diluted with EtOAc and washed with brine.The aqueous layer was further extracted with EtOAc and the combinedorganic layers were dried and concentrated. The residue was purified onsilica gel (cyclohexane/EtOAc), furnishing 243 mg of desired product asa pale yellow solid (94% yield).

Step 2: Synthesis of Intermediate 2s2 4-(2-methoxypyrimidin-4-yl)benzoicacid

The same conditions as in step 2 of route a were used.

The following intermediates were synthesized from ad-hoc reagents usinggeneral method D route b:

intermediate 2i: 2′,5′-dichloro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2j: 4-(pyrimidin-5-yl)benzoic acid;

intermediate 2k: 4-(furan-3-yl)benzoic acid;

intermediate 2l: 4-(6-methoxypyridin-3-yl)benzoic acid,

intermediate 2m: 4-(3-fluoropyridin-4-yl)benzoic acid;

intermediate 2n: 4-(pyridin-3-yl)benzoic acid;

intermediate 2o: 4-(6-(dimethylamino)pyridin-3-yl)benzoic acid;

intermediate 2p: 4-(pyridin-4-yl)benzoic acid;

intermediate 2q: 4-(6-methylpyridin-3-yl)benzoic acid;

intermediate 2r: 4-(2-methoxypyridin-3-yl)benzoic acid, rt=3.4 min(gradient A);

intermediate 2s: 4′-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2t: 4′-cyano-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2u: 4-(4-methoxypyridin-3-yl)benzoic acid;

intermediate 2v: 4′-chloro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2w: 3′-chloro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2x: 2′-chloro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2y: 4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2z: 3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2a1: 2′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2b1: 4-(naphthalen-2-yl)benzoic acid;

intermediate 2c1: 3′,5′-difluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2d1: 2′-hydroxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2e1: 2′-(trifluoromethoxy)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2f1: 4-(3-fluoropyridin-4-yl)benzoic acid;

intermediate 2g1: 4-(6-chloropyridin-3-yl)benzoic acid;

intermediate 2h1: 4-(6-fluoropyridin-3-yl)benzoic acid;

intermediate 2i1: 5-methoxy-6-phenylnicotinic acid;

intermediate 2j1: 4-(3-methoxypyridin-4-yl)benzoic acid;

intermediate 2k1: 2-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2l1: 4-(6-chloropyridin-3-yl)benzoic acid;

intermediate 2m1: 4-(6-fluoropyridin-3-yl)benzoic acid;

intermediate 2n1: 4-(thiophen-3-yl)benzoic acid;

intermediate 2o1: 4-cyclohexylbenzoic acid;

intermediate 2p1: 2′-(methylsulfonyl)-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2q1: 4-(pyrimidin-2-yl)benzoic acid;

intermediate 2r1: 4-(4,6-dimethoxypyrimidin-2-yl)benzoic acid;

intermediate 2s1: 4-(2,4-dimethoxypyrimidin-5-yl)benzoic acid, rt=3.4min (gradient A);

intermediate 2t1: 4-(2-methoxypyrimidin-5-yl)benzoic acid;

intermediate 2u1: 4-(pyridin-2-yl)benzoic acid;

intermediate 2v1: 2′-cyano-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2w1: 2′,6′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid,

intermediate 2x1: 2′,4′-dichloro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2y1: 2′-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2z1: 2,2′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2a2: 4′-chloro-2′-methoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2b2: 4-(4-methoxypyrimidin-5-yl)benzoic acid;

intermediate 2c2: 4-(3-fluoropyridin-4-yl)benzoic acid;

intermediate 2d2: 2-chlorobiphenyl-4-carboxylic acid;

intermediate 2e2: 2′-chloro-2-methoxybiphenyl-4-carboxylic acid,

intermediate 2f2: 3-methoxy-4-(pyrimidin-5-yl)benzoic acid;

intermediate 2g2: 2′-(methoxymethyl)biphenyl-4-carboxylic acid;

intermediate 2h2: 4-(2,6-dimethoxypyridin-3-yl)benzoic acid;

intermediate 2i2: 3-methoxy-4-(2-methoxypyrimidin-5-yl)benzoic acid,rt=3.2 min (gradient A);

intermediate 2j2: 4-(5-methoxypyrazin-2-yl)benzoic acid;

intermediate 2k2: 4-(3-methoxypyrazin-2-yl)benzoic acid;

intermediate 2l2: 4-(2-chloro-4-(dimethylamino)pyrimidin-5-yl)benzoicacid;

intermediate 2m2: 4-(2,6-dimethoxypyrimidin-4-yl)benzoic acid;

intermediate 2n2: 4-(2-methylthiophen-3-yl)benzoic acid;

intermediate 2o2: methyl 2′,6′-dichlorobiphenyl-4-carboxylate;

intermediate 2p2: 2′-chloro-4′-methoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2q2: 2′-(dimethylamino)-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2r2: 3-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2t2: 4-(2-chloro-4-methoxypyrimidin-5-yl)benzoic acid;

intermediate 2u2: 4-(3-methoxypyridin-2-yl)benzoic acid;

intermediate 2v2: 2-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2w2: 2′,4′-difluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2x2: 2-methyl-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2y2: 3-chloro-4-(pyrimidin-4-yl)benzoic acid;

intermediate 2z2: 2-fluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2a3: 2′-fluoro-4′-methoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2b3: 4′-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2c3: 4-(6-ethoxypyridin-3-yl)benzoic acid;

intermediate 2d3: 4-(6-isopropoxypyridin-3-yl)benzoic acid;

intermediate 2e3: 4-(6-methoxy-2-methylpyridin-3-yl)benzoic acid;

intermediate 2f3: 3-chloro-4-(2-methoxypyrimidin-4-yl)benzoic acid;

intermediate 2g3: 3-chloro-4-(pyrimidin-5-yl)benzoic acid; intermediate2h3: 2′,3′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2i3: 3′,4′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2j3: 2′,3′,4′-trimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2k3: 2′,3′,6′-trimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2l3: 3′,5′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2m3: 2′,5′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2n3: 2′-isopropyl-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2o3; 2′-ethyl-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2p3: 4-(2,6-dimethylpyridin-3-yl)benzoic acid;

intermediate 2q3: 4-(2,4-bis(benzyloxy)pyrimidin-5-yl)benzoic acid;

intermediate 2r3: 3-chloro-4-(6-methoxypyridin-3-yl)benzoic acid;

intermediate 2s3: 5-methoxy-6-(2-methoxyphenyl)nicotinic acid;

intermediate 2t3: 5-methoxy-6-(2-methoxyphenyl)nicotinic acid;

intermediate 2u3: 3′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2v3:3′-cyano-2′,4′-bis(2,2,2-trifluoroethoxy)-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2w3: 3′-amino-2′-methyl-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2x3:2′-methyl-3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylic acid wasobtained by sulfonylation of methyl3′-amino-2′-methyl-[1,1′-biphenyl]-4-carboxylate (which was synthesizedusing general method D, route b) and subsequent saponification.Sulfonylation procedure (as in J. Org. Chem. 2003, 68, 5300-5309):methyl 3′-amino-2′-methylbiphenyl-4-carboxylate (0.83 mmol) wasdissolved in dry Et₂O (5 mL) and cooled to 0° C. Then pyridine (5.00mmol) was added, followed by dropwise addition of methanesulfonylchloride (5.00 mmol). The reaction was stirred at RT for 2 h. Theprecipitate was filtered and washed with Et₂O. The organic layer waswashed with HCl 1M aqueous solution, brine, dried and concentrated,furnishing 265 mg of desired product as a brown oil in a quantitativeyield;

intermediate 2y3: 3′-acetamido-2′-methyl-[1,1′-biphenyl]-4-carboxylicacid was obtained by acetylation of methyl3′-amino-2′-methyl-[1,1′-biphenyl]-4-carboxylate (which was synthesizedusing general method D, route b) and subsequent saponification.Acetylation procedure: to a solution of methyl3′-amino-2′-methylbiphenyl-4-carboxylate (0.83 mmol) in dry DCM (5 mL)under N₇ was added acetyl chloride (0.95 mmol), followed by Et₃N (0.91mmol). The RM was stirred at RT overnight. The RM was then concentratedand the crude purified on silica gel (cyclohexane/EtOAc), furnishing 205mg of desired product as a yellow oil (87% yield);

intermediate 2z3: 5′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carboxylic acid,rt=3.7 min (gradient A);

intermediate 2a4: 5 cyano-2′-methyl-[1,1′-biphenyl]-4-carboxylic acid,rt=3.9 min (gradient A);

intermediate 2b4: 4-(4,6-dimethoxypyridin-3-yl)benzoic acid;

intermediate 2c4: 4′-acetamido-2′-methoxy-[1,1′-biphenyl]-4-carboxylicacid was obtained by the nitro group reduction of methyl2′-methoxy-4′-nitro-[1,1′-biphenyl]-4-carboxylate (which was synthesizedusing general method D, route b) followed by acetylation with acetylchloride (procedure described in the synthesis of intermediate 2y3) andsaponification;

intermediate 2d4: 3-methoxy-4-(5-methoxypyridin-3-yl)benzoic acid;

intermediate 2e4: 2′,3,6′-trimethoxy-[2,3′-bipyridine]-5-carboxylicacid;

intermediate 2f4: 5′-cyano-2′,3′-dimethoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2g4: 2′-cyano-4′,5′-dimethoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2h4: 3′,4′,5′-trimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2i4:2′-(cyanomethyl)-4′,5′-dimethoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2j4: 3′,4′-dicyano-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2k4: 5′-cyano-2′-fluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2l4: 2-fluoro-3′,4′-dimethoxy-[1,1′-biphenyl]-4-carboxylicacid;

intermediate 2m4: 4-(2,6-dimethoxypyridin-3-yl)-3-fluorobenzoic acid;

intermediate 2n4: 3-fluoro-4-(6-methoxypyridin-3-yl)benzoic acid;

intermediate 2r4: 4-(3,6-dimethoxypyridazin-4-yl)benzoic acid, rt=3.2min (gradient A);

intermediate 2s4: 2′-cyano-4′-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2u4: 3′-cyano-4′-fluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2v4: 2′-chloro-5′-cyano-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2w4:2′-cyano-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2x4:2′-methyl-3′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carboxylicacid was obtained by sulfonylation of methyl3′-amino-2′-methyl-[1,1′-biphenyl]-4-carboxylate, followed bysulfonamide N-methylation with iodomethane, and subsequentsaponification. Methyl 3′-amino-2′-methyl-[1,1′-biphenyl]-4-carboxylatewas synthesized using general method D (route b); sulfonamideN-methylation procedure: in a glass tube was introduced methyl2′-methyl-3′-(methylsulfonamido)biphenyl-4-carboxylate (0.438 mmol) andsodium hydride (0.570 mmol) in dry DMF (2 mL) at room temperature underargon atmosphere. After 30 minutes at room temperature, iodomethane(1.315 mmol) was added and the mixture was stirred at room temperaturefor 1.5 h. Brine was then added and the aqueous layer was extracted withEtOAc. The organic layer was dried over MgSO₄ and concentrated underreduced pressure, furnishing crude desired product as a pale yellow oilin a quantitative yield; rt=3.4 min (gradient A)

intermediate 2y4: 6-(5-cyano-2-methoxyphenyl)-5-methoxynicotinic acid;

intermediate 2z4: 6-(2,4-dimethoxyphenyl)-5-methoxynicotinic acid;

intermediate 2a5: 6-(2,4-dimethoxyphenyl)nicotinic acid; intermediate2f5: 4-(4,6-dimethoxypyrimidin-5-yl)benzoic acid.

Route c is exemplified for the synthesis of intermediate 2g53-chloro-4-(2,4-dimethoxypyrimidin-5-yl)benzoic acid

Step 1: Synthesis of methyl3-chloro-4-(2,4-dimethoxypyrimidin-5-yl)benzoate

In a oven dried glass tube were introduced under argon2-chloro-4-(methoxycarbonyl)phenylboronic acid (2.0 mmol) and5-iodo-2,4-dimethoxypyrimidine (1.0 mmol). The tube was subjected tothree vacuum/argon cycles and toluene (5 mL) was added, followed by a 2Maqueous solution of K₂CO₃ (3.0 mmol). The resulting mixture was degassed(argon bubbling into the solution for 5-10 minutes).Tris(dibenzylideneacetone)dipalladium(0) (5%) and S-Phos (10%) were thenadded and mixture was heated to 95° C. overnight. The mixture was cooleddown to room temperature and then diluted with EtOAc and washed withbrine. The aqueous layer was further extracted with EtOAc and thecombined organic layers were dried and concentrated. The residue waspurified on silica gel (cyclohex/EtOAc), furnishing 143 mg of desiredproduct as a pale yellow solid (93% yield).

Step 2: Saponification Using Same Procedure of 2h Synthesis

The following intermediates were synthesized from ad-hoc reagents usinggeneral method D route c:

intermediate 2h5: 2-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2j5: 5-(2-methoxyphenyl)pyrazine-2-carboxylic acid;

intermediate 2k5: 3-methoxy-4-(4-methoxypyridin-3-yl)benzoic acid;

intermediate 2l5: 3-methoxy-4-(6-methoxypyridin-3-yl)benzoic acid;

intermediate 2m5: 3-chloro-4-(2-methoxypyrimidin-5-yl)benzoic acid(exemplified above);

intermediate 2n5: 4-(2,4-dimethoxypyrimidin-5-yl)-3-methoxybenzoic acid;

intermediate 2r4: 4-(3,6-dimethoxypyridazin-4-yl)benzoic acid;

intermediate 2p5:2′-methoxy-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylic acid wasobtained by the nitro group reduction of methyl2′-methoxy-4′-nitro-[1,1′-biphenyl]-4-carboxylate (which was synthesizedusing general method D, route c) followed by sulfonylation withmethanesulfonyl chloride (procedure described in the synthesis ofintermediate 2x3) and saponification. Nitro reduction procedure: to asolution of methyl 2′-methoxy-4′-nitrobiphenyl-4-carboxylate (1.184mmol) in anhydrous EtOH (35 ml) was added a slurry of Raney Ni in water(0.4 mL). The mixture was stirred at 50° C. overnight. The RM wasfiltered on celite, and the solid was washed with MeOH. The filtrate wasevaporated to yield desired product which was used without furtherpurification;

intermediate 2q5: 4-(2,6-dimethoxypyridin-3-yl)benzoic acid;

intermediate 2s5:2-fluoro-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylic acid wasobtained by sulfonylation of methyl4′-amino-2-fluoro-[1,1′-biphenyl]-4-carboxylate and subsequentsaponification. methyl 4′-amino-2-fluoro-[1,1′-biphenyl]-4-carboxylatewas synthetized using general method D, route c;

intermediate 2t5:2-fluoro-3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carboxylic acid wasobtained by sulfonylation of methyl3′-amino-2-fluoro-[1,1′-biphenyl]-4-carboxylate and subsequentsaponification. methyl 3′-amino-2-fluoro-[1,1′-biphenyl]-4-carboxylatewas synthetized using general method D, route c;

intermediate 2u5: 2′-cyano-2-fluoro-[1,1′-biphenyl]-4-carboxylic acid;

intermediate 2v5:2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carboxylicacid was obtained by the nitro group reduction of2′-methoxy-4′-nitro-[1,1′-biphenyl]-4-carboxylate, followed bysulfonylation with methanesulfonyl chloride, followed by sulfonamideN-methylation with iodomethane, and subsequent saponification; rt=3.7min (gradient A). Methyl2′-methoxy-4′-nitro-[1,1′-biphenyl]-4-carboxylate was synthesized usinggeneral method D (route c).

Intermediate 2w5 4-(3,6-dimethoxypyridazin-4-yl)-3-fluorobenzoic acidwhich was obtained from methyl 4-bromo-3-fluorobenzoate and(3,6-dimethoxypyridazin-4-yl)boronic acid using a suzuki couplingprocedure described in the literature (J. Org. Chem., 2008, 73,2176-2181); rt=3.5 min (gradient A).

Unless otherwise stated compounds in examples 2 to 44 were synthesizedfrom intermediate 1a and commercially available carboxylic acids or acylchlorides using general method C.

Example 2

Compound n° 2:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 3

Compound n° 3:(2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 4

Compound n° 4:(2S,5R)-5-(2-chlorophenyl)-1-(2′-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2b using general methodC.

Example 5

Compound n° 5:(2S,5R)-5-(2-chlorophenyl)-1-(4′-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 6

Compound n° 6:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenethoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2c using general methodC.

Example 8

Compound n° 8:(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 9

Compound n° 9:(2S,5R)-5-(2-chlorophenyl)-1-(3-(3,3-diphenylpropoxy)-5-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2d using general methodC.

Example 10

Compound n° 10:(2S,5R)-5-(2-chlorophenyl)-1-(3′-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 11

Compound n° 11:(2S,5R)-5-(2-chlorophenyl)-1-(3′-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 12

Compound n° 12:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-((4-(methylsulfonyl)benzyl)oxy)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2e using general methodC.

Example 13

Compound n° 13:(2S,5R)-5-(2-chlorophenyl)-1-(3′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 14

Compound n° 14:(2S,5R)-5-(2-chlorophenyl)-1-(3,5-dimethoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 15

Compound n° 15:(2S,5R)-5-(2-chlorophenyl)-1-(4-(phenoxymethyl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 16

Compound n° 16:(2S,5R)-5-(2-chlorophenyl)-1-(4-((2-fluorobenzyl)oxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 17

Compound n° 17:(2S,5R)-1-(3-chloro-5-methoxybenzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 18

Compound n° 18:(2S,5R)-5-(2-chlorophenyl)-1-(4′-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 19

Compound n° 19:(2S,5R)-5-(2-chlorophenyl)-1-(4-phenethoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 20

Compound n° 20:(2S,5R)-5-(2-chlorophenyl)-1-(chroman-3-carbonyl)pyrrolidine-2-carboxylicacid.

Example 21

Compound n° 21:(2S,5R)-5-(2-chlorophenyl)-1-(3,5-diethoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 23

Compound n° 23:(2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 24

Compound n° 24:(2S)-1-([1,1′-biphenyl]-4-carbonyl)-4-benzyl-5-phenylpyrrolidine-2-carboxylicacid was synthesized as described in scheme 24.

Example 25

Compound n° 25:(2S,5R)-5-(2-chlorophenyl)-1-(1,2,3,4-tetrahydronaphthalene-2-carbonyl)pyrrolidine-2-carboxylicacid.

Example 26

Compound n° 26:(2S,5R)-5-(2-chlorophenyl)-1-(4-isobutylbenzoyl)pyrrolidine-2-carboxylicacid.

Example 27

Compound n° 27:(2S,5R)-5-(2-chlorophenyl)-1-(2,2-difluorobenzo[d][1,3]dioxole-6-carbonyl)pyrrolidine-2-carboxylicacid.

Example 28

Compound n° 28:(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-phenylpyrrolidine-2-carboxylicacid.

Example 29

Compound n° 29:(2S,5R)-5-(2-chlorophenyl)-1-(3-fluoro-5-methoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 30

Compound n° 30:(2S,5R)-5-(2-chlorophenyl)-1-(6-phenylnicotinoyl)pyrrolidine-2-carboxylicacid.

Example 31

Compound n° 31:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-(2-methoxyethoxy)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2f using general methodC.

Example 32

Compound n° 32:(2S,5R)-5-(2-chlorophenyl)-1-(3′-methoxy-[1,1′-biphenyl]-3-carbonyl)pyrrolidine-2-carboxylicacid.

Example 33

Compound n° 33:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 34

Compound n° 34:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methoxyphenyl)-5-phenyl-1H-pyrazole-3-carbonyl)pyrrolidine-2-carboxylicacid.

Example 35

Compound n° 35:(2S,5R)-5-(2-chlorophenyl)-1-(4-isopropoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 36

Compound n° 36: (2S,5R)-5-(2-chlorophenyl)-1-(3-((3,5-dimethylisoxazol-4-yl)methoxy)-5-methoxybenzoyl)pyrrolidine-2-carboxylic acid was synthesizedfrom intermediates 1a and 2g using general method C.

Example 37

Compound n° 37:(2S,5R)-5-(2-chlorophenyl)-1-(2,3-dihydro-1H-indene-2-carbonyl)pyrrolidine-2-carboxylicacid.

Example 38

Compound n° 38:(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5-(trifluoromethoxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 39

Compound n° 39:(2S,5R)-1-(3-(benzyloxy)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 40

Compound n° 40:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 41

Compound n° 41:(2S,5R)-5-(2-chlorophenyl)-1-(2-phenylpyrimidine-5-carbonyl)pyrrolidine-2-carboxylicacid.

Example 42

Compound n° 42:(2S,5R)-5-(2-chlorophenyl)-1-(4-(trifluoromethoxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 43

Compound n° 43:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 44

Compound n° 44:4-((2S,5R)-2-carboxy-5-(2-chlorophenyl)pyrrolidine-1-carbonyl)-2,6-dimethoxypyrimidin-1-iumformate.

Example 45

Compound n° 45:(2S,5R)-5-(2-chlorophenyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylicacid.

Example 46

Compound n° 46:(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5-(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 47

Compound n° 47:(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(3-chloropyridin-2-yl)pyrrolidine-2-carboxylicacid intermediate 1c using general method C.

Example 48

Compound n° 48:(2S,5R)-5-(2-chlorophenyl)-1-(3-hydroxy-5-(trifluoromethyl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 49

Compound n° 49:(2S,5S)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1b using general method C.

Example 50

Compound n° 50:(2S,5R)-1-(3,5-dimethoxybenzoyl)-5-phenylpyrrolidine-2-carboxylic acidwas synthesized from intermediate 1d ((2S,5R)-methyl5-phenylpyrrolidine-2-carboxylate). 1d was synthesized from commerciallyavailable(2S,5R)-1-(tert-butoxycarbonyl)-5-phenylpyrrolidine-2-carboxylic acidusing the synthetic steps described in scheme 4.

Example 51

Compound n° 51:(S)-5-([1,1′-biphenyl]-3-yl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1e using general method C.

Example 52

Compound n° 52:(2S,5R)-5-(2-chlorophenyl)-1-(3-phenylpropanoyl)pyrrolidine-2-carboxylicacid.

Example 53

Compound n° 53:(2S,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1b using general method C.

Example 54

Compound n° 54:(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(pyridin-2-yl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1f using general method C.

Example 55

Compound n° 55:(2S,5R)-5-(2-chlorophenyl)-1-(5-phenylpicolinoyl)pyrrolidine-2-carboxylicacid.

Example 57

Compound n° 57:(2S,5R)-5-(2-fluorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1g using general method C.

Example 58

Compound n° 58:(2S,5R)-1-(2-([1,1′-biphenyl]-4-yl)acetyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 59

Compound n° 59:(2R,5S)-1-([1,1′-biphenyl]-4-carbonyl)-5-phenylpyrrolidine-2-carboxylicacid was synthesized from intermediate 1h using general method C. 1h wassynthesized from commercially available(2R,5S)-1-(tert-butoxycarbonyl)-5-phenylpyrrolidine-2-carboxylic acidusing the synthetic steps described in scheme 4.

Example 60

Compound n° 60:(2S,5R)-5-phenyl-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid wassynthesized from intermediate 1d using general method C.

Example 61

Compound n° 61:(2R,5S)-5-phenyl-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid wassynthesized from intermediate 1h using general method C.

Example 62

Compound n° 62: (2S,5R)-1-(3-methoxybenzoy1)-5-(2-methoxyphenyl)pyrrolidine-2-carboxylic acid was synthesizedfrom intermediate 1i using general method C.

Example 63

Compound n° 63:(2R,5S)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1j using general method C.

Example 64

Compound n° 64:(2R,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1j using general method C.

Example 65

Compound n° 65:(2S)-5-(4-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1k using general method C.

Example 66

Compound n° 66:(2S)-5-([1,1′-biphenyl]-4-yl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1l using general method C.

Example 67

Compound n° 67: (2S,5R)-methyl5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylate wassynthesized using general method C without the last saponification step.

Example 68

Compound n° 68:(2S)-5-(2-chlorobenzyl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1m using general method C.

Example 69

Compound n° 69:(2S)-5-cyclohexyl-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylic acid wassynthesized from intermediate 1n using general method C.

Example 70

Compound n° 70:(2S,5R)-5-(2-chlorophenyl)-1-(2-(3-methoxyphenyl)acetyl)pyrrolidine-2-carboxylicacid.

Example 71

Compound n° 71:(2S,5S)-5-(2-chlorophenyl)-1-(3,5-dimethoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1b using general method C.

Example 72

Compound n° 72:(2S,5R)-5-([1,1′-biphenyl]-2-yl)-1-(3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1o using general method C.

Example 74

Compound n° 74:2-((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyrrolidin-2-yl)aceticacid. Compound n° 40 was reacted with ethyl chloroformate (1.03 eq) inTHF in the presence of triethylamine (1.03 eq) and then was added asolution of diazomethane in diethyl ether (2 eq), the mixture wasstirred at RT for 2.5 days. Reaction mixture was quenched with a 10%aqueous solution of citric acid and diluted with diethyl ether. Theorganic layer was washed with a saturated aqueous solution of sodiumbicarbonate and brine, then concentrated in vacuo. The residue wasdissolved in MeOH and silver benzoate (1 eq) and triethylamine (2 eq)were added. The RM was stirred at RT for 45 min and diluted with AcOEt,washed with a saturated aqueous solution of sodium bicarbonate and brine1M aqueous HCl, dried over anhydrous MgSO₄ and evaporated to dryness toyield title compound.

Example 75

Compound n° 75:(2S,5R)-5-(2-chlorophenyl)-1-(6-phenylpyrimidine-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 76

Compound n° 77:(2S,5R)-5-(2-chlorophenyl)-1-(6-(2-chlorophenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 77

Compound n° 78:(2S,5R)-5-(2-chlorophenyl)-1-(6-(2-methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 78

Compound n° 79:(2S,5R)-5-(2-chlorophenyl)-1-(6-(3-fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 79

Compound n° 80:(2S,5R)-5-(2-chlorophenyl)-1-(6-(3-methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 80

Compound n° 81:(2S,5R)-5-(2-chlorophenyl)-1-(6-(4-methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 81

Compound n° 82:(2S,5R)-5-(2-chlorophenyl)-1-(6-(4-fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 82

Compound n° 83:(2S,5R)-5-(2-chlorophenyl)-1-(2-(2-chlorophenyl)pyrimidine-5-carbonyl)pyrrolidine-2-carboxylicacid.

Example 83

Compound n° 84:(2S,5R)-5-(2-chlorophenyl)-1-(2-methyl-6-phenylnicotinoyl)pyrrolidine-2-carboxylicacid.

Example 84

Compound n° 88:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was was synthesized from intermediates 1a and 2u1 using generalmethod C.

Example 85

Compound n° 89:(2S,5R)-1-(4-((4-chlorophenoxy)methyl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 86

Compound n° 91:(2S,5R)-5-(2-chlorophenyl)-1-(4-((4-methoxyphenoxy)methyl)benzoyl)pyrrolidine-2-carboxylicacid

Example 87

Compound n° 92:(2S,5R)-1-(4-((2-chlorophenoxy)methyl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1b using general method C.

Example 88

Compound n° 95:(2S,5R)-1-(4-((3-chlorophenoxy)methyl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 89

Compound n° 96:(2S,5R)-5-(2-chlorophenyl)-1-(4-((p-tolyloxy)methyl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 90

Compound n° 99:(2S,5R)-5-(2-chlorophenyl)-1-(4-((3,5-dimethylisoxazol-4-yl)methoxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 91

Compound n° 102:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-4-ylmethoxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 92

Compound n° 104:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-1H-pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 93

Compound n° 105:(2S,5R)-5-(2-chlorophenyl)-1-(4-(isoxazol-5-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 94

Compound n° 106:(2S,5R)-1-(4-(4H-1,2,4-triazol-4-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 95

Compound n° 107:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-(p-tolyl)-1H-1,2,3-triazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 96

Compound n° 108:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 97

Compound n° 109:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 98

Compound n° 110:(2S,5R)-1-(4-(1H-pyrazol-1-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 99

Compound n° 111:(2S,5R)-5-(2-chlorophenyl)-1-(4-(oxazol-5-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 100

Compound n° 112:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,5-dimethyl-1H-pyrazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 101

Compound n° 113:(2S,5R)-5-(2-chlorophenyl)-1-(2′,5′-dichloro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2i using general methodC.

Example 102

Compound n° 114:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j using general methodC.

Example 103

Compound n° 115: (2S,5R)-5-(2-chlorophenyl)-1-(4-(furan-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k using general methodC.

Example 104

Compound n° 116:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l using general methodC.

Example 105

Compound n° 117:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-fluoropyridin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m using general methodC.

Example 106

Compound n° 118:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n using general methodC.

Example 107

Compound n° 119:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-(dimethylamino)pyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2o using general methodC.

Example 108

Compound n° 120:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2p using general methodC.

Example 109

Compound n° 121:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-methylpyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2q using general methodC.

Example 110

Compound n° 122:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2r using general methodC.

Example 111

Compound n° 123:(2S,5R)-5-(2-chlorophenyl)-1-(4′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2s using general methodC.

Example 112

Compound n° 124:(2S,5R)-5-(2-chlorophenyl)-1-(4′-cyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2t using general methodC.

Example 113

Compound n° 125:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2u using general methodC.

Example 114

Compound n° 126:(2S,5R)-1-(4′-chloro-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2v using general methodC.

Example 115

Compound n° 127:(2S,5R)-1-(3′-chloro-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2w using general methodC.

Example 116

Compound n° 128:(2S,5R)-1-(2′-chloro-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2x using general methodC.

Example 117

Compound n° 129:(2S,5R)-5-(2-chlorophenyl)-1-(4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2y using general methodC.

Example 118

Compound n° 130:(2S,5R)-5-(2-chlorophenyl)-1-(3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2z using general methodC.

Example 119

Compound n° 131:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2a1 using general methodC.

Example 120

Compound n° 132:(2S,5R)-5-(2-chlorophenyl)-1-(4-(naphthalen-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2b1 using general methodC.

Example 121

Compound n° 133:(2S,5R)-5-(2-chlorophenyl)-1-(3′,5′-difluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2c1 using general methodC.

Example 122

Compound n° 134:(2S,5R)-5-(2-chlorophenyl)-1-(2′-hydroxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2d1 using general methodC.

Example 123

Compound n° 135:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(trifluoromethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2e1 using general methodC.

Example 124

Compound n° 136:(2S,5R)-1-(2′-benzyloxy)-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 125

Compound n° 137:(2S,5R)-5-(2-chlorophenyl)-1-(2′-phenoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 126

Compound n° 138:(2S,5R)-5-(2-chlorophenyl)-1-(2′-isopropoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 127

Compound n° 139:(2S,5R)-5-(2-chlorophenyl)-1-(2′-isobutoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 128

Compound n° 140:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(cyclopropylmethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 129

Compound n° 141:(2S,5R)-5-(2-chlorophenyl)-1-(2′-((4-fluorobenzyl)oxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 130

Compound n° 142:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-chloropyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l1 using general methodC.

Example 131

Compound n° 143:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-fluoropyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m1 using general methodC.

Example 132

Compound n° 149:(2S,5R)-5-(2-chlorophenyl)-1-(4-(thiophen-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n1 using general methodC.

Example 133

Compound n° 150:(2S,5R)-5-(2-chlorophenyl)-1-(4-cyclohexylbenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2o1 using general methodC.

Example 134

Compound n° 152:(2S,5R)-5-(2-chlorophenyl)-1-(9-oxo-9H-fluorene-2-carbonyl)pyrrolidine-2-carboxylicacid.

Example 135

Compound n° 153:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(methylsulfonyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2p1 using general methodC.

Example 136

Compound n° 155:(2S,5R)-5-(2-chlorophenyl)-1-(9-methyl-9H-carbazole-2-carbonyl)pyrrolidine-2-carboxylicacid.

Example 137

Compound n° 156:(2S,5R)-5-(2-chlorophenyl)-1-(4-phenoxybenzoyl)pyrrolidine-2-carboxylicacid.

Example 138

Compound n° 157:(2S,5R)-1-(4-benzylbenzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 139

Compound n° 158:(2S,5R)-1-(4-benzoylbenzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Example 140

Compound n° 159:(2S,5R)-5-(2-chlorophenyl)-1-(4-(pyrimidin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2q1 using general methodC.

Example 141

Compound n° 160:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyrimidin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2r1 using general methodC.

Example 142

Compound n° 161:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2s1 using general methodC.

Example 143

Compound n° 162:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2t1 using general methodC.

Example 144

Compound n° 168:(2S,5R)-5-(2-chlorophenyl)-1-(cyclohexanecarbonyl)pyrrolidine-2-carboxylicacid.

Example 145

Compound n° 169:(2S,5R)-5-(2-chlorophenyl)-1-(4-methylpentanoyl)pyrrolidine-2-carboxylicacid.

Example 146

Compound n° 172:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-methylpiperidin-1-yl)-3-nitrobenzoyl)pyrrolidine-2-carboxylicacid.

Example 147

Compound n° 173:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-oxopiperidin-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 148

Compound n° 174:(2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-4-morpholinobenzoyl)pyrrolidine-2-carboxylicacid.

Example 149

Compound n° 175:(2S,5R)-5-(2-chlorophenyl)-1-(4-(piperidin-1-yl)benzoyl)pyrrolidine-2-carboxylicacid.

Example 150

Compound n° 176:(2S,5R)-5-(2-chlorophenyl)-1-(4-morpholinobenzoyl)pyrrolidine-2-carboxylicacid.

Example 151

Compound n° 177:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyanophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid.

Example 152

Compound n° 178:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-chlorophenyl)cyclohexanecarbonyl)pyrrolidine-2-carboxylicacid.

Example 153

Compound n° 179:(2S,5R)-5-(2-chlorophenyl)-1-(4-phenylcyclohexanecarbonyl)pyrrolidine-2-carboxylicacid.

Example 154

Compound n° 183:((2R,5S)-2-(2-chlorophenyl)-5-(1H-tetrazol-5-yl)pyrrolidin-1-yl)(2′-methoxy-[1,1′-biphenyl]-4-yl)methanone:

Step 1: Synthesis of(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxamide

In a glass tube containing compound n° 1 (0.2 g, 0.459 mmol) in THF (5mL) were added CDI (0.167 g, 0.11 mmol). The RM was stirred at RT for30mn, then NH₃ bubbling in the RM for 1 mn. The RM was diluted with HCl1M and extracted with EtOAc. The organic layer was dried overnight overMgSO4. The concentrated in vacuo and the residue (164 mg) diluted inMeCN and passed through a new PE-AX (2 g) cartridge. The filtrate wasconcentrated to yield title intermediate. Y: 0.14 g (70%), P>80%,rt=4.08 nm (gradient A).

Step 2: Synthesis of(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carbonitrile

In a 50 mL round bottom flask containing(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxamide(0.14 g, 0.322 mmol) were added DMF (3.22 mL). The RM was degassed andplaced under Ar. Cyanuric chloride (0.059 g, 0.322 mmol) was added andthe RM stirred at RT for 90 mn. The RM was diluted with NaHCO₃ (aqueoussaturated solution) and extracted with AcOEt. The organic phase waswashed with brine (2×), dried over MgSO₄ filtered and concentrated toafford 126 mg of title product. Y: 0.126 g (94%), P>80%, rt=4.53 mn(gradient A), (M+H)⁺=417/419.

Step 3: Synthesis of Compound n° 183

In a oven-dried glass tube were added under Ar sodium azide (0.086 g,1.330 mmol) and THF (5 mL). Were added successively aluminium chloride(0.101 g, 0.756 mmol) and(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carbonitrile(0.126 g, 0.302 mmol) diluted in 1 mL THF. The RM was heated at 60° C.overnight. Sodium azide (0.086 g, 1.33 mmol) and aluminium chloride(0.101 g, 0.756 mmol) were added and the RM stirred at 60° C. foranother 7 h. The RM was allowed to reach RT and quenched with HCl 6N andextracted with AcOEt (2×). The organic layer was dried over MgSO₄,filtered and concentrated to afford 160 mg of crude product as a yellowoil. Crude was purified by flash chromatography (DCM/MeOH: 95/5) and SPEusing a PEAX cartridge and elution with ACN, then ACN+HCl. Crude in MeCNsolution from the PEAX fractions were concentrated in vacuo. Residuelyophilized in ACN/Water (2 mL/1 mL). Y: 13 mg (9%), P=100%, rt =5.19 mn(gradient B), (M+H)⁺=460.

Example 155

Compound n° 184:(2R,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1j and 2h using general methodC.

Example 160

Compound n° 189:(2S,5R)-5-(2-chlorophenyl)-1-(6-(2-fluorophenyl)nicotinoyl)pyrrolidine-2-carboxylicacid.

Example 162

Compound n° 191:(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6-phenylnicotinoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2i1 using general methodC.

Example 163

Compound n° 192:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxyphenoxy)benzoyl)pyrrolidine-2-carboxylicacid.

Example 164

Compound n° 193:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-methoxypyridin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j1 using general methodC.

Example 165

Compound n° 194:(2S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-4,4-dimethylpyrrolidine-2-carboxylicacid was synthesized from intermediates 1p and 2h using general methodC.

Example 166

Compound n° 195:(2S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-4-methylpyrrolidine-2-carboxylicacid was synthesized from intermediates 1q and 2h using general methodC.

Example 167

Compound n° 196:(2S,5R)-5-(2-chlorophenyl)-1-(2-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k1 using general methodC.

Example 168

Compound n° 197:(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2v1 using general methodC.

Example 169

Compound n° 198:(2S,5R)-5-(2-chlorophenyl)-1-(2′,6′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2w1 using general methodC.

Example 170

Compound n° 199:(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-dichloro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2x1 using general methodC.

Example 171

Compound n° 200:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(trifluoromethyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2y1 using general methodC.

Example 172

Compound n° 201:(2S,5R)-5-(2-chlorophenyl)-1-(2,2′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2z1 using general methodC.

Example 173

Compound n° 202:(2S,5R)-1-(4′-chloro-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2a2 using general methodC.

Example 174

Compound n° 203:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4-methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2b2 using general methodC.

Example 175

Compound n° 204:(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2c2 using general methodC.

Example 176

Compound n° 205:(2S,5R)-1-([1,1′-biphenyl]-4-carbonyl)-5-(pyridin-3-yl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1r using general method C.

Example 177

Compound n° 206:(2R,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1j using general method C.

Example 178

Compound n° 207:(2S,5R)-5-(2-chlorophenyl)-1-(1-phenyl-1H-benzo[d]imidazole-5-carbonyl)pyrrolidine-2-carboxylicacid.

Example 179

Compound n° 208: (2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylatewas obtained in step 1 of general method C.

Example 180

Compound n° 217: (2S,4S,5S)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-4-(phenylsulfonyl)pyrrolidine-2-carboxylicacid was synthesized using the methodology described in scheme 9.

Example 181

Compound n° 220:(2S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the methodology described in scheme 9.

Example 182

Compound n° 224:(2S,5R)-1-(2-chloro-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2d2 using general methodC.

Example 183

Compound n° 225:(2S,5R)-1-(2′-chloro-2-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2e2 using general methodC.

Example 184

Compound n° 226:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(2-methoxyethoxy)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and2′-(2-methoxyethoxy)biphenyl-4-carboxylic acid which was obtained bysaponification of methyl 2′-(2-methoxyethoxy)biphenyl-4-carboxylate. Thelatter intermediate was prepared using Mitsunobu chemistry:

To a solution of methyl 2′-hydroxybiphenyl-4-carboxylate (300 mg, 1.31mmol), triphenylphosphine (517 mg, 1.97 mmol) and 2-methoxyethanol (130μL, 1.64 mmol) in THF (12.5 mL) was added slowlydiisopropylazodicarboxylate (388 μL, 1.97 mmol) at 0° C. The mixture wasstirred at RT overnight and the reaction was quenched with methanol. Thereaction mixture was diluted with water and extracted with DCM (25 mL).The organic layer was washed with water, dried and concentrated invacuo. Crude was purified by column chromatography(cyclohexane/EtOAc=1/1) to yield2′-(2-methoxyethoxy)biphenyl-4-carboxylate as a yellow oil. Y: 450 mg(78%), P: 65%, rt=2.5 mn (gradient A), Rf (cyclohexane/EtOAc=95/5)=0.75.

Example 185

Compound n° 230:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(pyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2f2 using general methodC.

Example 186

Compound n° 231:(2S,5R)-1-(2′-carbamimidoyl-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid.

Step 1:

To a solution of compound n° 197 precursor (2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-cyano-[1,1′-biphenyl]-4-carbonyflpyrrolidine-2-carboxylate(100 mg, 0.225 mmol) and hydoxylamine hydrochloride (32 mg, 0.45 mmol)in EtOH (1 mL) was triethylamine(64 μL, 0.45 mmol) dropwise at roomtemperature. The mixture was stirred at reflux for 2 days. The mixturewas cooled to RT and concentrated. Crude was purified by columnchromatography (DCM/MeOH=98/2) to yield(2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-((E)-N′-hydroxycarbamimidoyl)biphenylcarbonyl)pyrrolidine-2-carboxylateas a colorless solid. Y: 113 mg (63%), P: >80%, rt=3.6 mn (gradient A),Rf (DCM/MeOH=9/1)=0.3.

Step 2:

A solution of(2S,5R)-methyl5-(2-chlorophenyl)-1-(2′-((E)-N′-hydroxycarbamimidoyl)biphenylcarbonyl)pyrrolidine-2-carboxylatein (EtOH/THF/AcOH=1/1/0.025) (2 mL) was hydrogenated at RT for 45 min.under atmospheric pressure of H₂ using a slurry solution of Raney nickelcatalyst in water (2 vacuum/N2 cycles and then 2 vacuum/H₂ cycles). Thecatalyst was filtered off over Celite and the filtrate was concentratedin vacuo to yield (2S,5R)-methyl1-(2′-carbamimidoylbiphenylcarbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylateas a greenish solid. Y: 64 mg (99%), P: 70%, rt=3.5 mn (gradient A).

Step 3:

(2S,5R)-methyl1-(2′-carbamimidoylbiphenylcarbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylatewas saponified as exemplified in general method C to provide compound n°231.

Example 187

Compound n° 232:(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g using general method C.

Example 188

Compound n° 233:(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(o-tolyppyrrolidine-2-carboxylicacid was synthesized from intermediates 1s using general method C.

Example 189

Compound n° 234:(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-methoxyphenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1i using general method C.

Example 190

Compound n° 235:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(methoxymethyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2g2 using general methodC.

Example 191

Compound n° 236:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid was synthesized from intermediates 1aand 2h2 using general method C.

Example 192

Compound n° 237:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(2-methoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2i2 using general methodC.

Example 193

Compound n° 238:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methoxypyrazin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j2 using general methodC.

Example 194

Compound n° 239:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-(2-methoxyethoxy)pyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and4-(2-(2-methoxyethoxy)pyridin-3-yl)benzoic acid which was obtained bysaponification of methyl 4-(2-(2-methoxyethoxy)pyridin-3-yl)benzoate.The latter intermediate was prepared using Mitsunobu chemistry asdescribed for the synthesis of compound n° 226.

Example 195

Compound n° 240:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-methoxypyrazin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k2 using general methodC.

Example 196

Compound n° 241:(2S,5R)-1-(4-(2-chloro-4-(dimethylamino)pyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l2 using general methodC.

Example 197

Compound n° 242:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyrimidin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m2 using general methodC.

Example 198

Compound n° 227:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methylthiophen-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n2 using general methodC and further purified by preparative HPLC.

Example 199

Compound n° 228:(2S,5R)-5-(2-chlorophenyl)-1-(2′,6′-dichloro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2o2 using general methodC.

Example 200

Compound n° 229:(2S,5R)-1-(2′-chloro-4′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2p2 using general methodC.

Example 201

Compound n° 243:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(dimethylamino)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2q2 using general methodC.

Example 202

Compound n° 246:(2S,5R)-5-(2-fluorophenyl)-1-(4-(2-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid was synthesized from intermediates 1gand 2r using general method C.

Example 203

Compound n° 247:(2S,5R)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2s1 using general methodC.

Example 204

Compound n° 249:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2r2 using general methodC.

Example 205

Compound n° 269:(2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2h2 using general methodC.

Example 206

Compound n° 261:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(4-methylpiperidin-1-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and3-methoxy-4-(4-methylpiperidin-1-yl)benzoic acid using general method C(condition B). The synthesis of3-methoxy-4-(4-methylpiperidin-1-yl)benzoic acid is depicted in scheme11.

Example 207

Compound n° 272:(2S,5R)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-phenylpyrrolidine-2-carboxylicacid was synthesized from intermediates 1t and 2h using general method C(condition A).

Example 208

Compound n° 273:(2S,5R)-5-(3-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1u and 2h using general method C(condition A).

Example 209

Compound n° 274:(2S,5R)-5-(4-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1v and 2h using general method C(condition A).

Example 210

Compound n° 275:(2S,5R)-5-(3-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1w and 2h using general method C(condition A).

Example 211

Compound n° 276:(2S,5R)-5-(4-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1x and 2h using general method C(condition A).

Example 212

Compound n° 278:(2S,5R)-4-acetyl-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from (2S,4 S,5R)-methyl4-acetyl-5-(2-chlorophenyl)pyrrolidine-2-carboxylate using the samedipolar cycloaddition methodology as shown in scheme 9, except for thelast step (Me₃SnOH (10 eq), DCE, 90° C.) instead of (TFA, DCM).

Example 213

Compound n° 279: (2S,4S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylicacid was synthesized from (2S,4S,5R)-4-tert-butyl 2-methyl5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2,4-dicarboxylatewhich was obtained using the dipolar cycloaddition methodology shown inscheme 9. Last steps to perform the synthesis of compound n° 279 aredepicted in scheme 14.

Example 214

Compound n° 280:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2-methoxypyrimidin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2s2 using general methodC (condition B).

Example 215

Compound n° 281:(2S,5R)-5-cyclohexyl-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1y and 2h using general method C(condition B).

Example 216

Compound n° 283:(2S,5R)-1-(4-(2-chloro-4-methoxypyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2t2 using general methodC (condition B).

Example 217

Compound n° 284:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3-methoxypyridin-2-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2u2 using general methodC (condition B).

Example 218

Compound n° 285:(2R,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1z and 2h using general method C(condition A).

Example 219

Compound n° 286:(2S,5S)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a1 and 2h using general methodC (condition A).

Example 220

Compound n° 287:(2R,5S)-5-(2-fluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1b1 and 2h using general methodC (condition A).

Example 221

Compound n° 288:(2S,5R)-5-(2-chlorophenyl)-1-(2-(trifluoromethyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2v2 using general methodC (condition B).

Example 222

Compound n° 289:(2S,5R)-5-(2-chlorophenyl)-1-(2′,4′-difluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2w2 using general methodC (condition B).

Example 223

Compound n° 290:(2S,5R)-5-(2-chlorophenyl)-1-(2-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2x2 using general methodC (condition B).

Example 224

Compound n° 291:(2S,5R)-5-(2,6-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1d and 2h using general method C(condition A).

Example 225

Compound n° 292:(2S,5R)-5-(2,4-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1d1 and 2h using general methodC (condition A).

Example 226

Compound n° 293:(2S,5R)-5-(2,4-dichlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1e1 and 2h using general methodC (condition A).

Example 227

Compound n° 294:(2S,5R)-5-isobutyl-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1f1 and 2h using general methodC (condition A).

Example 228

Compound n° 295:(2S,5R)-5-isopropyl-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g1 and 2h using general methodC (condition A).

Example 229

Compound n° 296:(2S,5R)-1-(3-chloro-4-(pyrimidin-4-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2y2 using general methodC (condition B).

Example 230

Compound n° 297:(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2z2 using general methodC (conditions B).

Example 231

Compound n° 298:(2S,5R)-5-(2-chlorophenyl)-1-(2′-fluoro-4′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2a3 using general methodC (conditions B).

Example 232

Compound n° 299:(2S,5R)-5-(2-chlorophenyl)-1-(4′-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2b3 using general methodC (conditions B).

Example 233

Compound n° 300:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-ethoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2c3 using general methodC (conditions B).

Example 234

Compound n° 301:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-isopropoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2d3 using general methodC (condition B).

Example 234

Compound n° 302:(2S,5R)-5-(2-chlorophenyl)-1-(4-(6-methoxy-2-methylpyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2e3 using general methodC (condition B).

Example 235

Compound n° 303:(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-4-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2f3 using general methodC (condition B).

Example 236

Compound n° 304:(2S,5R)-1-(3-chloro-4-(pyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2g3 using general methodC (condition B).

Example 237

Compound n° 305:(2S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-3-methylpyrrolidine-2-carboxylicacid was synthesized using the 1,3-dipolar cycloaddition shown in scheme9.

Example 238

Compound n° 306:(2S,4S,5R)-5-(2-chlorophenyl)-4-cyano-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-4-methylpyrrolidine-2-carboxylicacid was synthesized using the 1,3-dipolar cycloaddition shown in scheme9.

Example 239

Compound n° 307:(2S,5R)-5-(2-chlorophenyl)-1-(2′,3′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2h3 using general methodC (condition B).

Example 240

Compound n° 308:(2S,5R)-5-(2-chlorophenyl)-1-(3′,4′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2i3 using general methodC (condition B).

Example 241

Compound n° 309:(2S,5R)-5-(2-chlorophenyl)-1-(2′,3′,4′-trimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j3 using general methodC (condition B).

Example 242

Compound n° 310:(2S,5R)-5-(2-chlorophenyl)-1-(2′,3′,6′-trimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k3 using general methodC (condition B).

Example 243

Compound n° 311:(2S,5R)-5-(2-chlorophenyl)-1-(3′,5′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l3 using general methodC (condition B).

Example 244

Compound n° 312:(2S,5R)-5-(2-chlorophenyl)-1-(2′,5′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m3 using general methodC (condition B).

Example 245

Compound n° 313:(2S,5R)-5-(2-chlorophenyl)-1-(2′-isopropyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n3 using general methodC (condition B).

Example 246

Compound n° 314:(2S,5R)-1-(2,2′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2z1 using general methodC (condition B).

Example 247

Compound n° 315:(2S,5R)-1-(2-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2h5 using general methodC (condition B).

Example 248

Compound n° 316:(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2h5 using general methodC (condition B).

Example 249

Compound n° 318:(2S,5R)-5-cyclopentyl-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1h1 and 2h using general methodC (condition A).

Example 250

Compound n° 319:(2S,5R)-5-(2-chlorophenyl)-1-(2′-ethyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2o3 using general methodC (condition B).

Example 251

Compound n° 320:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethylpyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2p3 using general methodC (condition B).

Example 252

Compound n° 321: (2S,5R)-1-(4-(2,4-bis(benzyloxy)pyrimidin-5-yl)benzoy1)-5-(2-chlorophenyl)pyrrolidine-2-carboxylic acid was synthesized fromintermediates 1a and 2q3 using general method C (conditions B).

Example 253

Compound n° 322:(2S,5R)-1-([1,1′:4′,1″-terphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1,1′:4′,1″-terphenyl]-4-carboxylic acid using general method C(conditions B).

Example 254

Compound n° 323:(2S,5R)-5-(2-chlorophenyl)-1-(4′-propyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial4′-propyl-[1,1′-biphenyl]-4-carboxylic acid using general method C(conditions B).

Example 255

Compound n° 324:(2S,5R)-1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial4′-(tert-butyl)-[1,1′-biphenyl]-4-carboxylic acid using general method C(conditions B).

Example 256

Compound n° 325:(2S,5R)-1-(3-chloro-4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2g5 using general methodC (conditions B).

Example 257

Compound n° 326:(2S,5R)-5-(2-chlorophenyl)-1-(5-(2-methoxyphenyl)pyrazine-2-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j5 using general methodC (conditions B).

Example 258

Compound n° 327:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(4-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k5 using general methodC (conditions B).

Example 259

Compound n° 328:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(6-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l5 using general methodC (conditions B).

Example 260

Compound n° 329:(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m5 using general methodC (conditions B).

Example 261

Compound n° 330:(2S,5R)-1-(3-chloro-4-(6-methoxypyridin-3-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2r3 using general methodC (conditions B).

Example 262

Compound n° 331:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(4-chlorophenyl)thiazol-2-yl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(4-(4-chlorophenyl)thiazol-2-yl)piperidine-4-carboxylic acid usinggeneral method C (conditions B).

Example 263

Compound n° 332:(2S,5R)-5-(2-fluorophenyl)-1-(5-methoxy-6-(2-methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2s3 using general methodC (conditions B).

Example 264

Compound n° 333:(2S,5R)-1-(1-(benzo[d]oxazol-2-yl)piperidine-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial 1-(benzo[d]oxazol-2-yl)piperidine-4-carboxylic acid using general method C(conditions B).

Example 265

Compound n° 334:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(pyrrolidin-1-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized using the same methodology as shown in scheme 11,replacing 4-methylpiperidine with pyrrolidine.

Example 266

Compound n° 335:(2S,5R)-5-(2-chlorophenyl)-1-(5-methoxy-6-(2-methoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2t3 using general methodC (conditions B).

Example 267

Compound n° 336:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-methoxyphenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the same methodology as shown in scheme 13replacing 2-cyano-4-trifluoromethyl-bromobenzene with2-methoxy-bromobenzene.

Example 268

Compound n° 337:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)-3-methoxybenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n5 using general methodC (conditions B).

Example 269

Compound n° 338:(2S,5R)-5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1i1 and 2h using general methodC (conditions A).

Example 270

Compound n° 339:(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial3′-cyano-[1,1′-biphenyl]-4-carboxylic acid using general method C(conditions B).

Example 271

Compound n° 340:(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2u3 using general methodC (conditions A).

Example 272

Compound n° 341:(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-2′,4′-bis(2,2,2-trifluoroethoxy)-[1,1′-biphenyl]-4-carbonyflpyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2v3 using general methodC (conditions B).

Example 273

Compound n° 342: (2S,5R)-1-(3′-amino-2′-methyl-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2w3 using general methodC (conditions B).

Example 274

Compound n° 343: (2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2x3 using general methodC (conditions B).

Example 275

Compound n° 344: (2S,5 R)-1-(3′-acetamido-2′-methyl-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2y3 using general methodC (conditions B).

Example 276

Compound n° 345:(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2z3 using general methodC (conditions B).

Example 277

Compound n° 346:(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2a4 using general methodC (conditions B).

Example 278

Compound n° 347:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2b4 using general methodC (conditions B).

Example 279

Compound n° 348:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyridazin-4-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2r4 using general methodC (conditions B).

Example 280

Compound n° 349:(2S,5S)-5-isopentyl-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1j1 and 2h using general methodC (conditions A).

Example 281

Compound n° 350:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2p5 using general methodC (conditions B).

Example 282

Compound n° 351:(2S,5R)-1-(4′-acetamido-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2c4 using general methodC (conditions B).

Example 283

Compound n° 352:(2S,5R)-1-(3′-carbamimidoyl-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-cyanobiphenylcarbonyl)pyrrolidine-2-carboxylatewhich was obtained from intermediate 1a and commercial3′-cyanobiphenyl-4-carboxylic acid using general method C (conditionsB).

Step 1: To a solution of (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-cyanobiphenylcarbonyl)pyrrolidine-2-carboxylate(1.0 mmol) and hydoxylamine hydrochloride (2.0 mmol) in dry EtOH (5 mL)under N₂ was added NEt₃ (2.0 mmol) dropwise at RT. The mixture wasstirred under reflux overnight. The mixture was cooled down to RT,concentrated and purified on silica gel (cyclohex/EtOAc), furnishing 300mg of (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-((4E)-N′-hydroxycarbamimidoyl)biphenylcarbonyl)pyrrolidine-2-carboxylateas a white solid (60% yield).

Step 2: A solution of (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-((E)-N′-hydroxycarbamimidoyl)biphenylcarbonyl)pyrrolidine-2-carboxylate(0.42 mmol) in EtOH/THF/AcOH (3 mL/3 mL/0.1 mL) was hydrogenated at RTunder atmospheric pressure using a slurry solution of Raney nickelcatalyst in water (0.5 mL) for 5 h. The catalyst was filtered off overCelite and the filtrate was concentrated, furnishing 160 mg of whitesolid (83% yield).

Step 3: Saponification using standard methodology described in generalmethod C.

Example 284

Compound n° 353:(2S,5R)-5-(2-chlorophenyl)-1-(3′-((E)-N′-hydroxycarbamimidoyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-((4E)-N′-hydroxycarbamimidoyl)biphenylcarbonyl)pyrrolidine-2-carboxylate(step 1 of synthesis of compound n° 352) using the saponificationstandard methodology described in general method C:(2S,5R)-1-(3′-carbamoyl-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was obtained by hydrolysis and saponification using LiOH of(2S,5R)-methyl5-(2-chlorophenyl)-1-(3′-cyanobiphenylcarbonyl)pyrrolidine-2-carboxylatewhich was obtained from intermediate 1a and commercial3′-cyanobiphenyl-4-carboxylic acid using general method C (conditionsB).

Example 285

Compound n° 360:(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′,3′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2f4 using general methodC (conditions B).

Example 286

Compound n° 361:(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′,5′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2g4 using general methodC (conditions B).

Example 287

Compound n° 362:(2S,5R)-5-(2-chlorophenyl)-1-(3′,4′,5′-trimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2h4 using general methodC (conditions B).

Example 288

Compound n° 363:(2S,5R)-5-(2-chlorophenyl)-1-(2′-(cyanomethyl)-4′,5′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2i4 using general methodC (conditions B).

Example 289

Compound n° 364:(2S,5R)-5-(2-chlorophenyl)-1-(3′,4′-dicyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2j4 using general methodC (conditions B).

Example 290

Compound n° 365:(2S,5R)-5-(2-chlorophenyl)-1-(5′-cyano-2′-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2k4 using general methodC (conditions B).

Example 291

Compound n° 366:(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3′,4′-dimethoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2l4 using general methodC (conditions B).

Example 292

Compound n° 367:(2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyridin-3-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2m4 using general methodC (conditions B).

Example 293

Compound n° 368:(2S,5R)-5-(2-chlorophenyl)-1-(3-fluoro-4-(6-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1a and 2n4 using general methodC (conditions B).

Example 294

Compound n° 369: (2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the methodology shown in scheme 13.

Example 295

Compound n° 370:(2S,5R)-1-(1-(2-chloro-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized using the methodology shown in scheme 13 replacing2-cyano-4-trifluoromethyl-bromobenzene with2-chloro-4-trifluoromethyl-bromobenzene.

Example 296

Compound n° 371:(2S,5R)-1-(5′-cyano-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2z3 using general methodC (conditions B).

Example 297

Compound n° 372:(2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)-3-fluorobenzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2m4 using general methodC (conditions B).

Example 298

Compound n° 373:(2S,5R)-1-(3-fluoro-4-(6-methoxypyridin-3-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediates 1g and 2n4 using general methodC (conditions B).

Example 299

Compound n° 374:(2S,5R)-1-(4-(3,6-dimethoxypyridazin-4-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2r4 usinggeneral method C (conditions B).

Example 300

Compound n° 375:(2S,5R)-1-(3′-carbamoyl-4′-cyano-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was obtained by the hydrolysis of the nitrile moiety of(2S,5R)-methyl5-(2-chlorophenyl)-1-(3′,4′-dicyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylateand subsequent saponification using LiOH. (2S,5R)-methyl5-(2-chlorophenyl)-1-(3′,4′-dicyano-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylatewas obtained from intermediates 1a and intermediate 2j4 using generalmethod C (conditions B).

Example 302

Compound n° 376:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine-4-carboxylic acid usinggeneral method C (conditions B).

Example 303

Compound n° 377:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(morpholinosulfonyl)-2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(2-nitro-4-(piperidin-1-ylsulfonyl)phenyl)piperidine-4-carboxylic acidusing general method C (conditions B).

Example 304

Compound n° 378:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitro-4-(piperidin-1-ylsulfonyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(4-(N,N-diethylsulfamoyl)-2-nitrophenyl)piperidine-4-carboxylic acidusing general method C (conditions B).

Example 305

Compound n° 379:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-(N,N-diethylsulfamoyl)-2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(4-methyl-2-nitrophenyl)piperidine-4-carboxylic acid using generalmethod C (conditions B).

Example 306

Compound n° 380:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methyl-2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the same methodology as depicted in scheme12, replacing 2-nitro-4-trifluoromethyl-fluorobenzene by2-nitro-4-methyl-fluorobenzene.

Example 307

Compound n° 381:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the same methodology as depicted in scheme12, replacing 2-nitro-4-trifluoromethyl-fluorobenzene by2-cyano-4-methyl-fluorobenzene.

Example 308

Compound n° 382:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(4-nitrophenyl)piperidine-4-carboxylic acid using general method C(conditions B).

Example 309

Compound n° 383:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-fluoro-4-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized using the same methodology as depicted in scheme13, replacing 2-cyano-4-trifluoromethyl-bromobenzene by2-fluoro-4-nitro-bromobenzene.

Example 310

Compound n° 384:(2S,5R)-5-(2-chlorophenyl)-1-(1-(3-methoxy-4-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(3-methoxy-4-nitrophenyl)piperidine-4-carboxylic acid using generalmethod C (conditions B).

Example 311

Compound n° 385:(2S,5R)-1-(1-(5-chloro-2-nitrophenyl)piperidine-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(5-chloro-2-nitrophenyl)piperidine-4-carboxylic acid using generalmethod C (conditions B).

Example 312

Compound n° 386:(2S,5R)-5-(2-cyanophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained by cyanation of (2S,5R)-methyl5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylateand subsequent saponification. (2S,5R)-methyl5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylatewas obtained from intermediates 1i1 and 2h using general method C,(conditions A). Cyanation method of cyanation: In a carrousel tube wereintroduced NMP (0.2 mL), i-PrOH (9.7 μL), sodium carbonate (0.021 g,0.202 mmol), palladium(II) acetate (0.908 mg, 4.05 μmol) and(2S,5R)-methyl5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylate(0.1 g, 0.202 mmol). The RM was heated at 140° C. and potassiumferrocyanide.3H₂O (0.026 g, 0.061 mmol) was added. Heating was stoppedand the RM was stirred overnight. The RM was diluted with water andextracted with three times with EtOAc. The aqueous layer was acidified(a color change from brown to blue was observed) and extracted twicewith diethyl ether. The combined organic layers were dried over MgSO₄,filtered and concentrated to afford a brown residue. Crude was purifiedby flash chromatography (EtOAc/PE: 1/2) to yield compound n° 386. Y=10%,P>90%.

Example 313

Compound n° 387:(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2s4 usinggeneral method C (conditions B).

Example 314

Compound n° 388:(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2s5 usinggeneral method C (conditions B).

Example 315

Compound n° 389:(2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2t5 usinggeneral method C (conditions B).

Example 316

Compound n° 390:(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-2-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2u5 usinggeneral method C (conditions B).

Example 317

Compound n° 391:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4-(methylsulfonamido)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained by reduction of nitro, sulfonylation andsaponification of (2S,5R)-methyl5-(2-chlorophenyl)-1-(1-(2-cyano-4-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylatewhich was obtained from intermediate 1a and commercial1-(2-cyano-4-nitrophenyl)piperidine-4-carboxylic acid using generalmethod C, condition B.

Example 318

Compound n° 392:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-cyano-4-methoxyphenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained using the same methodology as shown in scheme 13replacing 2-cyano-4-trifluoromethyl-bromobenzene with2-cyano-4-methoxy-bromobenzene.

Example 319

Compound n° 393:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-(methylsulfonamido)-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained by reduction of the nitro group of (2S,5R)-methyl5-(2-chlorophenyl)-1-(1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylate,followed by sulfonylation with methane sulfonyl chloride, and subsequentsaponification. (2S,5R)-methyl-5-(2-chlorophenyl)-1-(1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylatewas obtained from intermediates 1a and commercial 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine-4-carboxylic acid using generalmethod C (conditions B).

Example 320

Compound n° 394:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-nitrophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(2-nitrophenyl)piperidine-4-carboxylic acid using general method C(conditions B).

Example 321

Compound n° 395:(2S,5R)-5-(2-chlorophenyl)-1-(1-(4-cyanophenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial1-(4-cyanophenyl)piperidine-4-carboxylic acid using general method C(conditions B).

Example 322

Compound n° 396:(2S,5R)-5-(3,5-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1l1 and intermediate 2h usinggeneral method C (conditions A).

Example 323

Compound n° 397:(2S,5R)-5-(3,4-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1m1 and intermediate 2h usinggeneral method C (conditions A).

Example 324

Compound n° 398:(2S,5R)-5-(2,3-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1n1 and intermediate 2h usinggeneral method C (conditions A).

Example 325

Compound n° 399:(2S,5R)-5-(2,5-difluorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1o1 and intermediate 2h usinggeneral method C (conditions A).

Example 326

Compound n° 400:(2S,5R)-5-([1,1′-biphenyl]-2-yl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained by Suzuki coupling (2S,5R)-methyl5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylatewith phenylboronic acid and subsequent saponification. (2S,5R)-methyl5-(2-bromophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylatewas obtained from intermediates 1i1 and 2h using general method C(conditions A).

Example 327

Compound n° 401:(2S,5R)-1-(2′-cyano-4′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1g and 2s4 using general method C(conditions B).

Example 328

Compound n° 402:(2S,5R)-5-(4-cyanophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1p1 and 2h using general method C(conditions A).

Example 329

Compound n° 403:(2S,5R)-5-(2-chlorophenyl)-1-(4-(5-methyl-4-(phenylsulfonyl)-1H-1,2,3-triazol-1-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthesized from intermediate 1a and commercial4-(5-methyl-4-(phenylsulfonyl)-1H-1,2,3-triazol-1-yl)benzoic acid usinggeneral method C (conditions B).

Example 330

Compound n° 404:(2S,5R)-5-(2-chlorophenyl)-1-(3′-cyano-4′-fluoro-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2u4 usinggeneral method C (conditions B).

Example 331

Compound n° 405:(2S,5R)-1-(2′-chloro-5′-cyano-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2v4 usinggeneral method C (conditions B).

Example 332

Compound n° 406:(2S,5R)-5-(2-chlorophenyl)-1-(2′-cyano-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2w4 usinggeneral method C (conditions B).

Example 333

Compound n° 407:(2S,5R)-5-(2-chlorophenyl)-1-(1-(2-methoxy-4-(trifluoromethyl)phenyl)piperidine-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained using the same methodology as depicted in scheme 12,replacing 2-nitro-4-trifluoromethyl-fluorobenzene by2-methoxy-4-trifluoromethyl-fluorobenzene.

Example 334

Compound n° 408:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methyl-3′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2x4 usinggeneral method C (conditions B).

Example 335

Compound n° 409:(2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2v5 usinggeneral method C (conditions B).

Example 336

Compound n° 410:(2S,5R)-5-(2-chlorophenyl)-1-(6-(5-cyano-2-methoxyphenyl)-5-methoxynicotinoyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2y4 usinggeneral method C (conditions B).

Example 337

Compound n° 411:(2S,5R)-5-(2-chlorophenyl)-1-(6-(2,4-dimethoxyphenyl)-5-methoxynicotinoyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2z4 usinggeneral method C (conditions B).

Example 338

Compound n° 412:(2S,5R)-5-(2-chlorophenyl)-1-(6-(2,4-dimethoxyphenyl)nicotinoyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1a and intermediate 2a5 usinggeneral method C (conditions B).

Example 339

Compound n° 413:(2S,5R)-1-(2′-cyano-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1g and intermediate 2w4 usinggeneral method C (conditions B).

Example 340

Compound n° 414:(2S,5R)-1-(3′-cyano-4′-fluoro-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1g and intermediate 2u4 usinggeneral method C (conditions B).

Example 341

Compound n° 415:(2S,5R)-1-(2′-chloro-5′-cyano-[1,1′-biphenyl]-4-carbonyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylicacid was obtained from intermediates 1g and intermediate 2v4 usinggeneral method C (conditions B).

Example 342

Compound n° 416:(2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyridazin-4-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylicacid was synthetized from 1a and 2w5 using general method C (conditionsB).

Example 343

Compound n° 417:(2S,5R)-5-(2-fluorophenyl)-1-(2′-methyl-3′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1g and 2x4 using general methodC (conditions B).

Example 344

Compound n° 418:(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthetized from 1g and 2v5 using general method C (conditionsB).

Example 345

Compound n° 419:(2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthetized from 1a and 2f5 using general method C (conditionsB).

Example 346

Compound n° 420:(2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2,4-dimethoxypyrimidin-5-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1n1 and 2s1 using general methodC (conditions B).

Example 347

Compound n° 421:(2S,5R)-1-(5′-cyano-2′-methyl-[1,1′-biphenyl]-4-carbonyl)-5-(2,3-difluorophenyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1n1 and 2a4 using general methodC (conditions B).

Example 348

Compound n° 354:(2S,5R)-5-(2-fluorophenyl)-1-(2′-methoxy-4′-(methylsulfonamido)-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1g and 2p5 using general methodC (conditions B).

Example 349

Compound n° 355:(2S,5R)-5-(2,4-difluorophenyl)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1k1 and 2q5 using general methodC (conditions B).

Example 350

Compound n° 356:(2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(5-methoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1a and 2d4 using general methodC (conditions B).

Example 351

Compound n° 357:(2S,5R)-1-(4′-amino-2′-methoxy-[1,1′-biphenyl]-4-carbonyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylicacid was synthetized from intermediate 1a and methyl2′-methoxy-4′-amino-[1,1′-biphenyl]-4-carboxylate obtained in thesynthesis of intermediate 2p5.

Example 352

Compound n° 358:(2S,5R)-5-(2-chlorophenyl)-1-(2′,3,6′-trimethoxy-[2,3′-bipyridine]-5-carbonyl)pyrrolidine-2-carboxylicacid was synthetized from intermediates 1a and 2e4 using general methodC (conditions B).

BIOLOGY EXAMPLES BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 represents the effect of compounds 1; 2; 4; 5; 8; 10; 11 and 13on isoprenaline-induced lipolysis in adipocytes isolated from normalrat. Compounds are tested at 30 μM final concentration.

FIGS. 2A and 2B represent the inhibition of blood glucose concentrationin OGTT assay following bi-daily injection (at 50 mg/kg) of compound 1during 28 days.

MEMBRANE BINDING ASSAY: GTPγS BINDING ASSAY

The following assay can be used for determination of GPR43 activation.When a GPCR is in its active state, either as a result of ligand bindingor constitutive activation, the receptor couples to a G protein andstimulates the release of GDP and subsequent binding of GTP to the Gprotein. The alpha subunit of the G protein-receptor complex acts as aGTPase and slowly hydrolyses the GTP to GDP, at which point the receptornormally is deactivated. Activated receptors continue to exchange GDPfor GTP. The non-hydrolysable GTP analog, [³⁵S]GTPγS, was used todemonstrate enhance binding of [³⁵S]GTPγS to membranes expressingreceptors. The assay uses the ability of GPCR to stimulate [³⁵S]GTPγSbinding to membranes expressing the relevant receptors. The assay can,therefore, be used in the direct identification method to screencandidate compounds to endogenous or not endogenous GPCR.

Preparation of Membrane Extracts:

Membrane extracts were prepared from cells expressing the human GPR43receptor (hGPR43) as follows: the medium was aspirated and the cellswere scraped from the plates in Ca⁻⁺ and Mg⁺⁻-free Phosphate-bufferedsaline (PBS). The cells were then centrifuged for 3 min at 1500 g andthe pellets were resuspended in buffer A (15 mM Tris-HCl pH 7.5, 2 mMMgCl₂, 0.3 mM EDTA, 1 mM EGTA) and homogenized in a glass homogenizer.The crude membrane fraction was collected by two consecutivecentrifugation steps at 40.000×g for 25 min separated by a washing stepin buffer A. The final pellet was resuspended in 500 μl of buffer B (75mM Tris-HCl pH 7.5, 12.5 mM MgCl₂, 0.3 mM EDTA, 1 mM EGTA, 250 mMsucrose) and flash frozen in liquid nitrogen. Protein content wasassayed by the Folin method.

GTPγS Assay (SPA Method):

The assay was used to determine the activity of the compounds of theinvention. The [³⁵S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100mM NaCl, 10 μg/ml saponin, 30 mM of MgCl₂, 10 μM of GDP, 5 μgmembrane-expressing hGPR43, 250 μg of wheatgerm agglutinin beads(Amersham, ref: RPNQ001), a range concentration of compounds of theinvention (from 30 μM to 1 nM) in a final volume of 100 μl for 30 min atroom temperature. The SCFA propionate was used at 1 mM finalconcentration as positive control. The plates were then centrifuged for10 minutes at 2000 rpm, incubated for 2 hours at room temperature andcounted for 1 min in a scintillation counter (TopCount, PerkinElmer).The results of the tested compounds are reported as the concentration ofthe compound required to reach 50% (EC₅₀) of the maximum level of theactivation induced by these compounds.

When tested in the assay described above and by way of illustration thecompounds in Table 3 activate GPR43 receptor. The EC₅₀ value obtained isrepresented as follows: “+++” means EC₅₀<200 nM; “++” means 200nM≦EC₅₀≦1 μM; “+” means EC₅₀>1 μM.

TABLE 3 Compounds EC₅₀ values in GTPγ³⁵S assay. Compound n^(o) EC₅₀ (nM)1 +++ 2 +++ 3 +++ 4 +++ 5 +++ 6 +++ 8 ++ 9 ++ 10 ++ 11 ++ 12 ++ 13 ++ 14++ 15 ++ 16 ++ 17 ++ 18 ++ 19 ++ 20 ++ 21 ++ 23 + 24 + 26 + 27 + 30 +31 + 32 + 33 + 34 + 35 + 36 + 38 + 39 + 40 + 41 + 42 + 43 + 44 + 45 +47 + 48 + 49 + 52 + 53 + 58 + 59 + 77 +++ 78 ++ 83 + 88 + 89 ++ 91 ++ 96++ 99 ++ 102 + 105 + 107 + 108 + 109 + 113 +++ 114 + 116 ++ 117 ++ 120 +121 ++ 122 +++ 123 +++ 125 ++ 126 +++ 127 +++ 128 +++ 129 +++ 130 +++131 + 132 +++ 133 ++ 134 ++ 135 +++ 136 ++ 137 ++ 138 +++ 140 +++ 141 ++143 + 149 ++ 150 ++ 151 ++ 153 + 155 + 156 ++ 157 +++ 160 ++ 161 +++162 + 169 + 174 + 176 + 177 + 178 ++ 179 + 183 + 184 ++ 189 ++ 191 ++192 ++ 193 +++ 194 ++ 195 ++ 196 +++ 197 +++ 198 +++ 199 +++ 200 +++ 201+++ 202 +++ 203 ++ 204 +++ 206 + 207 + 224 +++ 225 +++ 226 ++ 227 +++228 +++ 229 +++ 230 + 231 + 232 +++ 233 ++ 234 + 235 +++ 236 +++ 237 ++239 ++ 240 ++ 242 ++ 246 +++ 247 +++ 261 ++ 268 +++ 269 +++ 272 ++ 273++ 274 ++ 275 +++ 276 ++ 278 ++ 279 + 280 + 281 ++ 283 +++ 284 ++ 285 +286 + 287 ++ 288 ++ 289 +++ 290 +++ 291 ++ 292 +++ 293 ++ 294 ++ 295 +296 + 297 +++ 298 +++ 299 +++ 300 ++ 301 ++ 302 +++ 303 ++ 304 + 305 +306 + 307 +++ 308 +++ 309 ++ 310 ++ 311 +++ 312 +++ 313 ++ 314 +++ 315+++ 316 +++ 318 + 319 ++ 320 +++ 321 ++ 322 ++ 323 ++ 324 ++ 325 +++326 + 327 ++ 328 +++ 329 ++ 330 ++ 331 ++ 332 + 333 + 334 ++ 335 + 336 +337 +++ 338 +++ 339 ++ 340 +++ 341 + 342 +++ 343 +++ 344 ++ 345 +++ 346+++ 347 +++ 348 +++ 349 ++ 350 +++ 351 +++ 352 + 353 ++ 354 +++ 355 +++356 +++ 357 +++ 358 ++ 359 ++ 360 +++ 361 +++ 362 +++ 363 ++ 364 + 365++ 366 +++ 367 +++ 368 +++ 369 ++ 370 + 371 +++ 372 +++ 373 ++ 374 ++375 ++ 386 ++ 387 +++ 388 +++ 389 +++ 390 +++ 391 + 392 + 393 + 395 ++396 ++ 397 ++ 398 +++ 399 +++ 400 ++ 401 +++ 402 + 403 + 404 ++ 405 +++406 +++ 407 ++ 408 +++ 409 +++ 410 ++ 411 ++ 412 ++ 413 +++ 414 + 415+++ 416 +++ 417 +++ 418 ++ 419 +++ 420 +++ 421 +++Radioligand Binding (RLB) Assay with Cell Membrane Extracts from HumanGPR43 Recombinant Cell Line

Human GPR43 radioligand binding assay is performed by addingsuccessively in the wells of a 96 well plate (Master Block, Greiner,786201), 50 μl of compound of the invention at increasing concentrations(diluted in assay buffer: 50 mM Tris pH 7.4), 25 μl radiolabeledantagonist (i.e. compound n° 277 described in EP10305100.9) diluted inassay buffer and 25 μl cell membrane extracts (10 protein/well). Thefinal concentration of radiolabeled antagonist in the assay is 10 nM.The plate is incubated 60 min at 25° C. in a water bath and thenfiltered over GF/B filters (Perkin Elmer, 6005177, presoaked in 0.05%Brij for 2 h at room temperature) with a Filtration unit (Perkin Elmer).The filters are washed 3 times with 0.5 ml of ice-cold wash buffer (50mM Tris pH 7.4). 50 μl of Microscint 20 (Packard), is added and theplate is incubated 15 min on an orbital shaker and then counted with aTopCount™ for 1 min/well.

In Table 4 biological results obtained using the RLB assay as describedabove with compounds of the invention are set out in tabulated form. Inthis table, the constant of inhibition of radioligand binding carriedout by the compound of the invention (Ki) is given. The Ki values (nM)obtained is represented as follows: “+++” means Ki<1 μM; “++” means 1μM≦Ki≦2 μM; “+” means 2 μM<Ki.

TABLE 4 Compounds Ki values in RLB assay. Compound n^(o) Ki (nM) 376 +++377 + 378 ++ 379 + 380 ++ 381 ++ 382 + 383 + 384 + 385 +++ 394 +Cell Based Assay: Calcium Flux. The Aequorin-Based Assay.

The following assay can be used for determination of GPR43 activation.The aequorin assay uses the responsiveness of mitochondrial apoaequorinto intracellular calcium release induced by the activation of GPCRs(Stables et al., 1997, Anal. Biochem. 252:115-126; Detheux et al., 2000,J. Exp. Med., 192 1501-1508). Briefly, GPCR-expressing clones aretransfected to coexpress mitochondrial apoaequorin and Gα16. Cellsexpressing GPR43 receptor are incubated with 5 μM Coelenterazine H(Molecular Probes) for 4 hours at room temperature, washed in DMEM-F12culture medium and resuspended at a concentration of 0.5×10⁶ cells/ml(the amount can be changed for optimization). Cells are then mixed withtest compounds and light emission by the aequorin is recorded with aluminometer for 30 sec. Results are expressed as Relative Light Units(RLU). Controls include assays using cells not expressing GPR43 (mocktransfected), in order to exclude possible non-specific effects of thecandidate compound.

Aequorin activity or intracellular calcium levels are “changed” if lightintensity increases or decreases by 10% or more in a sample of cells,expressing a GPR43 and treated with a compound of the invention,relative to a sample of cells expressing the GPR43 but not treated withthe compound of the invention or relative to a sample of cells notexpressing the GPR43 (mock-transfected cells) but treated with thecompound of the invention.

Cell Based Assay: Intracellular Inositol-Phosphate Accumulation Assay.(Gq-Associated Receptor)

The following assay can be used for determination of GPR43 activation.On day 1, GPR43-expressing cells in mid-log phase are detached withPBS-EDTA, centrifuged at 2000×g for 2 min and resuspended in mediumwithout antibiotics. After counting, cells are resuspended at 4×10⁵cells/ml (the amount can be changed for optimization) in medium withoutantibiotics, distributed in a 96 well plate (10 μl/well) and the plateis incubated overnight at 37° C. with 5% CO₂. On day 2, the medium isremoved and the compounds of the invention, at increasingconcentrations, are added (24 μl/well) and the plate is incubated for 30min. at 37° C. in a humidified atmosphere of 95% air with 5% CO₂. TheIPI concentrations are then estimated using the IPI-HTRF assay kit(Cisbio international, France) following the manufacturerrecommendations.

Cell Based Assay: cAMP Accumulation Assay (G_(i/o) Associated Receptor)

The following assay can be used for determination of GPR43 activation.Cells expressing GPR43 in mid-log phase and grown in media withoutantibiotics are detached with PBS-EDTA, centrifuged and resuspended inmedia without antibiotics. Cells are counted and resuspended in assaybuffer at 4.2×10⁵ cells/ml. 96 well plates are filled with 12 μl ofcells (5×10³ cells/well), 6 μl of compound of the invention atincreasing concentrations and 6 μl of Forskolin (final concentration of10 μM). The plate is then incubated for 30 min. at room temperature.After addition of the lysis buffer, cAMP concentrations are estimated,according to the manufacturer specification, with the HTRF kit fromCis-Bio International.

In Vitro Assays to Assess Compound Activity in 3T3-L1 Cell Line.

3T3-L1 adipocytes cell line has been described as cellular model toassess compounds mimicking insulin-mediated effect such as inhibition oflipolysis and activation of glucose uptake.

Lipolysis.

3T3-L1 cells (ATCC) are cultured in Dulbecco's modified eagle's medium(DMEM) containing 10% (v/v) bovine serum (fresh regular medium) in 24well plate. On day 0 (2 days after 3T3-L1 preadipocytcs reachedconfluence), cells are induced to differentiate by insulin (10 μg/ml),IBMX (0.5 mM) and dexamethasone (1 μM). On day 3 and every other 3^(rd)day thereafter, fresh regular medium is substituted until day 14.

On day 14, the medium is removed and cells are washed twice with 1 ml ofa wash buffer (Hank's balanced salt solution). The wash solution isremoved and the SCFA or the tested compounds, or a combination of both,are added at the desired concentration in Hank's buffer supplementedwith 2% BSA-FAF and incubated for 10 minutes à 37° C. Then,isoproterenol (100 nM) is added to induce lipolysis and incubate for 30minutes at 37° C. The supernatants are collected in a glycerol-freecontainer. 25 μl (the amount can be changed for optimization) ofcell-free supernatants are dispensed in 96-well microtiter plate, 25 μlof free glycerol assay reagent (Chemicon, the amount can be changed foroptimization) is added in each well and the assay plate is incubated for15 minutes at room temperature. The absorbance is recorded with aspectrophotometer at 540 or 560 nm. Using the supernatants, the freefatty acids amount can be assessed using the NEFA assay kit (Wako)according the manufacturer's recommendations.

Glucose Uptake.

3T3-L1 cells are differentiated as described previously with or withoutof 30 μM of tested compounds (the concentration can be changed foroptimization) during the 14 days of differentiation. The day of theexperiment, the cells are washed twice with a KREBS-Ringer bicarbonate(pH 7.3) supplemented with 2 mM sodium pyruvate and starved for 30minutes in the same buffer at 37° C. in an atmosphere containing 5% CO2and 95% O2. Various amount of SCFA, tested compounds or combination ofboth are then added with or without 10 nM of insulin (the amount can bechanged for optimization) for 30 minutes at 37° C. in an atmospherecontaining 5% CO2 and 95% O2. Then, D-(³H)-2 deoxyglucose (0.2 μCi/well)and D-2-deoxyglucose (0.1 mM) is added for 30 minutes. To stop thereaction, the cells are immersed in ice-cold saline buffer, washed for30 min, and then dissolved in NaOH 1M at 55° C. for 60 minutes. NaOH isneutralized with HCl 1M. The 3H labeled radioactivity of an aliquot ofthe extract is counted in the presence of a scintillation buffer.

In Vitro Assays to Assess Compound Activity in NCI-H716 Cell Line.

Human intestinal cell line NCI-H716 has been described as cellular modelto assess compounds mimicking nutrient-mediated effect such asglucagon-like peptide-1 (GLP-1) secretion.

GLP-1 Release.

NCI-H716 cells (ATCC, Manassas) are cultured in Dulbecco's modifiedeagle's medium (DMEM) containing 10% (v/v) bovine serum, 2 mML-glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin in 75 mlflask. Cell adhesion and endocrine differentiation is initiated bygrowing cells in 96-well plate coated with matrigel in High Glucose DMEMcontaining 10% (v/v) bovine serum, 2 mM L-glutamine, 100 IU/mlpenicillin and 100 μg/ml streptomycin for 2 days.

On day 2, the medium is removed and cells are washed once with apre-warmed wash buffer (Phosphate Buffered salt solution). The washsolution is removed and the SCFA or the tested compounds, or acombination of both, are added at the desired concentration in HighGlucose DMEM containing 0.1% (v/v) bovine serum and incubated for 2hours at 37° C. The supernatants are collected in a container. Using thecell-free supernatants, the GLP-1 amount is assessed using a GLP-1specific ELISA assay kit according the manufacturer's recommendations(ALPCON).

Ex Vivo Assays to Assess Compound Activity in Adipocytes from Normal Rator Mice and High-Fat Diet Fed Mice.

Mice C56Black6 male are housed in Makrolon type IV group housing cages(56×35×20 cm³) throughout the experimental phase. Animals' cages littersare changed once a week. They are housed in groups of 10 animals at 12light dark (at 8 h 30 pm lights off), 22+/−2° C. and 50+/−5% relativehumidity. Animals are acclimated one week. During the whole phase,standard diet or diet high in energy from fat (Research Diets, NewBrunswick, N.J.) and tap water are provided ad libitum. The animals are16 weeks old at the time of the study.

For keeping only mice that have responded to the high fat diet, fastedglycemia are measured in these mice just before performing the ex-vivostudy.

Glucose Uptake Assay in Isolated Adipocytes.

Animals are killed by cervical dislocation and epididymal fat pads areremoved and digested in collagenase buffer at 370° C./120rpm forapproximately 50 minutes. The digest is filtered through gauze torecover the adipocytes, which are washed and resuspended in Krebs-RingerHepes (KRH) buffer containing 1% BSA, 200 nM adenosine and 2 mM glucose.

Isolated adipocytes are washed in glucose-free KRH-buffer andresuspended to 30%. Adipocytes are then incubated at 370° C./80 rpm witheither the tested compound (30 μM, 10 μM and 1 μM) in the presence orabsence of insulin (10 nM) for 30 min 2-deoxyglucose and2-deoxy-D-[1-³H]-glucose (³H-2-DOG) are added and incubation continuedfor 10 min. The reactions are then stopped by addition of cytochalasin bfollowed by centrifugation through dinonylphthalate to recover theadipocytes. The uptake of ³H-2-DOG- was measured by scintillation. Eachdata point is investigated in triplicates in two independentexperiments.

Lipolysis Assay in Isolated Adipocytes.

Isolated adipocytes are diluted to 5% in KRH-buffer and are pre-treatedwith the tested compound (30 μM, 100/1 and 10/1) for 30 min at 370°C./120 rpm. After the pre-treatment, Isoprenaline (1 μM) is added to theadipocytes followed by 30 min incubation at 37° C./150 rpm. Thereactions are put on ice and the buffer is assayedspectrophotometrically for the production of NADH⁺ from glycerolbreakdown in reactions catalyzed by glycerol kinase andglycerol-3-phosphate dehydrogenase and/or Non Esterified Fatty Acid(NEFA). Each data point is investigated in triplicates in twoindependent experiments.

According to the method described above and by way of illustration thecompounds n° 1; 2; 4; 5; 8; 10; 11 and 13 inhibit isoprenaline-inducedlipolysis in adipocytes from normal rat, at the concentration of 30 μM(FIG. 1).

In Vivo Assay to Assess Compound Activity in Rodent Diabetes Model.Genetic Rodent Models:

Rodent models of T2D associated with obesity and insulin resistance havebeen developed. Genetic models such as db/db and ob/ob in mice and fa/fain Zucker rats have been developed for understanding the pathophysiologyof disease and testing candidate therapeutic compounds. The homozygousanimals, C57 Black/6-db/db mice developed by Jackson Laboratory areobese, hyperglycemic, hyperinsulinemic and insulin resistant (J ClinInvest, 1990, 85:962-967), whereas heterozygotes are lean andnormoglycemic. In the db/db model, mice progressively developinsulinopenia with age, a feature commonly observed in late stages ofhuman T2D when sugar levels are insufficiently controlled. Since thismodel resembles that of human T2D, the compounds are tested foractivities including, but not limited to, lowering of plasma glucose andtriglycerides. Zucker (fa/fa) rats are severely obese, hyperinsulinemic,and insulin resistant, and the fa/fa mutation may be the rat equivalentof the murine db mutation. Genetically altered obese diabetic mice(db/db) (male, 7-9 weeks old) are housed under standard laboratoryconditions at 22° C. and 50% relative humidity, and maintained on a dietof Purina rodent chow and water ad libitum. Prior to treatment, blood iscollected from the tail vein of each animal and blood glucoseconcentrations are determined using one touch basic glucose monitorsystem (Lifescan). Mice that have plasma glucose levels between 250 to500 mg/dl are used. Each treatment group consists of several mice thatare distributed so that the mean of glucose levels are equivalent ineach group at the start of the study. Db/db mice are dosed bymicro-osmotic pumps, inserted using isoflurane anesthesia, to providecompounds of the invention, saline, or an irrelevant compound to themice intravenously (i.v). Blood is sampled from the tail vein atintervals thereafter and analyzed for blood glucose concentrations.Significant differences between groups (comparing compounds of theinvention to saline-treated) are evaluated using Student t-test.

Ob/ob or obese mice are leptin-deficient mice that eat excessively andbecome profoundly obese, hyperinsulinemic and hyperglycemic. It is ananimal model of type II diabetes. Such model can be used for oralglucose tolerance tests (OGTTs). A total of sixteen (16) male ob/ob mice(6 weeks of age) were obtained from Harlan. Upon arrival to the animalunit, mice were housed 4 per cage in rodent cages mounted with feederscontaining regular chow. The mice were put in a 12/12 h light-dark cycle(light from 0600-1800 h) with controlled temperature conditions (22-24°C.). Fed blood glucose and body-weight was measured on day −2 in themorning between 08:00 AM and 09:00 AM. Animals were randomized into 2groups according to fed glucose levels (on day −2). The 16 mice withblood glucose and body-weight closest to the mean were distributed intothe following groups: Group 1: Vehicle p.o. bi-daily, (n=8) and Group 2:Compound of the invention, p.o., bi-daily, (n=8).

Day 1 is the first day of dosing. Animals were dosed with compounds ofthe invention at 07:00 AM and 04:00 PM for 28 days. On the evening ofday 27, food was removed and mice were transferred to clean cages. Micewere fasted for the subsequent 17 hours until the OGTT was performed. At−15 min, blood glucose was measured (using a glucose analyzer) andanimals were dosed with compounds of the invention or vehicle. At timepoint 0, blood glucose was measured again and glucose was administeredby oral gavage (1 g/kg glucose). The blood glucose was then measured attime points 15, 30, 45, 60 and 120 minutes. The blood glucose area underthe curve (AUC) from time −15 to 120 min was then calculated (GraphPadsoftware). The percentages of AUC inhibition induced by compounds of theinvention were calculated as follows: % of AUC inhibition: [1−(AUCcompound/AUC vehicule)]*100.

When tested in the above-described assay, the compound 1 showed a % ofAUC inhibition of 40%, indicating that compound 1 is able tosignificantly reduce the level of blood glucose in diabetic animal model(FIGS. 2A and 2B).

The High-Fat Diet Fed Mouse:

This model was originally introduced by Surwit et al. in 1988. The modelhas shown to be accompanied by insulin resistance, as determined byintravenous glucose tolerance tests, and of insufficient isletcompensation to the insulin resistance. The model has, accordingly, beenused in studies on pathophysiology of impaired glucose tolerance (IGT)and type 2 diabetes and for development of new treatments.

C57BL/6J mice are maintained in a temperature-controlled room (22° C.)on a 12-h light-dark cycle. One week after arrival, mice are dividedinto two groups and are fed either a high-fat diet or receivedcontinuous feeding of a normal diet for up to 12 months. On caloricbasis, the high-fat diet consist of 58% fat from lard, 25.6%carbohydrate, and 16.4% protein (total 23.4 kJ/g), whereas the normaldiet contains 11.4% fat, 62.8% carbohydrate, and 25.8% protein (total12.6 kJ/g). Food intake and body weight are measured once a week, andblood samples are taken at indicated time points from the intraorbitalretrobulbar plexus from nonfasted anesthetized mice.

For intravenous glucose tolerance tests (IVGTTs), 4-h fasted mice areanesthetized with 7.2 mg/kg fluanison/fenlanyl and 15.3 mg/kg midazolam.Thereafter a blood sample is taken from the retrobulbar, intraorbital,capillary plexus, after which D-glucose (1 g/kg) is injectedintravenously in a tail vein (volume load 10 l/g). Additional bloodsamples are taken at 1, 5, 10, 20, 50, and 75 min after injection.Following immediate centrifugation at 4 C, plasma is separated andstored at −20 C until analysis. For oral glucose tolerance tests(OGTTs), 16-h fasted anesthetized mice are given 150 mg glucose bygavage through a gastric tube (outer diameter 1.2 mm), which is insertedin the stomach. Blood samples are taken at 0, 15, 30, 60, 90, and 120min after glucose administration and handled as above.

Administration of the compounds: Five-week-old mice are fed a high-fator a normal diet for 8 weeks. After 4 weeks, the mice are additionallygiven the compound of the invention in their drinking water (0.3 mg/ml,the amount can be changed for optimization. Control groups are given tapwater without compound. After another 4 weeks, the mice are subjected toan OGTT as described above. Insulin and glucose measurements: Insulin isdetermined enzymatically using an ELISA assay kit (Linco Research, St.Charles, Mo.). Plasma glucose is determined by the glucose oxidasemethod.

In Vivo Assay to Assess Compound Anti-Obesity Activity in Rodent Model.Mouse Acute Food Intake and Weight Change:

Male C57BL/6N wild-type mice are weighed and vehicle or the testedcompounds are administered by oral gavage to male mice approximately 30min prior to the onset of the dark phase of the light cycle. Mice arefed ad libitum in the dark phase following dosing. A preweighed aliquotof a highly palatable medium high fat diet is provided in the foodhopper of the cage 5 min prior to the onset of the dark phase of thelight cycle and weighed 2 and 18 h after the onset of the dark phase ofthe light cycle.

Acute Studies in Diet-Induced Obesity (DIO) Rats:

For acute experiments, male Sprague-Dawley DIO rats from Charles RiverLaboratories are raised from 4 weeks of age on a diet moderately highfat (32% kcal) and high in sucrose (25% kcal). Animals are used at 12weeks of age and are maintained on a 12/12 h light dark cycle. The ratsare randomized into groups (n=6/group) for the tested compounds andvehicle dosing. Rats are weighed 17 h after dosing to determine effectson overnight body weight gain. The tested compounds are administeredorally or s.c. at amount desired 1 h before the start of the dark cycle.Powdered food is provided in food cups which are weighed continuously at5 min intervals over 18 h and the data are recorded using a computerizedsystem.

Chronic Studies in Diet-Induced Obesity Rats:

For the 14-day chronic experiment, male Sprague-Dawley DIO rats areobtained as described above. Animals are used at 15 weeks of age and aremaintained on a 12/12 hour light-dark cycle. Rats are conditioned todosing for 4 days prior to baseline measurements, using an oral gavageor a s.c. route of vehicle. Thereafter, animals are dosed daily withvehicle or compound by oral gavage or s.c. The tested compound orvehicle is administered 1 h before the dark cycle for 14 days. Bodycomposition is measured by dual energy X-ray densitometry (DEXAscan) 5days prior to the study and at the end of the 14-day study. Dailyendpoints included body weight and food intake.

In Vivo Assay to Assess Compound Anti-Lipolytic Activity in RodentModel.

Male C57BL/6N wild-type are housed one per cage in a room maintained ona 12 h light/dark cycle under constant temperature (22-25° C.) with adlibitum access to food and water. The anti-lipolytic effects of thetested compounds are studied in awake mice. Animals are fasted overnightbefore experimental use. On the day of the experiment, animals are putin metabolic cages and left undisturbed to acclimate to the environmentfor 1-2 h. blood samples are taken at indicated time points from theintraorbital retrobulbar plexus. A 1% sodium citrate saline solution isused to flush the lines. A pre-treatment blood sample is obtained fromeach animal to determine baseline values for free fatty acids (FFA) andtriglycerides (TG). The tested compounds are given via oral gavage, scinjection, iv injection or ip injection for each different series ofexperiments. Blood samples are collected into pre-cooled tubespre-coated with heparin (200 μl blood, Li-heparin, Sarstedt) fordetermination triglycerides and glycerol and in tri-potassium EDTA addedsodium fluoride (200 μI blood, K₃-EDTA, 1.6 mg/mL+1% NaF, Sarstedt) fordetermination of plasma free fatty acids. The tubes are placed on wetice pending processing. Blood samples will be centrifuged at 4000×g, at4° C., 15 min the resulting plasma will be transferred into non-coatedtubes and stored at −80° C. until analyses. The plasma is thawed at 4°C. for determinations of FFA and TG using commercial kits (WakoChemicals).

While embodiments of the invention have been illustrated and described,it is not intended that these embodiments illustrate and describe allpossible forms of the invention. Rather, the words used in thespecification are words of description rather than limitation ant it isunderstood that various changes may be made without departing from thespirit and scope of the invention.

1-32. (canceled)
 33. A method of treatment and/or prevention of type IIdiabetes, obesity, dyslipidemia such as mixed or diabetic dyslipidemia,hypercholesterolemia, low HDL cholesterol, high LDL cholesterol,hyperlipidemia, hypertriglyceridemia, hypoglycemia, hyperglycemia,glucose intolerance, insulin resistance, hyperinsulinemia, hypertension,hyperlipoproteinemia, metabolic syndrome, syndrome X, thromboticdisorders, cardiovascular disease, atherosclerosis and its sequelaeincluding angina, claudication, heart attack, stroke and others, kidneydiseases, ketoacidosis, nephropathy, diabetic neuropathy, diabeticretinopathy, nonalcoholic fatty liver diseases such as steatosis ornonalcoholic steatohepatitis (NASH), comprising the administration to apatient in need thereof of a therapeutically effective amount of acompound of formula:

or a pharmaceutically acceptable salt or solvate thereof, wherein R¹ andR² are H, D is C═O; L² is single bond; R is H, linear or branched alkyl,aryl, acyloxyalkyl, or dioxolene; Ar¹ is a 5- to 6-membered aryl, 5- to6-membered heteroaryl, 3- to 6-membered cycloalkyl group, or a linear orbranched C₃-C₆ alkyl group, each of which being optionally substitutedby one or more group(s) selected from halo, cyano, alkyl, haloalkyl,cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, haloalkoxy, amino,alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl,alkylcarbamoyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,haloalkylsulfonylamino, or two substituents form an alkylenedioxy groupor a haloalkylenedioxy group, each of said aryl or heteroarylsubstituents being optionally substituted by one or more furthersubstituents selected from halo, cyano, alkyl, haloalkyl, hydroxy,alkoxy and haloalkoxy; Ar² is aryl, heteroaryl, cycloalkyl, ormonocyclic heterocyclyl group, each of which being optionallysubstituted by one or more group(s) selected from halo, cyano, nitro,alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl,heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl,benzoxazol-2-yl, heteroarylalkyl, hydroxy, hydroxyalkyl, alkoxy,haloalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy,heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl,arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,amino, alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl,aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl,carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,heteroarylsulfonylamino, oxo, or two substituents form an alkylenedioxygroup or a haloalkylenedioxy group, or fused to the aryl, heteroaryl orcycloalkyl group may be one or more aryl or heteroaryl moiety, each ofsaid substituents being optionally substituted by one or more furthersubstituents selected from halo, cyano, nitro, alkyl, hydroxyalkyl,haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, C₅-C₁₂ aryl optionallysubstituted by a chloro or methyl group, heteroaryl, heteroalkyl,hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by afluoro group, carboxy, alkoxycarbonyl, alkylcarbonyloxy, amino,alkylamino, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy, carbamoylamino,alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,haloalkylsulfonylamino, oxo, and haloalkoxyalkyl; R³ is H, cyano, alkyl,hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl, or arylsulfonyl; R³ is H orC₁-C₄ alkyl; R⁴ is H, cyano, or C₁-C₄ alkyl; under the condition thatthe compound is not (2S)-methyl1-benzoyl-5-mesitylpyrrolidine-2-carboxylate, (2S)-methyl1-benzoyl-5-(2,4,6-triethylphenyl)pyrrolidine-2-carboxylate,(2S,5S)-1-benzoyl-5-mesitylpyrrolidine-2-carboxylic acid, (2S)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate, (2S,5S)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate, (2S,5R)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate,(2S,5R)-5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylicacid, (2S,5R)-methyl5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylate,(2R,5R)-1-(4-bromothiophene-2-carbonyl)-5-phenylpyrrolidine-2-carboxylicacid,(2R,5S)-1-(3-bromo-2,6-dimethoxybenzoyl)-5-phenylpyrrolidine-2-carboxylicacid,1-[7-(4-tert-butyl-phenoxy)-1-cyclopentylmethyl-isoquinoline-3-carbonyl]-(5R)-phenyl-pyrrolidine-(2S)-carboxylicacid, and under the condition that: Ar² is not phthalazin-6-yl,pyrido[2,3-d]pyridazin-2-yl, pyrido[2,3-d]pyridazin-3-yl, orpyrazino[2,3-d]pyridazin-2-yl; and/or R³ is not a mono substitutedhydroxymethyl.
 34. Method for modulating GPR43 receptor activity, in apatient in need of such treatment, which comprises administering to saidpatient an effective amount of a compound of formula:

or a pharmaceutically acceptable salt or solvate thereof, wherein R¹ andR² are H, D is C═O; L² is single bond; R is H or linear or branchedalkyl, aryl, acyloxyalkyl, dioxolene; Ar¹ is a 5- to 6-membered aryl, 5-to 6-membered heteroaryl, 3- to 6-membered cycloalkyl group, or a linearor branched C₃-C₆ alkyl group, each of which being optionallysubstituted by one or more group(s) selected from halo, cyano, alkyl,haloalkyl, cycloalkyl, aryl, heteroaryl, hydroxy, alkoxy, haloalkoxy,amino, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy,alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl,alkylcarbamoyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl,haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,haloalkylsulfonylamino, or two substituents form an alkylenedioxy groupor a haloalkylenedioxy group, each of said aryl or heteroarylsubstituents being optionally substituted by one or more furthersubstituents selected from halo, cyano, alkyl, haloalkyl, hydroxy,alkoxy and haloalkoxy; Ar² is aryl, heteroaryl, cycloalkyl, ormonocyclic heterocyclyl group, each of which being optionallysubstituted by one or more group(s) selected from halo, cyano, nitro,alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl,heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl,benzoxazol-2-yl, heteroarylalkyl, hydroxy, hydroxyalkyl, alkoxy,haloalkoxy, alkoxyalkoxy, cycloalkyloxy, cycloalkylalkyloxy,heterocyclyloxy, aryloxy, heteroaryloxy, alkoxyalkyl, haloalkoxyalkyl,arylalkyloxy, heteroarylalkyloxy, aryloxyalkyl, heteroaryloxyalkyl,amino, alkylamino, arylcarbonyl, carboxy, alkoxycarbonyl,aryloxycarbonyl, heteroaryloxycarbonyl, alkylcarbonyloxy,arylcarbonyloxy, heteroarylcarbonyloxy, alkylcarbonylamino, carbamoyl,hydroxycarbamoyl, alkylcarbamoyl, arylcarbamoyl, heteroarylcarbamoyl,carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, arylsulfonyl,heteroarylsulfonyl, sulfamoyl, alkylsulfamoyl, arylsulfamoyl,heteroarylsulfamoyl, alkylsulfonylamino, arylsulfonylamino,heteroarylsulfonylamino, oxo, or two substituents form an alkylenedioxygroup or a haloalkylenedioxy group, or fused to the aryl, heteroaryl orcycloalkyl group may be one or more aryl or heteroaryl moiety, each ofsaid substituents being optionally substituted by one or more furthersubstituents selected from halo, cyano, nitro, alkyl, hydroxyalkyl,haloalkyl, cyanomethyl, cycloalkyl, heterocyclyl, C₅-C₁₂ aryl optionallysubstituted by a chloro or methyl group, heteroaryl, heteroalkyl,hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, haloalkoxy, cycloalkyloxy,cycloalkylalkyloxy, aryloxy, aralkyloxy optionally substituted by afluoro group, carboxy, alkoxycarbonyl, alkylcarbonyloxy, amino,alkylamino, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl,hydroxycarbamoyl, alkylcarbamoyl, carbamoylalkyloxy, carbamoylamino,alkylcarbamoylamino, carbamimidoyl, hydroxycarbamimidoyl, alkylsulfonyl,haloalkylsulfonyl, cycloalkylsulfonyl, heterocyclylsulfonyl,arylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino,haloalkylsulfonylamino, oxo, and haloalkoxyalkyl; R³ is H, cyano, alkyl,hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl, arylsulfonyl; R³ is H orC₁-C₄ alkyl; R⁴ is H, cyano, C₁-C₄ alkyl; under the condition that thecompound is not (2S)-methyl1-benzoyl-5-mesitylpyrrolidine-2-carboxylate, (2S)-methyl1-benzoyl-5-(2,4,6-triethylphenyl)pyrrolidine-2-carboxylate,(2S,5S)-1-benzoyl-5-mesitylpyrrolidine-2-carboxylic acid, (2S)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate, (2S,5S)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate, (2S,5R)-methyl1-benzoyl-5-propylpyrrolidine-2-carboxylate,(2S,5R)-5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylicacid, (2S,5R)-methyl5-(tert-butyl)-1-(4-phenylbutanoyl)pyrrolidine-2-carboxylate,(2R,5R)-1-(4-bromothiophene-2-carbonyl)-5-phenylpyrrolidine-2-carboxylicacid,(2R,5S)-1-(3-bromo-2,6-dimethoxybenzoyl)-5-phenylpyrrolidine-2-carboxylicacid,1-[7-(4-tert-butyl-phenoxy)-1-cyclopentylmethyl-isoquinoline-3-carbonyl]-(5R)-phenyl-pyrrolidine-(2S)-carboxylicacid, and under the condition that: Ar² is not phthalazin-6-yl,pyrido[2,3-d]pyridazin-2-yl, pyrido[2,3-d]pyridazin-3-yl, orpyrazino[2,3-d]pyridazin-2-yl; and/or R³ is not a mono substitutedhydroxymethyl.
 35. Method according to claim 34, wherein the compound isan agonist or partial agonist of GPR43 receptor activity.
 36. Thecompound of formula E

wherein R⁸ is Cl or F and R⁹ is H, or R⁸ and R⁹ are both F; R is methyl,ethyl, benzyl, allyl, phenacyl, methoxymethyl, methylthiomethyl,2-methoxyethoxymethyl, 2-trimethylsilylethyl or tert-butyldiphenylsilyl.37. A compound of formula F

wherein R′ is OH or Cl; A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selectedfrom the combinations 1 to 7, 9, 10, 13 to 15, 17 to 21, 23 and 24:Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CH C—NHSO₂CH₃CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CH CH CH 4 CHCH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CH C—OCH₃ N NC—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CH C—CN CH 9 C—FCH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CH CH CH CHC—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH N C—OCH₃ NC—OCH₃ 14 N C—OCH₃ CH CH CH CH CH 15 CH CH C—OCH₃ N CH N CH 16 CH C—OCH₃C—OCH₃ CH CH CH CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CH C—OCH₃ NC—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CH C—OCH₃C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 22 N CH C—OCH₃ CHC—OCH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CH


38. A process for the preparation of a compound of formula Ib-1b′

wherein Ar² is aryl, heteroaryl, cycloalkyl, or monocyclic heterocyclylgroup, each of which being optionally substituted by one or moregroup(s) selected from halo, cyano, nitro, alkyl, haloalkyl, cycloalkyl,cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,aralkyl, heteroaryl, benzoxazol-2-yl, heteroarylalkyl, hydroxy,hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkoxy, cycloalkyloxy,cycloalkylalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy,alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy, heteroarylalkyloxy,aryloxyalkyl, heteroaryloxyalkyl, amino, alkylamino, arylcarbonyl,carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl, alkylsulfonylamino,arylsulfonylamino, heteroarylsulfonylamino, oxo, or two substituentsform an alkylenedioxy group or a haloalkylenedioxy group, or fused tothe aryl, heteroaryl or cycloalkyl group may be one or more aryl orheteroaryl moiety, each of said substituents being optionallysubstituted by one or more further substituents selected from halo,cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl, cycloalkyl,heterocyclyl, C₅-C₁₂ aryl optionally substituted by a chloro or methylgroup, heteroaryl, heteroalkyl, hydroxy, alkoxy, alkoxyalkyl,alkoxyalkoxy, haloalkoxy, cycloalkyloxy, cycloalkylalkyloxy, aryloxy,aralkyloxy optionally substituted by a fluoro group, carboxy,alkoxycarbonyl, alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino, carbamimidoyl,hydroxycarbamimidoyl, alkylsulfonyl, haloalkylsulfonyl,cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl, sulfamoyl,alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, oxo, andhaloalkoxyalkyl; Ar¹ is 2-chlorophenyl, 2-fluorophenyl,2,3-difluorophenyl; R¹, R², R³, R^(3′), R⁴ and R are H; D is C═O; L² isa single bond; which consists of: a) the coupling of a compound offormula A

wherein R⁸ is Cl or F and R⁹ is H, or R⁸ and R⁹ are both F; R is methyl,ethyl, tert-butyl, benzyl, allyl, phenacyl, methoxymethyl,methylthiomethyl, 2-methoxyethoxymethyl, 2-trimethylsilylethyl,tert-butyldiphenylsilyl, with a compound of formula B

wherein: Ar² is aryl, heteroaryl, cycloalkyl, or monocyclic heterocyclylgroup, each of which being optionally substituted by one or moregroup(s) selected from halo, cyano, nitro, alkyl, haloalkyl, cycloalkyl,cycloalkylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, aryl,aralkyl, heteroaryl, benzoxazol-2-yl, heteroarylalkyl, hydroxy,hydroxyalkyl, alkoxy, haloalkoxy, alkoxyalkoxy, cycloalkyloxy,cycloalkylalkyloxy, heterocyclyloxy, aryloxy, heteroaryloxy,alkoxyalkyl, haloalkoxyalkyl, arylalkyloxy, heteroarylalkyloxy,aryloxyalkyl, heteroaryloxyalkyl, amino, alkylamino, arylcarbonyl,carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl,alkylcarbonyloxy, arylcarbonyloxy, heteroarylcarbonyloxy,alkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,arylcarbamoyl, heteroarylcarbamoyl, carbamoylamino, alkylcarbamoylamino,alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl,alkylsulfamoyl, arylsulfamoyl, heteroarylsulfamoyl, alkylsulfonylamino,arylsulfonylamino, heteroarylsulfonylamino, oxo, or two substituentsform an alkylenedioxy group or a haloalkylenedioxy group, or fused tothe aryl, heteroaryl or cycloalkyl group may be one or more aryl orheteroaryl moiety, each of said substituents being optionallysubstituted by one or more further substituents selected from halo,cyano, nitro, alkyl, hydroxyalkyl, haloalkyl, cyanomethyl, cycloalkyl,heterocyclyl, C₅-C₁₂ aryl optionally substituted by a chloro or methylgroup, heteroaryl, heteroalkyl, hydroxy, alkoxy, alkoxyalkyl,alkoxyalkoxy, haloalkoxy, cycloalkyloxy, cycloalkylalkyloxy, aryloxy,aralkyloxy optionally substituted by a fluoro group, carboxy,alkoxycarbonyl, alkylcarbonyloxy, amino, alkylamino, alkylcarbonylamino,haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,carbamoylalkyloxy, carbamoylamino, alkylcarbamoylamino, carbamimidoyl,hydroxycarbamimidoyl, alkylsulfonyl, haloalkylsulfonyl,cycloalkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl, sulfamoyl,alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, oxo, andhaloalkoxyalkyl; R″ is Cl or OL wherein L is a carboxylic acidactivating group, followed by b) an alkaline or acidic treatment,hydrogenolysis or treatment with fluoride of the ester intermediateobtained in step a); step b) being optionally followed by conversion ofa compound of formula Ib-1b′ to a pharmaceutically acceptable salt orsolvate thereof.
 39. A process for the preparation of a compound offormula Ib-1b′

wherein Ar¹ is a 5- to 6-membered aryl, 5- to 6-membered heteroaryl, 3-to 6-membered cycloalkyl group, or a linear or branched C₃-C₆ alkylgroup, each of which being optionally substituted by one or moregroup(s) selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl,heteroaryl, hydroxy, alkoxy, haloalkoxy, amino, alkylamino, carboxy,alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino,or two substituents form an alkylenedioxy group or a haloalkylenedioxygroup, each of said aryl or heteroaryl substituents being optionallysubstituted by one or more further substituents selected from halo,cyano, alkyl, haloalkyl, hydroxy, alkoxy and haloalkoxy; R³ is H, cyano,alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl, or arylsulfonyl; R³is H or C ₁-C₄ alkyl; R⁴ is H, cyano, or C ₁-C₄ alkyl; R¹, R², and R areH; D is C═O; L² is a single bond; Ar² is selected from4′-(2-methoxy-4-methylsulfonylamido-1,1′-biphenyl),4′-(2-methyl-3-methylsulfonylamino-1,1′-biphenyl),4-(2-methoxypyridin-3-yl)phenyl, 4-(2,6-dimethoxypyrimidin-5-yl)phenyl,3-methoxy-4-(2-methoxypyrimidin-5-yl)phenyl,4-(3,6-dimethoxypyridazin-5-yl)phenyl,4′-(5-cyano-2-methoxy-1,1′-biphenyl),4′-(5-cyano-2-methyl-1,1′-biphenyl),3-fluoro-4-(3,6-dimethoxypyridazin-5-yl)phenyl,(4-(4-methoxypyridin-3-yl)phenyl),(4′-(methylsulfonamido)-[1,1′-biphenyl]-4-yl),(3′-(methylsulfonamido)-[1,1′-biphenyl]-4-yl),(4-(2,4-dimethoxypyrimidin-5-yl)phenyl),(5-methoxy-6-phenylpyridin-3-yl), (4-(4-methoxypyrimidin-5-yl)phenyl),(2,2′-dimethoxy-[1,1′-biphenyl]-4-yl),(3-methoxy-4-(4-methoxypyridin-3-yl)phenyl),(4-(2,4-dimethoxypyrimidin-5-yl)-3-methoxyphenyl),(4′-acetamido-2′-methoxy-[1,1′-biphenyl]-4-yl),(2′-cyano-4′,5′-dimethoxy-[1,1′-biphenyl]-4-yl),(2′-methoxy-4′-(N-methylmethylsulfonamido)-[1,1′-biphenyl]-4-yl),(6-(2,4-dimethoxyphenyl)pyridin-3-yl),(4-(4,6-dimethoxypyrimidin-5-yl)phenyl),(4-(3-methoxypyridin-4-yl)phenyl); which consists of: a) the coupling ofa compound of formula C

wherein: Ar¹ is a 5- to 6-membered aryl, 5- to 6-membered heteroaryl, 3-to 6-membered cycloalkyl group, or a linear or branched C₃-C₆ alkylgroup, each of which being optionally substituted by one or moregroup(s) selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, aryl,heteroaryl, hydroxy, alkoxy, haloalkoxy, amino, alkylamino, carboxy,alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino,haloalkylcarbonylamino, carbamoyl, hydroxycarbamoyl, alkylcarbamoyl,carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl,sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino,or two substituents form an alkylenedioxy group or a haloalkylenedioxygroup, each of said aryl or heteroaryl substituents being optionallysubstituted by one or more further substituents selected from halo,cyano, alkyl, haloalkyl, hydroxy, alkoxy and haloalkoxy; R³ is H, cyano,alkyl, hydroxyalkyl, aralkyl, alkoxyalkyl, acetyl, or arylsulfonyl; R³is H or C ₁-C₄ alkyl; R⁴ is H, cyano, or C₁-C₄ alkyl; R is methyl,ethyl, tert-butyl, benzyl, allyl, phenacyl, methoxymethyl,methylthiomethyl, 2-methoxyethoxymethyl, 2-trimethylsilylethyl,tert-butyldiphenylsilyl, with a compound of formula D

wherein R″ is Cl or OL, wherein L is a carboxylic acid activating group;A⁰, A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations 1to 24: Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CHC—NHSO₂CH₃ CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CHCH CH 4 CH CH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CHC—OCH₃ N N C—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CHC—CN CH 9 C—F CH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CHCH CH CH C—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH NC—OCH₃ N C—OCH₃ 14 N C—OCH₃ CH CH CH CH CH 15 CH CH C—OCH₃ N CH N CH 16CH C—OCH₃ C—OCH₃ CH CH CH CH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CHC—OCH₃ N C—OCH₃ N CH 19 CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CHC—OCH₃ C—OCH₃ CH 21 CH CH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 22 N CH C—OCH₃CH C—OCH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CH C—OCH₃ CH N CH CH

followed by b) an alkaline or acidic treatment, a hydrogenolysis or atreatment with fluoride of the ester intermediate obtained in step a);step b) being optionally followed by conversion of a compound of formulaIb-1b′ to a pharmaceutically acceptable salt or solvate thereof.
 40. Aprocess for the preparation of a compound of the formula Ib-1h″

wherein R⁸ is F or Cl and R⁹ is H, or both R⁸ and R⁹ are F; R is H; A⁰,A^(0′), A¹, A², A³, A⁴ and A⁵ are selected from the combinations 1 to24: Combination n^(o) A⁰ A^(0′) A¹ A² A³ A⁴ A⁵ 1 CH CH C—OCH₃ CHC—NHSO₂CH₃ CH CH 2 CH CH C—CH₃ C—NHSO₂CH₃ CH CH CH 3 CH CH C—OCH₃ N CHCH CH 4 CH CH C—OCH₃ N C—OCH₃ N CH 5 C—OCH₃ CH CH N C—OCH₃ N CH 6 CH CHC—OCH₃ N N C—OCH₃ CH 7 CH CH C—OCH₃ CH CH C—CN CH 8 CH CH C—CH₃ CH CHC—CN CH 9 C—F CH C—OCH₃ N N C—OCH₃ CH 10 CH CH CH N CH CH C—OCH₃ 11 CHCH CH CH C—NHSO₂CH₃ CH CH 12 CH CH CH C—NHSO₂CH₃ CH CH CH 13 CH CH CH NC—OCH₃ N C—OCH₃ 15 CH CH C—OCH₃ N CH N CH 16 CH C—OCH₃ C—OCH₃ CH CH CHCH 17 C—OCH₃ CH CH N CH CH C—OCH₃ 18 C—OCH₃ CH C—OCH₃ N C—OCH₃ N CH 19CH CH C—OCH₃ CH C—NHCOCH₃ CH CH 20 CH CH C—CN CH C—OCH₃ C—OCH₃ CH 21 CHCH C—OCH₃ CH C—N(CH₃)SO₂CH₃ CH CH 23 CH CH C—OCH₃ N CH N C—OCH₃ 24 CH CHC—OCH₃ CH N CH CH

which consists of: a) the coupling of a compound of formula A accordingto claim 6 with a compound of formula D according to claim 7, followedby b) an alkaline or acidic treatment, a hydrolysis, a hydrogenolysis ora treatment with fluoride of the ester intermediate obtained in step a);step b) being optionally followed by conversion of a compound of formulaIb-1h″ to a pharmaceutically acceptable salt or solvate thereof.